<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006643.pub2" GROUP_ID="MS" ID="610905122310025917" MERGED_FROM="" MODIFIED="2009-11-03 12:36:51 +0100" MODIFIED_BY="Liliana Coco" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-11-03 12:33:09 +0100" MODIFIED_BY="Liliana Coco">
<TITLE>Interferon Beta for Primary Progressive Multiple Sclerosis</TITLE>
<CONTACT>
<PERSON ID="DA06951382E26AA201BA4B5459D56A6A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Juan</FIRST_NAME>
<MIDDLE_INITIALS>Ignacio</MIDDLE_INITIALS>
<LAST_NAME>Rojas</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>juan.rojas@hospitalitaliano.org.ar</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology Department</DEPARTMENT>
<ORGANISATION>Hospital Italiano Buenos Aires</ORGANISATION>
<ADDRESS_1>Gascon 450</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1411</ZIP>
<REGION>Buenos Aires</REGION>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>+54-11-4959-0322</PHONE_1>
<PHONE_2>+54-11-1558722348</PHONE_2>
<FAX_1>+54-11-49590322</FAX_1>
<FAX_2>+54-11-49590322</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-11-03 12:33:09 +0100" MODIFIED_BY="Liliana Coco">
<PERSON ID="DA06951382E26AA201BA4B5459D56A6A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Juan</FIRST_NAME>
<MIDDLE_INITIALS>Ignacio</MIDDLE_INITIALS>
<LAST_NAME>Rojas</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>juan.rojas@hospitalitaliano.org.ar</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology Department</DEPARTMENT>
<ORGANISATION>Hospital Italiano Buenos Aires</ORGANISATION>
<ADDRESS_1>Gascon 450</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1411</ZIP>
<REGION>Buenos Aires</REGION>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>+54-11-4959-0322</PHONE_1>
<PHONE_2>+54-11-1558722348</PHONE_2>
<FAX_1>+54-11-49590322</FAX_1>
<FAX_2>+54-11-49590322</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="523F287582E26AA2007C9B46D852CC0E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Romano</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>marina.romano@hospitalitaliano.org.ar</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>(54 11) 9 15-5180-7185</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Neurology Department</DEPARTMENT>
<ORGANISATION>Hospital Italiano Buenos Aires</ORGANISATION>
<ADDRESS_1>Gascon 450</ADDRESS_1>
<ADDRESS_2/>
<CITY>CABA (Ciudad Autonoma de Buenos Aires)</CITY>
<ZIP>1181</ZIP>
<REGION>Buenos Aires</REGION>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>54 11-49615170</PHONE_1>
<PHONE_2>54 11-49590322</PHONE_2>
<FAX_1>54 11-49590322</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13819" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Agustín</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ciapponi</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinator</POSITION>
<EMAIL_1>agustin.ciapponi@hospitalitaliano.org.ar</EMAIL_1>
<EMAIL_2>aciapponi@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Family and Preventive Medicine Division</DEPARTMENT>
<ORGANISATION>Hospital Italiano de Buenos Aires</ORGANISATION>
<ADDRESS_1>Independencia 1253 PB 'A'</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1099</ZIP>
<REGION>Capital Federal</REGION>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>+54 11 4383 9878</PHONE_1>
<PHONE_2/>
<FAX_1>+54 11 4953 4058</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5246142F82E26AA2007C9B46807AB4CC" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Liliana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Patrucco</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>liliana.patrucco@hospitalitaliano.org.ar</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology Department</DEPARTMENT>
<ORGANISATION>Hospital Italiano Buenos Aires</ORGANISATION>
<ADDRESS_1>Gascon 450</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1411</ZIP>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>54 11-49590322 ext: 8621</PHONE_1>
<PHONE_2>54 11-49590200</PHONE_2>
<FAX_1>54 11-49590322</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="301F33FA82E26AA201AFF01220B376A4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Edgardo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cristiano</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology Department</DEPARTMENT>
<ORGANISATION>Hospital Italiano Buenos Aires</ORGANISATION>
<ADDRESS_1>Gascon 450</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1411</ZIP>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>54 11-49590322 ext: 8621</PHONE_1>
<PHONE_2>54 11-49590200</PHONE_2>
<FAX_1>54 11-49590322</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-09-15 11:35:00 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="23" MONTH="8" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="5" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2009-09-15 11:53:34 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-09-15 11:53:34 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="23" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Conclusions unchanged. 'Risk of bias' table has been added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-23 11:57:06 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated May 21, 2009.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-17 10:20:55 +0200" MODIFIED_BY="Liliana Coco"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Hospital Italiano Buenos Aires</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Instituto de Efectividad Clínica y Sanitaria (IECS)</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-03 12:34:15 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-11-03 11:04:19 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-11 11:32:17 +0100" MODIFIED_BY="Liliana Coco">Treatments of patients with Primary Progressive Multiple Sclerosis (PPMS) with interferon beta (INF beta) seems not associated with a reduction of  the disability progression</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-03 11:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>This is an updated Cochrane review of the previous version published (<I>Cochrane Database of Systematic Reviews</I> 2009, Issue 1. Art. No.: CD006643. DOI: 10.1002/14651858.CD006643.pub2).</P>
<P>Treatments of patients with Primary Progressive Multiple Sclerosis ( PPMS) with interferon beta ( INF beta) seems not associated with a reduction of  the disability progression</P>
<P>To date there is no proven or licensed disease-modifying treatments to slow the progression of PPMS. Studies on the effects of INF beta have mainly focused on Relapsing-Remitting MS and have demonstrated a modest reduction on the progression of the disease.  The objective of this review was to assess the efficacy of INF beta in  patients with PPMS.</P>
<P>Among the pertinent medical literature only  two studies, comprising  a total of 123 participants,  met the criteria of the methodological quality necessary for their inclusion in this review. Taking into account  the disability progression, the analysis of the data showed that INF beta treatment in  patients with PPMS was  not associated with a reduction of  this parameter during the first two years of therapy. Adverse effects, mainly flu-like symptoms and injection site reactions, occurred frequently and were the same as  reported by the many studies on   IFN beta treatments in MS patients with different types of the disease.</P>
<P>It is worth nothing that the patients&#8217; population analysed was too small to allow a definitive conclusion on the efficacy of IFN beta therapy  in PPMS.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-09-15 11:54:19 +0200" MODIFIED_BY="Liliana Coco">
<ABS_BACKGROUND MODIFIED="2009-09-15 11:38:49 +0200" MODIFIED_BY="Liliana Coco">
<P>This is an updated Cochrane review of the previous version published (<I>Cochrane Database of Systematic Reviews</I> 2009, Issue 1. Art. No.: CD006643. DOI: 10.1002/14651858.CD006643.pub2).</P>
<P>Therapeutic trials with ß-interferon in Multiple Sclerosis (MS) have mainly focused on remitting-relapsing multiple sclerosis (RRMS), demonstrating a reduction in relapse rate. However, there is not enough evidence about their efficacy in patients with primary progressive multiple sclerosis (PPMS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-06-16 18:44:07 +0200" MODIFIED_BY="[Empty name]">
<P>Identify and summarize the evidence that ß-interferon is beneficial and safe in patients with PPMS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-09-15 11:54:19 +0200" MODIFIED_BY="Liliana Coco">
<P>We searched the Cochrane MS Group Trials Register (May 2009); The Cochrane Central Register of Controlled Trials (CENTRAL) The Cochrane Library, (2009, Issue 2); MEDLINE (PubMed) (January 1966 to May 2009), EMBASE (January 1974 to May 2009); NICE (January 1999 to May 2009); LILACS (January 1986 to May 2009); Screening of reference lists of all primary studies found; Contact and inquiry of drug manufactures and multiple sclerosis experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-06-15 17:46:52 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double or single blind, placebo-controlled trials of recombinant ß-interferon in patients with PPMS including trials of MS which report separate outcomes in subgroups of patients with PPMS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-15 17:47:06 +0200" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently extracted and assessed trials' quality according to the criteria outlined in The Cochrane Handbook.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-29 12:05:27 +0200" MODIFIED_BY="Juan Ignacio Rojas">
<P>Of 1777 potential studies evaluated, only two Randomized Control Trials (123 patients) were included. ß-interferon treatment compared to placebo did not show differences regarding the proportion of patients with progression of the disease (RR 0.89, 95% CI 0.55 to1.43), and it was associated with a greater frequency of treatment-related adverse events (RR 1.90, 95% CI 1.45-2.48). One of the trials evaluated the MRI secondary outcome pre-specified in the protocol. This trial showed that at two years the numbers of active lesions on brain MRI scan in ß-interferon arm were significantly lower than in placebo arm (weighted mean difference -1.3, 95% CI -2.15 to -0.45, P = 0.003); also, the number of participants with active lesions was significantly higher in placebo arm vs. ß-interferon arm at two years (RR 0.43, 95% CI 0.22 to 0.86, P = 0.02).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-06-16 18:47:08 +0200" MODIFIED_BY="[Empty name]">
<P>Limited data on the effect of ß-interferon treatment on PPMS exists. Only two single-centre placebo controlled trials of interferon beta have been done. Based on this review, the included studies showed that ß-interferon treatment was not associated with reduced disability progression in PPMS patients. However, the trial population was too small to allow definitive conclusions on the efficacy of ß-interferon therapy in PPMS patients. Larger research studies need to be done in patients with PPMS in order to clarify whether ß-interferon is effective in this population.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-09-21 10:03:36 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-09-15 12:05:48 +0200" MODIFIED_BY="Liliana Coco">
<CONDITION MODIFIED="2009-09-15 12:05:30 +0200" MODIFIED_BY="Liliana Coco">
<P>Multiple sclerosis (MS) is a chronic central nervous system disease that produces symptoms and signs occurring from lesions in the brain, spinal cord and optic nerves.<BR/>MS is largely a disease of young adults with a mean age of onset of thirty years. Females are more affected than males at a ratio of 2:1 (<LINK REF="REF-van-Lambalgen-1986" TYPE="REFERENCE">van Lambalgen 1986</LINK>). The age of onset for females is slightly younger than for males.<BR/>International consensus (<LINK REF="REF-Lublin-1996" TYPE="REFERENCE">Lublin 1996</LINK>) describes four disease types: relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS) and progressive relapsing multiple sclerosis (PRMS). About 10&#8211;15% of patients with MS present with gradually increasing neurological disability, the type known as PPMS (<LINK REF="REF-Miller-2007" TYPE="REFERENCE">Miller 2007</LINK>, <LINK REF="REF-Thompson-2000" TYPE="REFERENCE">Thompson 2000</LINK>). The precise proportion of PPMS varies between studies and is probably influenced by the criteria set and the strictness to which these are adhered, ranging from 9% to 37%. However, when patients are seen from their initial presentation the percentage falls to 7.7% (<LINK REF="REF-Montalban-2005" TYPE="REFERENCE">Montalban 2005</LINK>). Compared with RRMS, people with PPMS are older at onset and a higher proportion are men (<LINK REF="REF-Miller-2007" TYPE="REFERENCE">Miller 2007</LINK>).<BR/>In PPMS the illness is progressive from onset, with occasional plateaus and temporary but minor improvements. These patients have no acute exacerbations (<LINK REF="REF-Lublin-1996" TYPE="REFERENCE">Lublin 1996</LINK>), show a higher mean age of onset, have an equal sex distribution (<LINK REF="REF-Thompson-1997" TYPE="REFERENCE">Thompson 1997</LINK>) and about 85% will develop a progressive myelopathy (<LINK REF="REF-Stevenson-1999" TYPE="REFERENCE">Stevenson 1999</LINK>). Although this group is considered to have the poorest prognosis in terms of disability (<LINK REF="REF-Confavreux-2006" TYPE="REFERENCE">Confavreux 2006</LINK>, <LINK REF="REF-Kremenchutzky-2006" TYPE="REFERENCE">Kremenchutzky 2006</LINK>), there is a wide range in the rate of progression.<BR/>Clinical characteristics of PPMS make diagnosis difficult. Thompson et al proposed new diagnostic criteria on the basis of a review of their clinical experience (<LINK REF="REF-Thompson-2000" TYPE="REFERENCE">Thompson 2000</LINK>). Three levels of diagnostic certainty were established (definite, probable and possible), based upon clinical findings, abnormal cerebrospinal fluid, abnormalities in MRI of the brain and spinal cord, and in evoked potentials. The criteria for definite PPMS are: clinical progression for at least one year, evidence of intrathecal synthesis of IgG, and either nine brain lesions on MRI and two spinal cord lesions, or four to eight brain lesions and one spinal cord lesion. A lesser degree of MRI abnormalities, together with a delayed visual evoked response, may also be used to support a definite diagnosis of PPMS. The categories of probable and possible PPMS require lesser degrees of abnormality within this spectrum of findings. These criteria have been incorporated in the McDonald criteria currently in use (<LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-09-15 12:05:48 +0200" MODIFIED_BY="Liliana Coco">
<P>Therapeutic trials with ß-interferon have mainly focused on RRMS, demonstrating a reduction in relapse rate and most likely slowing disability progression (<LINK REF="REF-IFNB-MSSG-1993" TYPE="REFERENCE">IFNB MSSG 1993</LINK>, <LINK REF="REF-MSCRG-1996" TYPE="REFERENCE">MSCRG 1996</LINK>, <LINK REF="STD-PRISMS-1998" TYPE="STUDY">PRISMS 1998</LINK>, <LINK REF="REF-Rice-2001" TYPE="REFERENCE">Rice 2001</LINK>). Rice et al. demonstrated a modest reduction on the progression of the disease in RRMS patients after one and two years of treatment (RR 0.69, 95% CI 0.55 to 0.87) (<LINK REF="REF-Rice-2001" TYPE="REFERENCE">Rice 2001</LINK>). Also a recent meta-analyses (<LINK REF="REF-Clerico-2008" TYPE="REFERENCE">Clerico 2008</LINK>) showed that the proportion of patients converting from clinically isolated syndromes (CIS) to clinically definite MS (CDMS) was significantly lower in ß-interferon beta-treated than in placebo-treated patients after two years of follow-up (OR 0.52, 95% CI 0.38 to 0.70).<BR/>On the other hand, trials on SPMS have shown controversial results (<LINK REF="REF-ESG-1998" TYPE="REFERENCE">ESG 1998</LINK>, <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>, <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>, <LINK REF="REF-NASG-2004" TYPE="REFERENCE">NASG 2004</LINK>), and pathological findings and the effect of ß-interferon in this group of patients is still unknown (<LINK REF="STD-Leary-2003" TYPE="STUDY">Leary 2003</LINK>). To date, there are no systematic reviews on the effects of ß-interferon in PPMS.</P>
</INTERVENTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-06-11 11:22:25 +0200" MODIFIED_BY="Liliana Coco">
<P>The primary objective was to evaluate whether ß-interferon is more effective than placebo in delaying disability progression during the follow up in patients with PPMS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-09-21 10:03:36 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-11 11:10:52 +0100" MODIFIED_BY="Liliana Coco">
<CRIT_STUDIES MODIFIED="2008-11-10 11:11:22 +0100" MODIFIED_BY="Liliana Coco">
<P>We included randomized double or single blind, placebo-controlled trials of recombinant ß-interferon in patients with PPMS including trials of MS which reported separate outcomes in subgroups of patients with PPMS.<BR/>Uncontrolled, non-randomized or quasi-randomized trials were excluded.<BR/>We also excluded trials that are confounded by other treatments such as immunosuppressive drugs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-10 11:12:23 +0100" MODIFIED_BY="Liliana Coco">
<P>Patients with definitive diagnosis of multiple sclerosis according to widely accepted international criteria (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>, <LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>) and with primary progressive course according to the current consensus (<LINK REF="REF-Lublin-1996" TYPE="REFERENCE">Lublin 1996</LINK>) regardless of any age, gender, nationality or score disability measured by the Expanded Disability Status Scale (EDSS) (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-10 11:17:53 +0100" MODIFIED_BY="Liliana Coco">
<P>Recombinant ß-interferon1a or recombinant ß-interferon 1b versus placebo, whatever the administration route and the duration of treatment.<BR/>For trials in which treatment effects were reported for more than one dose (more than one arm) we considered all doses used (all arms).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-11 11:10:52 +0100" MODIFIED_BY="Liliana Coco">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-11 11:10:52 +0100" MODIFIED_BY="Liliana Coco">
<UL>
<LI>The number of patients who worsened the physical disability at one, two and three years. Physical worsening is defined as patients who experienced an increase (for at least 3 or 6 months) of the Expanded Disability Status Scale (EDSS) score by greater than or equal to 1.0 point for those with an entry score of less than 5.5, or by greater than or equal to 0.5 points for those with an entry score of greater than or equal to 5.5. The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>). Its range of possible score goes from 0 (normal neurological examination) to 10 (death due to MS). EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the ambulation impairment (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-10 13:28:34 +0100" MODIFIED_BY="Liliana Coco">
<UL>
<LI>Number of patients with severe adverse events defined as severe when leading to one of the following: death, hospitalizations, and treatment discontinuation.</LI>
</UL>
<UL>
<LI>Number of patients with any related adverse events, (leucopenia, lymphopenia, thrombocytopenia. increased plasma hepatic enzymes, depression or depressive symptoms and influenza-like reaction).</LI>
</UL>
<UL>
<LI>Progression of disease assessed by the change in EDSS at the group level and measured at one, two and three years.</LI>
</UL>
<UL>
<LI>Mean change of quality of life (QOL) assessment using validated multidimensional questionnaires (e.g. Multiple Sclerosis Quality of Life-54 instrument [MSQOL-54] (<LINK REF="REF-Vickrey-1995" TYPE="REFERENCE">Vickrey 1995</LINK>). Assessment of functional results or one-dimensional aspects of QOL (e.g. sexual function, urinary function) was not included in the review .</LI>
</UL>
<UL>
<LI>Change on MRI markers, defined as; a) Number of "active" lesions, defined as the number of T1 enhancing lesions on MRI scans at 6 months/1 year and 2 years; b) number of participants with "active" lesions at 6 month/ 1 year and longer from the inclusion into the study; c) Mean and standard deviation (SD) change of total area or volume on brain MRI scans at 6 months/ 1 year and longer from the inclusion into the study.</LI>
</UL>
<P>Although we had not planned to evaluate spasticity we did it because it has been suggested that spasticity may be increased in PPMS following treatment with interferon beta (<LINK REF="REF-Bramanti-1998" TYPE="REFERENCE">Bramanti 1998</LINK>).<B>
<BR/>
</B>
</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-09-21 10:01:13 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic search without language restrictions was conducted using the optimally sensitive strategy developed for the Cochrane Collaboration to identify all relevant published and unpublished randomised controlled trials (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). For additional information about the Group's search strategy please see: <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Cochrane Multiple Sclerosis Group</A>.<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-09-21 09:33:58 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following databases :<BR/>1. The Cochrane MS Group Trials Register (May 21, 2009)<BR/>2. The Cochrane Central Register of Controlled Trials (CENTRAL) The Cochrane Library, (Issue 2, 2009) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)<BR/>3. PUBMED (January 1966 to May 21, 2009) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)<BR/>4. EMBASE (January 1974 to May 21, 2009) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>)<BR/>5. LILACS (January 1986 to May 21 2009) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>)<BR/>6. NICE (January 1999 to May 2009) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-09-15 12:06:07 +0200" MODIFIED_BY="Liliana Coco">
<P>7. Screening of reference lists of all available review articles and primary studies found.<BR/>8. The Science Citation Index was used to find references from 1985 to 2006 that have cited the identified trials. Investigators were be contacted to identify additional published and unpublished studies. Manual searches of conference proceeding abstracts were not conducted specifically for this review.<BR/>9. Hand searching of the references quoted in the recent abstract books of ECTRIMS, EFNS, ENS, AAN, ANA ,ACTRIMS and LACTRIMS from 1995 to 2009.<BR/>10. Contact with corresponding authors of relevant trials or reviewers and other multiple sclerosis experts.<BR/>11. Contact and inquiry of drug manufactures.<BR/>12. On going trials was searched at: TrialsCentralTM (www.trialscentral.org), ClinicalTrials.gov (www.clinicaltrial.gov) and Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>).<BR/>13. Grey literature in The British Library, INSIDE, SIGLE and Current Controlled Trials in the USA.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-09-21 10:03:36 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-06-16 17:37:48 +0200" MODIFIED_BY="[Empty name]">
<P>Titles and abstracts identified from the searches were independently checked by two reviewers. If it was clear that the study did not meet the eligibility criteria, it was excluded. If it was not clear from the abstract and title, the full text of study was obtained and evaluated independently by the reviewers. If no consensus was met about the possible inclusion/exclusion of any individual study, an additional reviewer independently assessed the full text of the studies to decide whether they fit the inclusion criteria. A final decision was be made by discussion amongst all the reviewers. Authors were contacted in case of ambiguities or missing descriptions of the methodology.<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-12 14:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently extracted the data on a predefined collection form for each trial included. Disagreement about extracted data was resolved by consensus but when this was not possible, and further information was necessary to resolve the dilemma, data was not entered and the trial was added to those awaiting assessment. A third methodologist could resolve the dilemma.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-09-21 10:03:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Quality assessment of the trials</B>
</P>
<P>Two reviewers independently judged the trial quality according to the criteria outlined in The Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 related to the following criteria:</P>
<P>
<B>a) Protection against selection bias: </B>evaluating the randomizations procedure and allocation concealment.<BR/>
<B>b) Protection against performance bias: </B>evaluating blinding of patients and people administering the treatment.<BR/>
<B>c) Protection against attrition bias: </B>evaluating the number of patients withdrawn form the studies reported for each group and intention to treat analysis.<BR/>
<B>d) Protection of detection bias: </B>evaluating the blinding of outcome assessment.<B> </B>
</P>
<P>
<B>A) PROTECTING AGAINST SELECTION BIAS</B>
</P>
<P>
<B>1) Randomization method </B>
</P>
<P>We considered the method:<BR/>Adequate if the method allows each study participant to have the same chance of receiving each intervention and provides some assurance that allocations were not know until the point of allocation. Partially adequate if the method allow each study participant to have the same chance of receiving each intervention but not provides assurance that allocations were not know prior the point of allocation (e.g. flip coin, open random number list, serially numbered envelopes not defined sealed and opaque).<BR/>Inadequate for quasi-randomization methods like alternation date of birth, date of admission, hospital numbers or similar others considered like inappropriate randomization methods (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>).</P>
<P>
<B>2) Allocation concealment </B>
</P>
<P>A) Adequate allocation concealment for central randomization (e.g. allocation by a central office unaware of subject characteristics), pre-numbered or coded identical bottles or containers which are administered serially to participants, drug prepared by the pharmacy, serially numbered, opaque, sealed envelopes, on-site computer system combined with allocations kept in a locked unreadable; computer file that can be accessed only after the characteristics of an enrolled participant have been entered or other description that contained elements convincing of concealment.<BR/>B) Unclear allocation concealment: when the authors either did not report an allocation concealment approach at all or report an approach that did not fall in the category A or C.<BR/>C) Inadequate allocation concealment: alternation or reference to case numbers dates of birth, day of the week. Any procedure that is entirely transparent before allocation, such as an open list of random numbers or other description that contained elements convincing of not concealment<BR/>D) Allocation concealment not used</P>
<P>
<B>
<BR/>B) PROTECTION AGAINST PERFORMANCE BIAS</B>
</P>
<P>Blinded of patients and people administering the treatment:</P>
<P>Adequate: study described adequately methods of blinding patients and people administering the treatment were appropriate. We considered that the method of blinding was appropriate if is stated that neither the person administering the treatment nor the study participant could identify the intervention being assessed, or if in the absence of such a statement the use of active placebos, identical placebos, or dummies is mentioned (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>).<BR/>Partially adequate: study described as single blind or double blind when the method of blinding used was partially reported or inappropriate.<BR/>Inadequate: open-label study or when method of blinding was not reported.</P>
<P>
<B>C) PROTECTION AGAINST ATTRITION BIAS</B>
</P>
<P>
<B>Losses to follow up</B>·<BR/>· Adequate: studies with less than 10 percent and differences in exclusion between groups were less than 5 percent (with adequate reporting of withdrawals and dropouts).<BR/>· Unclear: Not reported / unclear<BR/>· Inadequate: exclusions of 10 percent or more or wide differences in exclusion between groups (more than 5 percent).</P>
<P> <B>Intention to treat analysis</B>
<BR/>· Adequate: Intention-to-treat<BR/>· Unclear: Not reported / unclear methods<BR/>· Inadequate: Not intention-to-treat<BR/>
<B>
<BR/>D) PROTECTION AGAINST DETECTION BIAS</B>
</P>
<P>
<B>Masking outcome assessment<BR/>
</B>· Adequate: Blinded, standardized assessment<BR/>· Unclear: Assessment procedures not stated<BR/>· Inadequate: Assessment not blinded or not standardized</P>
<P>On these criteria, studies were subdivided into the following three categories based on The Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (section 6.7): <B>
<BR/>
</B>
<BR/>A - Low Risk of Bias - When all quality criteria met, i.e. all criteria are "adequate". Plausible bias unlikely to seriously alter the results.</P>
<P>B - Moderate Risk of Bias - One or more of the quality criteria partially met, i.e. at least one criterion is "partially adequate", but none is "inadequate". Plausible bias that raises some doubt about the results.</P>
<P>C - High Risk of Bias - One or more criteria not met, i.e. at least one criterion is "inadequate". Plausible bias that seriously weakens confidence in the results.</P>
<P>· Each study report was assessed independently by two reviewers. In cases of disagreement a judgment was made based on consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-10 12:45:14 +0100" MODIFIED_BY="Liliana Coco">
<P>Data was processed according to intention to treat analysis. If data were reported separately, we considered patients who received more than one dose of treatment.</P>
<P>We calculated a weighted estimate of the Risk Ratio for each dichotomous data (95% confidence intervals). Where possible we planned to calculate the number need to treat/harm.</P>
<P>Continuous outcomes were estimated according to their weighted or standardized mean difference.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2008-11-10 12:45:33 +0100" MODIFIED_BY="Liliana Coco">
<P>We also addressed the effect of withdrawn and lost to follow-up to imputing missing data by contact with the authors. If we were unable to contact the authors to obtain any items of missing data, we used different approaches to include missing data. The best case scenario (with regards to treatment) assumed that none of the patients excluded from the analysis in the treatment group had an outcome of interest whilst all those excluded from the control group did and vice versa for the worst case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-10 12:46:44 +0100" MODIFIED_BY="Liliana Coco">
<P>Heterogeneity among trials were examined using the I-squared statistic (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). The I-squared estimate greater than the 50% was interpreted as indicating moderate or high levels of heterogeneity and its causes were investigated.</P>
<P>If there is no statistically significant heterogeneity, the fixed effect model was used and if there was a moderate level of heterogeneity a random effect model was applied.</P>
<P>If heterogeneity persisted, we planned to present results separately and to report its reasons.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-10 12:47:52 +0100" MODIFIED_BY="Liliana Coco">
<P>Publication bias was investigated through a funnel-plot in an attempt to investigate the likelihood of overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-06-16 18:37:46 +0200" MODIFIED_BY="[Empty name]">
<P>Review Manager Software 5.0 developed by the Cochrane Collaboration was used for data organizing and analysis.</P>
<P>Data was entered so that the area to the left of the line of no effect indicates a favourable outcome for interferon.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-10 16:07:15 +0100" MODIFIED_BY="Liliana Coco">
<P>Subgroups analyses was planned whenever possible since potentially sources of heterogeneity were: disability score at inclusion (EDSS less than 6 versus 6 or more), age (18 to 50 vs. older than 50 years), time since the beginning of the disease (one to three years vs. more than three years), dose (less than 60 µg per week vs. 60 µg per week) and route of administration of ß-interferon (intramuscular vs. subcutaneous).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-10 12:54:36 +0100" MODIFIED_BY="Liliana Coco">
<P>Sensitivity analysis was planned to address the methodological quality of the trial by including or excluding trials with moderate or high risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco">
<STUDY_DESCRIPTION MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco">
<P>The search strategy identified 1777 potential articles. Two reviewers (JIR and MR) reviewed titles and abstracts and excluded 1766 articles, as they were not randomized controlled trials of ß-interferon in PPMS (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the flow diagram of trial selection). Of the remaining 11 articles, we excluded 9 because they did not include patients with PPMS (<A HREF="file:///f:\rs%20cochrane\prisms%201998">PRISMS 1998</A>; <A HREF="file:///f:\rs%20cochrane\spectrims%202001">SPECTRIMS 2001</A>; <A HREF="file:///f:\rs%20cochrane\panitch%202004">Panitch 2004</A>; <A HREF="file:///f:\rs%20cochrane\jacobs%201996">Jacobs 1996</A>; <A HREF="file:///f:\rs%20cochrane\ifnb%20ms%20group%201993">IFNB MS group 1993</A>; <A HREF="file:///f:\rs%20cochrane\esg%20in%20spms%201998">ESG in SPMS 1998</A>; <A HREF="file:///f:\rs%20cochrane\ebers%201999">Ebers 1999</A>; <A HREF="file:///f:\rs%20cochrane\cohen%202002">Cohen 2002</A>; <A HREF="file:///f:\rs%2! 0cochrane\andersen%202004">Andersen 2004</A>). Two studies (123 patients) were included and are the subject of this review (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>; <A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>).</P>
<P>One of the studies (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>) was a double blind placebo controlled trial that evaluated two doses of ß-interferon 1a (30µg and 60µg) vs. placebo in patients with PPMS. The study period lasted 24 months. This trial included 50 patients at a single centre (The National Hospital, London, UK). Inclusion criteria were as follows: 1) PPMS of at least 2 year's duration, 2) aged 18 to 60 years and 3) EDSS score of 2.0 to 7.0 inclusive. Exclusion criteria were: 1) interferon, immunosuppressant or chronic steroid therapy within the previous 3 months; 2) pregnancy or lactation; 3) seizure within the previous 3 months; and 4) history of severe depression. Twenty patients received placebo, 15 patients received intramuscular ß-interferon 1a 30µg once a week, and 15 received intramuscular ß-interferon 1a 60 µg once a week. The primary clinical endpoint was time to sustained progression in disability, defined as a 1.0 point increase in EDSS score for subjects with a baseline EDSS score &lt;5.0, or a 0.5 point increase for subjects with a baseline &gt;5.5 point. Progression was considered sustained if documented at two consecutive visits 3 months apart; the time of the first visit was recorded as the time of progression. Data was obtained from contact with the first author as the full outcome was not reported in tables or the text.<BR/>Secondary outcomes of the trial included the timed 10-meter walk (TTMW) and the nine-hold peg test (NHPT). Secondary outcome measures also included the following on magnetic resonance: 1)T2-weighted brain lesion load; 2) new T2 brain lesions; 3) new T2 spinal cord lesions; 4) T1 weighted brain lesion load; 5) new T1 brain lesions; 6) spinal cord cross-sectional area; 7) whole brain volume; and 8) ventricular volume. T2 and T1 weighted imaging were performed at baseline and at 6, 12, 18 and 24 months; spinal cord area and brain volumes were performed at baseline, at 12 and 24 months. Finally, safety evaluations such as adverse events, physical examination findings, and hematological and biochemical parameters were monitored throughout the study.</P>
<P>The second study (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>) was also a randomized double blind placebo controlled trial designed to establish the evolution of primary progressive and transitional MS in outpatients treated with 8 MIU of ß-interferon 1b or placebo injected subcutaneously every other day over a two years period. A total of 73 patients were enrolled and received interferon (n=36) or placebo (n=37), with 49 having diagnosis of PPMS and 24 having a diagnosis of transitional MS, defined as progressive disease with history of a single episode of relapse prior to, at the onset of, or during the progressive phase. Patients with transitional MS were equally stratified in both groups of treatment. Inclusion criteria were age 18-65 years and EDSS score of 3.0 -7.0. Exclusion criteria included previous immunosuppressive or immunomodulatory therapy. The primary outcome measure was sustained progression defined as &gt;/= 1 and &gt;/= 0.5 point increases on the EDSS for six months in those whose baseline EDSS scores of &lt;/=5.0 and &gt;/=5.5 respectively. Additional clinical outcome measures included the proportion of patients with confirmed progression, changes in MS functional composite (MSFC) score, changes on the Beck depression scale, changes in spasticity (Ashworth scale), and changes on the Krupp fatigue scale. Magnetic resonance imaging (MRI) outcome measures included T2 weighted lesion load, T1 weighted lesion load, new MS lesions, brain volume and spinal cord cross-sectional area. Clinical outcomes and safety parameters were assessed every 3 months and MRI outcomes were assessed at 12 and 24 months. Some of the outcomes were reported for patients with PPMS and transitional MS separately, and some outcomes were reported for both types of patients together.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco">
<P>The assessment of the quality of the trials is reported in Characteristics of included studies table and Risk of bias table (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The authors of both trials responded to our request for further information regarding methodological quality (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>, <A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>). Both studies met methodological standards set by our protocol, having an adequate randomization method, adequate allocation concealment, adequate blinding of patients, of those administering the treatment and of the evaluating neurologist, adequate losses to follow up with less than 10 percent, and intention to treat analysis (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>;<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>
<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-09-15 12:08:42 +0200" MODIFIED_BY="Liliana Coco">
<UL>
<LI>
<B>Primary outcome measure</B>
</LI>
</UL>
<P>
<B>1- The proportion of patients with progression of disease and worsened the physical disability during the study.</B>
</P>
<P>The information was available from both trials (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>, <A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>). From the first trial (<LINK REF="STD-Montalban-2004" TYPE="STUDY">Montalban 2004</LINK>) we obtained the information of both populations unified, without being able to stratify for patients with PPMS and transitional MS. From the second trial (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>), data was obtained through contact with the first author because it was not reported in tables or in the text of the published article. A non significant trend in favour of beta-1b interferon was observed (23/66 interferon versus 21/57 placebo had sustained progression of disease during the study (RR 0.89, P = 0.32, 95% CI 0.55 to 1.43).</P>
<UL>
<LI>
<B>Secondary outcome measures</B>
</LI>
</UL>
<P>
<B>1- Patients with severe adverse events.</B>
</P>
<P>Regarding this outcome, only a descriptive analysis was possible. The information for this outcome was fully available from one trial (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). In that trial, there were no differences in the frequency of serious adverse events between ß-interferon arm compared to placebo arm in patients with PPMS and transitional MS (RR 0.80, 95% CI 0.33 to 1.92). The second trial (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>) reported that there were no significant differences in serious adverse events between patients under ß-interferon treatment compared with patients in placebo arm; however, data was not shown in the published article.</P>
<P>
<B>2- Patients with any related adverse events</B>.</P>
<P>Data concerning the number of participants with any related adverse event (attributed to ß-interferon during the study, according the authors) were reported in both trials (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>, <A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). When we gathered all the information, there was not heterogeneity between these two trials (I-squared = 0%), and we observed a significant high frequency of related adverse events in participants under ß-interferon arm compared with participants under placebo arm (RR 1.90, 95% CI 1.45 to 2.48). As regards to the type of adverse event described, flu-like reactions was the most common in both groups. The frequency of that reaction was significantly higher on interferon arm compared with placebo arm (RR 2.48, 95% CI 1.60 to 3.83). Also, the frequency of injection site reaction was higher in the interferon arm compared to placebo arm (RR 10.80, 95% CI 3.34 to 35.03). There was no difference in the frequency of fatigue/malaise between the groups (RR1.62, 95% CI 0.68 to 3.85). Concerning hematological parameters, there were no differences in the frequency of anaemia between the groups (RR 2.51, 95% CI 0.27-23.20) but significant differences were found in the frequency of leucopenia between the groups, being more frequent on interferon arm (RR 4.10, 95% CI 1.34 to 12.57).</P>
<P>
<B>3 - Mean EDSS change at one year, two years, and three years.</B>
</P>
<P>The information for this outcome was available from one trial (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). Again, for this outcome we obtained the information of both populations unified (PPMS and transitional MS patients), without being able to stratify them. The effect of the treatment on EDSS change at one year was not statistically significant (weighted mean difference -0.10, 95% CI -0.47 to 0.27, P = 0.60). Also, there was no statistically significant difference over the EDSS change at two years (mean difference -0.10, 95 % CI -0.51 to 0.31, P = 0.64). No data were available for the mean EDSS change at three years.</P>
<P>
<B>4 - Quality of life assessments</B>.</P>
<P>No data were available for this outcome.</P>
<P>
<B>5 - Change on MRI markers</B>
</P>
<P>
<B>a) Number of "active" lesions on MRI scan</B>.</P>
<P>Only one trial reported the outcome prespecified in the protocol at 1 and 2 years (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). For this outcome, we obtained the information of both populations unified (PPMS and transitional MS patients), without being able to stratify them. At one year, the effect of the treatment on the number of active lesion on MRI was not statistically significant (weighted mean difference -1.20, 95% CI -2.99 to 0.59, P = 0.19). However, at two years the effect of the treatment was statistically significant (weighted mean difference -1.3, 95% CI -2.15 to -0.45, P = 0.003).</P>
<P>
<B>b) Number of participants with "active" lesions on MRI scan</B>.</P>
<P>Only one trial (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>) reported this outcome at one year. There was no difference in the proportion of participants with active lesions on MRI scan (11/36 interferon versus 14/37 placebo, RR 0.81, 95% CI 0.42 to 1.54, P = 0.51). At two years evaluation, the proportion of patients with active lesions in placebo arm was significantly higher than the interferon arm (8/36 interferon versus 19/37 placebo, RR 0.43, 95% CI 0.22 to 0.86, P = 0.02). For this outcome, we only obtained the aggregated information of both populations (PPMS and transitional MS patients)</P>
<P>
<B>c) Changes of total area or volume on brain MRI scans</B>.</P>
<P>Regarding this outcome, only descriptive analysis was possible. One of the studies included (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>) evaluated the brain/ventricular volume. In this trial, the change in brain volume was measured from the registered scans by integrating the shifts in brain-CSF (central system fluid) boundaries. The resulting brain boundary shift integral (BBSI) was a direct measure of change in cerebral volume. The analysis was performed in the placebo arm, in beta-interferon 30µg and 60 µg at 12 and 24 months. No significant treatment effect was reported by investigators on BBSI at those periods of time.</P>
<P>
<B>6 - Spasticity</B>
</P>
<P>A retrospective analysis of the study (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>) found no significant increase in spasticity in patients with PPMS treated with interferon beta-1a. There were no statistically significant differences in sustained increase in spasticity (RR 0.56, 95% CI 0.32 to 1.00); post-dose spasticity, (RR 2.22, 95% CI 0.70 to 7.09); nor increase in anti-spasticity medication (RR 0.44, 95% CI 0.14 to 1.38). In <A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>, there were no differences in spasticity evaluation at 2 years of follow up in patients under interferon treatment vs. placebo, as evaluated by Ashworth scale (mean difference 0.15, 95% CI -0.3 to 0.6).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-09-15 12:16:35 +0200" MODIFIED_BY="Liliana Coco">
<P>To date, there is no proven or licensed disease-modifying treatment to slow the course of primary progressive MS (<LINK REF="REF-Leary-2005" TYPE="REFERENCE">Leary 2005</LINK>).<BR/>Our systematic review planned to evaluate the benefit of ß-interferon therapy in patients with PPMS was only able to answer a limited extent of previously defined aims. The difficulties that we encountered were mostly related to the small number of ß-interferon RCTs available in PPMS patients (only two studies met our inclusions criteria). Both of the trials (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>, <A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>) evaluated the primary outcome settled in the protocol of our review. One of the trials (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>) included patients with PPMS and transitional MS. The authors reported a non statistically significant difference (RR 0.69, 95% CI 0.32 to 1.48) between the ß-interferon1b group and placebo group with regard to the proportion of patients with progression of disease confirmed at 6 months. Progression was less frequent in the ß-interferon 1b group (27.8%) than the placebo group (37.8%) but the results were not statistically significant.</P>
<P>Primary outcome data from <A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A> was obtained from information by the authors because it was not reported in tables or the text. A non statistically significant trend favouring placebo (RR 1.11, 95% CI 0.61 to 2.03) was inversely related to the one found in the <A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A> study, but with overlapping confidence intervals between studies.</P>
<P>Considering both studies, ß-interferon treatment compared to placebo did not show differences regarding the proportion of patients with progression of disease (RR 0.89, 95% CI 0.55 to1.43; I² = 0%).</P>
<P>As regards to secondary outcome, ß-interferon therapy was associated with a greater frequency of treatment-related adverse events, mainly flu-like reactions and injection site reactions. Treatment with ß-interferon was associated with the side effect profile reported by the randomised controlled trials with this drug for relapsing-remitting MS. There was no suggestion of a sustained increase in spasticity or increased requirements for anti-spasticity medication (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>). The effect of the treatment on EDSS change at one and two years was not statistically significant between the groups (<A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). There was a significant effect of the treatment over the number of active lesions on MRI scans at two years as well as the number of participants with active lesions at two years. Those outcomes were obtained from only one trial (<A HREF="file:///f:\rs%20cochrane! ! \montalban%202004">Montalban 2004</A>) and this result is of questionable clinical importance.</P>
<P>
<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-03 01:07:01 +0200" MODIFIED_BY="[Empty name]">
<P>There is limited data on the effect of ß-interferon treatment on primary progressive MS. Only two small single-centre placebo controlled trials of interferon beta have been done for PPMS (<A HREF="file:///f:\rs%20cochrane\leary%202003">Leary 2003</A>; <A HREF="file:///f:\rs%20cochrane\montalban%202004">Montalban 2004</A>). Based on this review and the results evaluated, the included studies showed that ß-interferon treatment in patients with PPMS was not associated with reduced disability progression as measured by the EDSS. However, the trial population was too small to allow definitive conclusions on the efficacy of ß-interferon therapy in PPMS patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-03 01:07:17 +0200" MODIFIED_BY="[Empty name]">
<P>Due to scarce data provided by these trials, it was impossible to conduct all of the attempted analyses. There is a need for effective disease-modifying treatment for PPMS. Future trials need to be performed on the use of ß-interferon in PPMS. Such trials should include standard outcome measures and include, if possible, more sensitive and reproducible clinical scales, such as the MS functional composite scales, the MS impact scale and the quality of life scales.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-03 12:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>Authors wish to thank to:</P>
<P>Ms. Liliana Coco and Ms. Deirdre Beecher (Cochrane Multiple Sclerosis Review Group, Neuroepidemiology Unit, Fondazione I.R.C.S.S. Istituto Nazionale Neurologico C. Besta) for their invaluable help.</P>
<P>Dr. Graziella Filippini for her comments on the protocol and review, and for assisting us during the whole process.</P>
<P>Dr. Silvana Simi (MSCRG Consumer Co-ordinator) for writing the Plain Language Summary.</P>
<P>Ms. Virginia Garrote (Italian Hospital of Buenos Aires, Argentina), for her useful help.</P>
<P>Dr. Xavier Montalban (University Hospital Vall d'Hebron, Unitat de Neuroimmunología Clínica, Barcelona, Spain), Dr Jaume Garriga-Sastre (University Hospital Vall d'Hebron, Unitat de Neuroimmunología Clínica, Barcelona, Spain) for all the information and help they gave to reviewers about their trial.</P>
<P>Dr. Siobhan Leary (Institute of Neurology, University College London, Queen Sqaure, London, UK.) and Dr Alan Thompson (Institute of Neurology, University College London, Queen Sqaure, London, UK.) for all the information and help they gave to reviewers about their trial.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Liliana Patrucco has participated in clinical trials sponsored by SERONO and TEVA TUTEUR.<BR/>Dr Edgardo Cristiano has participated in clinical trials sponsored by SERONO and TEVA TUTEUR<BR/>Dr Juan Ignacio Rojas has no conflict of interest<BR/>Dr Marina Romano has no conflict of interest.<BR/>Dr Agustín Ciapponi has no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-27 22:43:28 +0200" MODIFIED_BY="[Empty name]">
<P>Dr Agustín Ciapponi contributed with methodological aspects of the Review.<BR/>Dra Marina Romano contributed with methodological aspects of the Review.<BR/>Dra Liliana Patrucco contributes with the clinical aspects of the disease, patients, outcomes to evaluate, ways of evaluation in the Review because she is one of the multiple sclerosis expert in the group.<BR/>Dr Edgardo Cristiano contributes with the clinical aspects of the disease, patients, outcomes to evaluate, ways of evaluation in the Review because he is the principal multiple sclerosis expert in the reviewers group.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-09-21 09:57:30 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-12 14:35:41 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-12 14:32:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Leary-2003" MODIFIED="2008-06-03 01:07:50 +0200" MODIFIED_BY="[Empty name]" NAME="Leary 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ</AU>
<TI>Interferon beta-1a in primary progressive MS</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60(1)</VL>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-05-03 12:45:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Leary SM, Thompson AJ</AU>
<TI>The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>3</NO>
<PG>508-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-05-01 21:21:05 +0200" MODIFIED_BY="[Empty name]" NOTES="Clinical Trial" NOTES_MODIFIED="2008-05-01 21:21:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Miller DH, Leary SM, Thompson AJ</AU>
<TI>Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis</TI>
<SO>Multiple sclerosis (Houndmills, Basingstoke, England)</SO>
<YR>2004</YR>
<VL>10 Suppl 1</VL>
<PG>S56-7</PG>
<IDENTIFIERS MODIFIED="2008-05-01 21:20:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1352-4585" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Montalban-2004" MODIFIED="2008-11-12 14:32:26 +0100" MODIFIED_BY="[Empty name]" NAME="Montalban 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-12 14:32:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montalban X.</AU>
<TI>Overview of European pilot study of interferon B-1b in primary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2004</YR>
<VL>10 suppl.1</VL>
<PG>S62-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-12 14:35:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-2004" MODIFIED="2008-11-12 14:32:52 +0100" MODIFIED_BY="[Empty name]" NAME="Andersen 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-12 14:32:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr K-M, et al</AU>
<TI>Multicentre randomised double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>5</NO>
<PG>706-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2002" MODIFIED="2008-11-12 14:33:17 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-12 14:33:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al</AU>
<TI>Benefit of Interferon beta-1a on MSFC progression in secondary progressive MS.</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>5</NO>
<PG>679-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebers-1999" MODIFIED="2008-11-12 14:33:29 +0100" MODIFIED_BY="[Empty name]" NAME="Ebers 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-12 14:33:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebers G, Lee D, Rice G, Lesaux J, Kennedy K, Sanders EA, et al.</AU>
<TI>Evidence of interferon (beta)-1a dose response in relapsing-remitting MS: The OWIMS Study</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>4</NO>
<PG>679-86</PG>
<IDENTIFIERS MODIFIED="2008-05-06 00:34:42 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESG-in-SPMS-1998" MODIFIED="2008-11-12 14:33:35 +0100" MODIFIED_BY="[Empty name]" NAME="ESG in SPMS 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-12 14:33:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Study Group on Interferon B-1b in Secondary Progressive MS</AU>
<TI>Placebo controlled multicentre randomised trial of interferon B-1b in treatment of secondary progressive multiple sclerosis</TI>
<SO>The Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>7</NO>
<PG>1491-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IFNB-MS-group-1993" MODIFIED="2008-11-12 14:33:45 +0100" MODIFIED_BY="[Empty name]" NAME="IFNB MS group 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-11-12 14:33:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The IFNB Multiple Sclerosis Study Group</AU>
<TI>Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>665-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1996" MODIFIED="2008-11-12 14:34:01 +0100" MODIFIED_BY="[Empty name]" NAME="Jacobs 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-12 14:34:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs LD, Cookfair DL, Rudick R, Herndon RM, Richert JR, Salazar AM, et al.</AU>
<TI>Intramuscular Interferon beta-1a for Disease Progression in Relapsing Multiple Sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>3</NO>
<PG>285-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panitch-2004" MODIFIED="2008-11-12 14:34:16 +0100" MODIFIED_BY="[Empty name]" NAME="Panitch 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-12 14:34:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panitch H, Miller A, Paty D, Weinshenker B.</AU>
<TI>Interferon beta-1-b in Secondary Progressive MS. Results from a 3-year controlled study. The North American Study Group on Interferon beta-1-b in Secondary Progressive MS</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRISMS-1998" MODIFIED="2008-11-12 14:35:33 +0100" MODIFIED_BY="[Empty name]" NAME="PRISMS 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-12 14:35:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>PRISMS (Prevention of Relapses and disability by Interferon B-1a subcutaneously in Multiple Sclerosis) Study group</AU>
<TI>Randomized double-blind placebo-controlled study of Interferon B-1a in relapsing/remitting multiple sclerosis</TI>
<SO>The Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPECTRIMS-2001" MODIFIED="2008-11-12 14:35:41 +0100" MODIFIED_BY="[Empty name]" NAME="SPECTRIMS 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-12 14:35:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group</AU>
<TI>Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>11</NO>
<PG>1496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-09-21 09:57:30 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-09-21 09:57:30 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bramanti-1998" MODIFIED="2008-05-03 12:55:23 +0200" MODIFIED_BY="[Empty name]" NAME="Bramanti 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bramanti P, Sessa E, Rifici C, D'Aleo G, Floridia D, Di Bella P, et al</AU>
<TI>Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>6</NO>
<PG>1720-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clerico-2008" MODIFIED="2008-11-12 14:36:41 +0100" MODIFIED_BY="[Empty name]" NAME="Clerico 2008" TYPE="OTHER">
<AU>Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L</AU>
<TI>Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005278.pub3"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD005278"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Confavreux-2006" NAME="Confavreux 2006" TYPE="JOURNAL_ARTICLE">
<AU>Confavreux C, Vukusic S</AU>
<TI>Natural history of multiple sclerosis: a unifying concept</TI>
<SO>Brain</SO>
<YR>2006</YR>
<VL>129</VL>
<PG>606-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-06-11 12:14:13 +0200" MODIFIED_BY="Liliana Coco" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in Meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315(7109)</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESG-1998" MODIFIED="2008-11-12 14:37:09 +0100" MODIFIED_BY="[Empty name]" NAME="ESG 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, et al</AU>
<TI>Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS</TI>
<SO>The Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1491-7</PG>
<IDENTIFIERS MODIFIED="2008-05-06 00:35:29 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S, editor</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [Updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<VL>Issue 3,</VL>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IFNB-MSSG-1993" NAME="IFNB MSSG 1993" TYPE="JOURNAL_ARTICLE">
<AU>The IFNB Multiple Sclerosis Group</AU>
<TI>Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>655-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-11-12 14:37:44 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et. al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS MODIFIED="2008-11-12 14:37:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kremenchutzky-2006" NAME="Kremenchutzky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC</AU>
<TI>The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease</TI>
<SO>Brain</SO>
<YR>2006</YR>
<VL>129</VL>
<PG>584-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" MODIFIED="2008-05-04 01:22:04 +0200" MODIFIED_BY="[Empty name]" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leary-2005" NAME="Leary 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leary SM, Thompson AJ</AU>
<TI>Primary progressive multiple sclerosis: current and future treatment options</TI>
<SO>CNS Drugs</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-09-21 09:57:30 +0200" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lublin-1996" NAME="Lublin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lublin FD, Reingold SC</AU>
<TI>Defining the clinical course of multiple sclerosis: results of an international survey. Natinal Multiple Sclerosis Society (USA) Advisory Committe on Cinical Tials of new agents in Multiple Sclerosis</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>4</NO>
<PG>907-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2001" MODIFIED="2008-11-12 14:38:07 +0100" MODIFIED_BY="[Empty name]" NAME="McDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et. al</AU>
<TI>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>121-7</PG>
<IDENTIFIERS MODIFIED="2008-11-12 14:38:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2007" MODIFIED="2008-05-01 21:35:17 +0200" MODIFIED_BY="[Empty name]" NAME="Miller 2007" TYPE="OTHER">
<AU>Miller DH, Leary SM</AU>
<TI>Primary-progressive multiple sclerosis</TI>
<SO>Lancet neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>10</NO>
<PG>903-12</PG>
<IDENTIFIERS MODIFIED="2008-05-01 21:35:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1474-4422" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Montalban-2005" MODIFIED="2008-05-01 21:32:52 +0200" MODIFIED_BY="[Empty name]" NAME="Montalban 2005" TYPE="OTHER">
<AU>Montalban X</AU>
<TI>Primary progressive multiple sclerosis</TI>
<SO>Current opinion in neurology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>261-6</PG>
<IDENTIFIERS MODIFIED="2008-05-01 21:32:49 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1350-7540" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MSCRG-1996" NAME="MSCRG 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et. al</AU>
<TI>Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)</TI>
<SO>Annals of neurology</SO>
<YR>1996</YR>
<VL>39(3)</VL>
<PG>285-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NASG-2004" NAME="NASG 2004" TYPE="JOURNAL_ARTICLE">
<AU>Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS</AU>
<TI>Interferon beta-1b in Secondary Progressive MS: Results from a 3 year controlled study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>1788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" MODIFIED="2008-11-12 14:38:32 +0100" MODIFIED_BY="[Empty name]" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, et al</AU>
<TI>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rice-2001" MODIFIED="2008-11-11 11:46:03 +0100" MODIFIED_BY="[Empty name]" NAME="Rice 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rice G</AU>
<TI>The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta</TI>
<SO>Archives of neurology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>8</NO>
<PG>1297-8</PG>
<IDENTIFIERS MODIFIED="2008-11-11 11:45:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11493173"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stevenson-1999" NAME="Stevenson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et. al</AU>
<TI>Primary and transitional MS: a clinical and MRI cross-sectional study</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52(4)</VL>
<PG>839-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1997" NAME="Thompson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et. al</AU>
<TI>Primary progressive multiple sclerosis</TI>
<SO>Brain</SO>
<YR>1997</YR>
<VL>120(6)</VL>
<PG>1085-1096</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2000" NAME="Thompson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, et. al</AU>
<TI>Diagnostic criteria for PPMS: a position paper</TI>
<SO>Annals of neurology</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>831-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Lambalgen-1986" NAME="van Lambalgen 1986" TYPE="JOURNAL_ARTICLE">
<AU>van Lambalgen R, Sanders EA, D'Amaro J</AU>
<TI>Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?</TI>
<SO>Journal of neurological sciences</SO>
<YR>1986</YR>
<VL>76</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vickrey-1995" MODIFIED="2008-11-12 14:39:30 +0100" MODIFIED_BY="[Empty name]" NAME="Vickrey 1995" TYPE="JOURNAL_ARTICLE">
<AU>Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW</AU>
<TI>A health-related quality of life measure for multiple sclerosis</TI>
<SO>Quality of life research</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>187-206</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2008-05-03 16:02:28 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-09-15 12:10:56 +0200" MODIFIED_BY="Liliana Coco">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-09-15 12:10:56 +0200" MODIFIED_BY="Liliana Coco" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-09-15 12:10:32 +0200" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Leary-2003">
<CHAR_METHODS MODIFIED="2009-09-15 12:09:12 +0200" MODIFIED_BY="Liliana Coco">
<P>Double blind placebo controlled trial of two doses of interferon B-1a (Avonex, Biogen, Cambridge, MA). Study period of 24 months long. Individuals subjects were randomized to IM interferon ß-1a 30µg, 60µg or placebo once a week. The randomization was carried out off-site by Biogen using a randomization block method. The study drug was blinded off-site by Biogen and delivered to the study centre with the study numbers already allocated. Subjects were allocated study numbers consecutively as they were entered into the study. All personnel at the study site (dispensing pharmacists, treating physicians and EDSS physicians) were blinded to the study drug. A copy of the randomization codes was kept in pharmacy and by Biogen, but no codes were broken until the study and analysis was completed. EDSS and clinical assessments were performed by an independent evaluating physician blinded to all clinical and treatment information. A questionnaire to test blinding was given to all subjects and the treating physician at the end of the study. Fifty-eight percent (28/48) of the patients correctly identified whether they received placebo or ß-interferon 1a. The treating physician correctly identified placebo vs. ß-interferon in 86% (43/50). Analysis was carried out on an intention to treat basis. 49 subjects completed 24 months of follow up. Forty-three completed 24 months on study drug; 7 patients had their dose reduced (2 in interferon 30µg arm, 5 in 60µg interferon arm). Withdrawals 7 patients (2 in placebo arm; 1 in interferon 30µg arm; 2 in 60µg arm). Lost to follow up 1 patient (interferon 60µg arm). Source of funding: Biogen, Multiple Sclerosis Society of Great Britain and Northern Ireland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Fifty subjects with PPMS were enrolled at a single center (The National Hospital, London, UK). Inclusion criteria were as follows: 1-PPMS of at least 2 year´s duration, 2-aged 18 to 60 years and 3-EDSS score of 2.0 to 7.0 inclusive. Exclusion criteria: 1-interferon, immunosuppressant or chronic steroid therapy within the previous 3 months, 2-pregnancy or lactation, 3-seizure within the previous 3 moths and 4-history of severe depression. Baseline characteristics: 50 patients, 32 males. Mean age of the cohort 45 years. Placebo arm, 20 patients, 15 males, mean age 43 years, range 30-59, mean disease duration 8 years, median EDSS 4.5. IM interferon B-1a 30µg once a week arm, 15 patients, 10 males, mean age 46.5 years, range 29-58, mean disease duration 8 years, median EDSS 5.5. IM interferon B-1a 60 µg once a week arm 15 patients, 7 males, mean age 47 years, range 25-59, mean disease duration 8 years, median EDSS 5.5.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 00:32:57 +0200" MODIFIED_BY="[Empty name]">
<P>Individual subjects were randomized to IM interferon B-1a 30µg, 60 µg, or placebo once a week. The study period was 24 months. Nonsteroidal anti-inflammatory drugs or paracetamol were recommended for prophylaxis of interferon associated flu like reactions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-15 12:10:32 +0200" MODIFIED_BY="Liliana Coco">
<P>Primary outcome: The primary clinical endpoint was time to sustained progression in disability defined as a &gt;/= 1.0 point increase in EDSS score for subjects with a baseline EDSS score &lt;/= 5.0, or a &gt;/=0.5 point increase for subjects with a baseline &gt;/=5.5 point. Progression was considered sustained if documented at two consecutive visits 3 month apart; the time of the first visit was recorded as the time of progression.<BR/>Secondary outcomes: secondary clinic outcome measure included the timed 10-meter walk (TTMW) and nine-hold peg test (NHPT). The time to walk 10 meters, with assistance as required, was recorded on one attempt. The time to perform the NHPT was recorded on two consecutive trials for both right and left arms. If a subject was unable to complete the TTMW or NHPT, a time of 300 seconds was recorded.<BR/>Also secondary outcome measure included the following on magnetic resonance: 1)T2-weighted brain lesion load, 2)new T2 brain lesion, 3) new T2 spinal cord lesion, 4) T1 weighted brain lesion load, 5) new T1 brain lesions, 6)spinal cord cross-sectional area, 7) whole brain volume and 8) ventricular volume. T2 and T1 weighted imaging were performed at baseline and at 6, 12, 18 and 24 months; spinal cord area, brain volumes, were performed at baseline, at 12 and 24 months.<BR/>Safety evaluations: adverse events, physical examination findings, hematological and biochemical parameters were monitored throughout the study.<BR/>Neutralizing antibodies assay at baseline, and every 3 month were collected. An antibody titter &gt;1/10 was reported as positive.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-15 12:10:56 +0200" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Montalban-2004">
<CHAR_METHODS MODIFIED="2008-05-06 00:26:55 +0200" MODIFIED_BY="[Empty name]">
<P>Double blind placebo controlled trial, randomized and pilot study to establish the evolution of primary progressive and transitional MS in outpatients treated with 8 MIU of interferon beta-1b or placebo injected subcutaneously every other day in two years period. Patients were randomized to one or other group based on a randomization list. This randomization was performed in blocks of 6 and for each treatment was assigned in a 1:1 ratio. Prior to randomization, patients were stratified into PP or transitional forms of MS. SAS program previously prepared, was used for randomization. Subjects and study personnel were blinded to treatment status. EDSS assessments were performed by an independent evaluating physician blinded to all clinical and treatment information. Analysis was carried out on an intention to treat basis. One patient dropped out from the study, four additional patients were withdrew from treatment but remained on-study for observation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-15 12:10:56 +0200" MODIFIED_BY="Liliana Coco">
<P>A total of 73 patients were enrolled and received interferon (n=36) or placebo (n=37), with 49 having diagnosis of PPMS and 24 having a diagnosis of transitional MS, defined as progressive disease with history of a single episode of relapse prior to, at the onset of, or during the progressive phase. Patients with transitional MS were equally stratified in both groups of treatment. Additional inclusion criteria were age 18-65 years and EDSS score of 3.0 -7.0. Exclusion criteria included previous immunosuppressive or immunomodulatory therapy. Eligible patients were randomized to placebo or interferon B-1b 8 MIU given subcutaneously every other day for two years. Baseline characteristics: Placebo arm, 37 patients (25 with PPMS, 12 with TMS), mean age 48.6 years, 40.5% men, 100% Caucasian, mean time disease duration 11.4 years, mean baseline EDSS 5.2; interferon B-1b arm, 36 patients (24 with PPMS, 12 with TMS). mean age 48.8 years, 61.1% men, 100% Caucasian, mean time disease duration 11.3 years, mean baseline EDSS 5.3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Individuals subjects were randomized to subcutaneous interferon B1-b 8 MIU every other day for two years vs. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: the primary outcome measure was sustained progression defined as &gt;/= 1 and &gt;/= 0.5 point increases on the EDSS for six months in those whose baseline scores of &lt;/=5.0 and &gt;/=5.5 respectively. Additional clinical outcomes measures included the proportion of patients with confirmed progression, change in MS functional composite (MSFC) score, change on the Beck depression scale, change in spasticity (Ashworth scale), and change on the Krupp fatigue scale. Magnetic resonance imaging (MRI)outcome measures included T2 weighted lesion load, T1 weighted lesion load, new MS lesions, brain volume and spinal cord cross-sectional area. Clinical outcomes and safety parameters were assessed every 3 months and MRI outcomes were assessed at 12 and 24 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-11 11:22:06 +0100" MODIFIED_BY="Liliana Coco" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:21:54 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Andersen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:21:54 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with secondary progressive MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:21:56 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Cohen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:21:56 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with secondary progressive MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:21:59 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Ebers-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:21:59 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with relapsing-remitting MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:22:00 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-ESG-in-SPMS-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:22:00 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with secondary progressive MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:22:03 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-IFNB-MS-group-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:22:03 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with relapsing-remitting MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:22:04 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Jacobs-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:22:04 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with relapsing-remitting MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panitch-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Include only patients with secondary progressive MS and no patients with PPMS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 00:33:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRISMS-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 00:33:46 +0200" MODIFIED_BY="[Empty name]">
<P>Include only patients with relapsing-remitting MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 11:22:06 +0100" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-SPECTRIMS-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 11:22:06 +0100" MODIFIED_BY="Liliana Coco">
<P>Included only patients with secondary progressive MS and no patients with PPMS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-10 16:07:54 +0100" MODIFIED_BY="Liliana Coco" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-28 14:10:06 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-28 13:55:59 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 13:53:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leary-2003">
<DESCRIPTION>
<P>Central allocation. Patients were randomly allocated using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 13:55:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montalban-2004">
<DESCRIPTION>
<P>Central allocation. Patients were randomly allocated using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-28 13:57:03 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-28 13:54:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leary-2003">
<DESCRIPTION>
<P>Double blind placebo controlled trial. All personnel at the study site (dispensing pharmacists, treating physicians and EDSS physicians) and participants were blinded to the outcome assessment and study drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-28 13:57:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montalban-2004">
<DESCRIPTION>
<P>Double blind placebo controlled trial. All personnel at the study site (dispensing pharmacists, treating physicians and EDSS physicians) and participants were blinded to the outcome assessment and study drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-08-28 13:57:05 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-28 13:54:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leary-2003">
<DESCRIPTION>
<P>7 patients were withdrawn (2 in placebo arm; 1 in interferon 30µg arm; 2 in 60µg arm). Lost to follow up 1 patient (interferon 60µg arm). Missing outcome data balanced across intervention group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-28 13:57:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montalban-2004">
<DESCRIPTION>
<P>7 patients were withdrawn (2 in placebo arm; 1 in interferon 30µg arm; 2 in 60µg arm). Lost to follow up 1 patient (interferon 60µg arm). Missing outcome data balanced across intervention group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-28 13:57:06 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 13:55:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leary-2003">
<DESCRIPTION>
<P>All outcomes listed in methods were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 13:57:06 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Montalban-2004">
<DESCRIPTION>
<P>Not all study pre-specified outcomes were reported. Extra data was obtained by contact with investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-28 14:10:06 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 14:10:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leary-2003">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-28 13:57:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montalban-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-08-23 11:52:02 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-08-23 11:52:02 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2008-05-04 15:47:43 +0200" MODIFIED_BY="Grade Profiler">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Interferon Beta compared to Placebo for Primary Progressive Multiple Sclerosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with Primary Progressive Multiple Sclerosis</P>
<P>
<B>Settings:</B> Tertiary referral hospitals</P>
<P>
<B>Intervention:</B> Interferon Beta</P>
<P>
<B>Comparision: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Interferon Beta</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Patients with progression of the disease</B>
<BR/>(follow-up: 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 0.89 (0.55 to 1.43)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>123<BR/>(2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>368 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>328 per 1000<BR/>(202 to 526)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Patients with severe adverse event</B>
<BR/>(follow-up: 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 0.8 (0.33 to 1.92)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>73<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>243 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>194 per 1000<BR/>(80 to 467)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Patients with any related adverse event</B>
<BR/>(follow-up: 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.9 (1.45 to 2.48)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>123<BR/>(2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>491 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>933 per 1000<BR/>(712 to 1218)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>Mean EDSS change at two years</B>
<BR/>(follow-up: 24 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>The mean Mean EDSS change at two years score ranged across control groups from<BR/>
<B>3-7 EDSS points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>The mean Mean EDSS change at two years score in the intervention groups was on average<BR/>
<B>-0.10 lower</B>
<BR/>(95% CI -0.51 to 0.31)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>73<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Sustained increase in spasticity</B>
<BR/>(follow-up: 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 0.56 (0.32 to 1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>50<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>650 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>364 per 1000<BR/>(208 to 650)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-08-28 13:57:33 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-10 15:51:07 +0100" MODIFIED_BY="Liliana Coco">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-10 15:51:07 +0100" MODIFIED_BY="Liliana Coco" NO="1">
<NAME>Recombinant ß-interferon versus Placebo</NAME>
<DICH_OUTCOME CHI2="0.9692211329465115" CI_END="1.4316169392964195" CI_START="0.5513087814121354" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8884047446138951" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.15582682844347606" LOG_CI_START="-0.25860508989246955" LOG_EFFECT_SIZE="-0.05138913072449671" METHOD="MH" MODIFIED="2008-11-10 15:51:07 +0100" MODIFIED_BY="Liliana Coco" NO="1" P_CHI2="0.32487470621067516" P_Q="0.0" P_Z="0.6269196451217334" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="57" WEIGHT="99.99999999999999" Z="0.4860670279512027">
<NAME>Patients with progression of the disease</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0293042872302793" CI_START="0.6083700256305983" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.30734717288686436" LOG_CI_START="-0.21583219176551408" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2008-05-04 15:49:52 +0200" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="47.71241830065359">
<FOOTNOTE>Data was obtained from Figure 2.A of the paper Leary 2003</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4768345813320483" CI_START="0.31789527678435364" EFFECT_SIZE="0.6851851851851852" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.16933185317387964" LOG_CI_START="-0.49771592468582665" LOG_EFFECT_SIZE="-0.1641920357559735" ORDER="1" O_E="0.0" SE="0.39182716665454487" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.1535285285285285" WEIGHT="52.2875816993464"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.917020248125682" CI_START="0.3333364513720012" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7993827160493827" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.28262670004697854" LOG_CI_START="-0.47711719229769917" LOG_EFFECT_SIZE="-0.09724524612536031" METHOD="MH" MODIFIED="2008-05-03 12:25:54 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6158499998304052" Q="0.0" RANDOM="NO" SCALE="170.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0" Z="0.501740604943146">
<NAME>Patients with severe adverse event</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.917020248125682" CI_START="0.3333364513720012" EFFECT_SIZE="0.7993827160493827" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28262670004697854" LOG_CI_START="-0.47711719229769917" LOG_EFFECT_SIZE="-0.09724524612536031" ORDER="22" O_E="0.0" SE="0.44627732315618407" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.19916344916344914" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4796860543678848" CI_END="2.483510462820291" CI_START="1.449924845894933" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8976046809288716" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3950659939811499" LOG_CI_START="0.16134549198738934" LOG_EFFECT_SIZE="0.27820574298426964" METHOD="MH" MODIFIED="2008-05-03 13:25:37 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4885645959910897" P_Q="0.0" P_Z="3.0707744859997386E-6" Q="0.0" RANDOM="NO" SCALE="137.32" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.0" Z="4.666028284980598">
<NAME>Patients with any related adverse event</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9414601178089637" CI_START="1.4364664053723963" EFFECT_SIZE="2.0555555555555554" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="17" LOG_CI_END="0.46856296432199845" LOG_CI_START="0.1572954736053793" LOG_EFFECT_SIZE="0.31292921896368886" ORDER="23" O_E="0.0" SE="0.18284006484587081" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.033430489312842246" WEIGHT="55.95172792100933"/>
<DICH_DATA CI_END="2.551392583547801" CI_START="1.1286801455027717" EFFECT_SIZE="1.696969696969697" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" LOG_CI_END="0.40677728877467473" LOG_CI_START="0.05257088548195111" LOG_EFFECT_SIZE="0.22967408712831294" ORDER="24" O_E="0.0" SE="0.2080625946441198" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.04329004329004331" WEIGHT="44.04827207899068"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.113952129546472" CI_END="4.742894951695082" CI_START="2.313111248828287" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3122263909305456" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="23" I2="59.301711664758955" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.6760435057599496" LOG_CI_START="0.364196520617735" LOG_EFFECT_SIZE="0.5201200131888423" METHOD="MH" MODIFIED="2008-05-03 12:27:37 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.008524774612087449" P_Q="0.0" P_Z="6.237713743331548E-11" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="330" TOTAL_2="285" WEIGHT="500.0" Z="6.5379275225234865">
<NAME>Patients with specific related adverse event</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.830019211125379" CI_END="3.8306118204439334" CI_START="1.603666074513021" DF="1" EFFECT_SIZE="2.478512098230408" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" I2="82.84739785948375" ID="CMP-001.04.01" LOG_CI_END="0.5832681444704857" LOG_CI_START="0.20511394181970805" LOG_EFFECT_SIZE="0.3941910431450969" MODIFIED="2008-05-02 05:01:32 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01575498662039354" P_Z="4.3856181141735903E-5" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.0" Z="4.086165073279138">
<NAME>Flulike reaction</NAME>
<DICH_DATA CI_END="2.551392583547801" CI_START="1.1286801455027717" EFFECT_SIZE="1.696969696969697" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" LOG_CI_END="0.40677728877467473" LOG_CI_START="0.05257088548195111" LOG_EFFECT_SIZE="0.22967408712831294" ORDER="26" O_E="0.0" SE="0.2080625946441198" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.04329004329004331" WEIGHT="86.99891657638136"/>
<DICH_DATA CI_END="31.32914634946137" CI_START="1.8965854388432557" EFFECT_SIZE="7.708333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.4959485614706225" LOG_CI_START="0.27797241191219313" LOG_EFFECT_SIZE="0.8869604866914078" ORDER="25" O_E="0.0" SE="0.7154452193297973" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.5118618618618618" WEIGHT="13.001083423618633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7433224124226787" CI_END="3.8540295817794266" CI_START="0.6827806683291087" DF="1" EFFECT_SIZE="1.62217659137577" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.5859150437792849" LOG_CI_START="-0.16571878362767076" LOG_EFFECT_SIZE="0.21009813007580708" MODIFIED="2008-05-02 05:01:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3885986958259813" P_Z="0.27320756538812196" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.00000000000001" Z="1.0957057895821434">
<NAME>Fatigue/malaise</NAME>
<DICH_DATA CI_END="3.3201025058033937" CI_START="0.5354587018534216" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.5211514924442603" LOG_CI_START="-0.2712740192276605" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="27" O_E="0.0" SE="0.46547466812563143" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.21666666666666673" WEIGHT="92.40246406570843"/>
<DICH_DATA CI_END="103.39290382594349" CI_START="0.2550427725725857" EFFECT_SIZE="5.135135135135135" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.014490732810238" LOG_CI_START="-0.5933869790385705" LOG_EFFECT_SIZE="0.710551876885834" ORDER="28" O_E="0.0" SE="1.531880277142861" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="2.3466571834992886" WEIGHT="7.597535934291582"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.995904331305818" CI_END="35.02532840809599" CI_START="3.336985594223911" DF="1" EFFECT_SIZE="10.811059907834101" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="2" I2="88.88383020570826" ID="CMP-001.04.03" LOG_CI_END="1.544382216053608" LOG_CI_START="0.5233543318083537" LOG_EFFECT_SIZE="1.033868273930981" MODIFIED="2008-05-02 05:01:32 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0027058842712354148" P_Z="7.210684224029429E-5" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.00000000000001" Z="3.9692247644366554">
<NAME>Injection site reaction</NAME>
<DICH_DATA CI_END="5.459616783460526" CI_START="0.18316303866407257" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7371621601645829" LOG_CI_START="-0.7371621601645829" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.8660254037844386" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.7499999999999999" WEIGHT="82.94930875576038"/>
<DICH_DATA CI_END="924.1258474952515" CI_START="3.7083638511650627" EFFECT_SIZE="58.54054054054054" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="0" LOG_CI_END="2.9657311174875622" LOG_CI_START="0.5691823389570508" LOG_EFFECT_SIZE="1.7674567282223066" ORDER="29" O_E="0.0" SE="1.4077446156166018" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="1.9817449027975342" WEIGHT="17.050691244239633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.033307508081445836" CI_END="23.15130756146575" CI_START="0.27151565012561985" DF="1" EFFECT_SIZE="2.5071781595669567" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="1.3645755245415643" LOG_CI_START="-0.5662051326780375" LOG_EFFECT_SIZE="0.39918519593176344" MODIFIED="2008-05-02 05:01:32 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8551877002417864" P_Z="0.4176887307533167" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.00000000000001" Z="0.8104375857115649">
<NAME>Anemia</NAME>
<DICH_DATA CI_END="47.534487208765576" CI_START="0.08688581876674242" EFFECT_SIZE="2.032258064516129" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.677008813201179" LOG_CI_START="-1.061051101962561" LOG_EFFECT_SIZE="0.30797885561930904" ORDER="32" O_E="0.0" SE="1.6083499477823506" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="2.58678955453149" WEIGHT="54.718757354671695"/>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="31" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="45.28124264532832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2551359357681294" CI_END="12.56710201645152" CI_START="1.338272261726436" DF="1" EFFECT_SIZE="4.101000370507595" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="1.0992351405843537" LOG_CI_START="0.1265444764638646" LOG_EFFECT_SIZE="0.6128898085241091" MODIFIED="2008-05-02 05:01:32 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6134817383318085" P_Z="0.01351371436227645" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.0" Z="2.469936220237236">
<NAME>Leucopenia</NAME>
<DICH_DATA CI_END="127.740454438207" CI_START="0.43468245908254266" EFFECT_SIZE="7.451612903225806" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.1063284568325704" LOG_CI_START="-0.3618278847168275" LOG_EFFECT_SIZE="0.8722502860578716" ORDER="34" O_E="0.0" SE="1.4498072525970496" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="2.101941069683005" WEIGHT="16.769173768062245"/>
<DICH_DATA CI_END="11.441340945499299" CI_START="1.0258385363953697" EFFECT_SIZE="3.425925925925926" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0584769275253991" LOG_CI_START="0.011079009634691522" LOG_EFFECT_SIZE="0.5347779685800453" ORDER="33" O_E="0.0" SE="0.615246721672313" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.37852852852852853" WEIGHT="83.23082623193775"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2705485083453616" CI_START="-0.47054850834536155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-05-03 12:28:25 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5968499384592427" Q="0.0" RANDOM="NO" SCALE="1.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.5289358721998451">
<NAME>Mean EDSS change at one year</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2705485083453616" CI_START="-0.47054850834536155" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.3" ORDER="35" SD_1="0.9" SD_2="0.7" SE="0.1890588354011609" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.31295232736407746" CI_START="-0.5129523273640775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-05-03 12:32:20 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6350561842948281" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" UNITS="" WEIGHT="100.00000000000001" Z="0.4746223364451609">
<NAME>Mean EDSS change at two years</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.31295232736407746" CI_START="-0.5129523273640775" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.7" ORDER="36" SD_1="0.9" SD_2="0.9" SE="0.2106938344895073" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5868795893353023" CI_START="-2.9868795893353024" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-05-03 12:29:04 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.18809455533270342" Q="0.0" RANDOM="NO" SCALE="11.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.316236860886057">
<NAME>Number of active lesion on MRI scan at 1 year</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.586879589335302" CI_START="-2.9868795893353024" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.6" ORDER="37" SD_1="0.7" SD_2="5.5" SE="0.9116900123828705" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.4472764828252065" CI_START="-2.1527235171747936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-05-03 12:29:28 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0028079305796602206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="2.988017954921471">
<NAME>Number of active lesion on MRI scan at 2 years</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4472764828252065" CI_START="-2.1527235171747936" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.8" ORDER="38" SD_1="1.1" SD_2="2.4" SE="0.4350710134987009" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.535647759572199" CI_START="0.42465489550673985" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8075396825396826" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.18629161047592263" LOG_CI_START="-0.3719638649165331" LOG_EFFECT_SIZE="-0.09283612722030525" METHOD="MH" MODIFIED="2008-05-03 13:27:07 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.5144839631023888" Q="0.0" RANDOM="NO" SCALE="105.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0" Z="0.6518716746595685">
<NAME>Patients with active lesion on MRI scan at 1 year</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5356477595721987" CI_START="0.42465489550673985" EFFECT_SIZE="0.8075396825396826" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18629161047592258" LOG_CI_START="-0.3719638649165331" LOG_EFFECT_SIZE="-0.09283612722030525" ORDER="39" O_E="0.0" SE="0.32792202965469935" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.10753285753285752" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.014092767680024E-31" CI_END="0.8601085065568652" CI_START="0.21772985120323193" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.43274853801169594" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="100.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.06544675709790637" LOG_CI_START="-0.6620820242244487" LOG_EFFECT_SIZE="-0.3637643906611776" METHOD="MH" MODIFIED="2008-05-03 13:27:49 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.016850531911685687" Q="0.0" RANDOM="NO" SCALE="138.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0" Z="2.3899529372032626">
<NAME>Patients with active lesions on MRI scan at 2 years</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8601085065568649" CI_START="0.21772985120323188" EFFECT_SIZE="0.4327485380116959" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.06544675709790654" LOG_CI_START="-0.6620820242244488" LOG_EFFECT_SIZE="-0.36376439066117766" ORDER="40" O_E="0.0" SE="0.3504665093023349" STUDY_ID="STD-Montalban-2004" TOTAL_1="36" TOTAL_2="37" VAR="0.1228267741425636" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.191120793994234" CI_END="1.202672474412139" CI_START="0.4772047591319598" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7575757575757576" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="61.47267460403038" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.08014737137783666" LOG_CI_START="-0.32129523378953645" LOG_EFFECT_SIZE="-0.12057393120584987" METHOD="MH" MODIFIED="2008-05-05 00:52:42 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.07460416756140975" P_Q="0.0" P_Z="0.23905320097167493" Q="0.0" RANDOM="NO" SCALE="137.32" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="60" WEIGHT="300.0" Z="1.1773566611812265">
<NAME>Patients with spasticity</NAME>
<GROUP_LABEL_1>ß-interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ß-interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9972203996676423" CI_START="0.31909866959514904" DF="0" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.0012088459198965845" LOG_CI_START="-0.4960750064886893" LOG_EFFECT_SIZE="-0.24864192620429298" MODIFIED="2008-05-05 00:52:42 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04889117353088513" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.0" Z="1.9695394805211588">
<NAME>Sustained increase in spasticity</NAME>
<DICH_DATA CI_END="0.9972203996676423" CI_START="0.31909866959514904" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="-0.0012088459198965845" LOG_CI_START="-0.4960750064886893" LOG_EFFECT_SIZE="-0.24864192620429298" MODIFIED="2008-05-03 12:16:52 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.2906868323451107" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.08449883449883451" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.0854120297348" CI_START="0.6969632230580535" DF="0" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.8503651103403166" LOG_CI_START="-0.15679013789100402" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2008-05-03 12:17:19 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17710441744844704" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.0" Z="1.349724353783831">
<NAME>Post-dose spasticity</NAME>
<DICH_DATA CI_END="7.0854120297348" CI_START="0.6969632230580535" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8503651103403166" LOG_CI_START="-0.15679013789100402" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2008-05-03 12:17:19 +0200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3780307921238502" CI_START="0.14334285222545146" DF="0" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="0.1392589219983594" LOG_CI_START="-0.8436239582210844" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2008-05-03 12:18:02 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1601484876932277" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.0" Z="1.4045723358794966">
<NAME>Increase in anti-spasticity medication</NAME>
<DICH_DATA CI_END="1.3780307921238502" CI_START="0.14334285222545146" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.1392589219983594" LOG_CI_START="-0.8436239582210844" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2008-05-03 12:18:02 +0200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.5773502691896257" STUDY_ID="STD-Leary-2003" TOTAL_1="30" TOTAL_2="20" VAR="0.3333333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco">
<FIGURE FILENAME="RCTs flow diagrama.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCALQA8ADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPvin4w1HwN4attU06O1lnkvVgZblGZdpRz/CRz8or0GvIP2jP+SeWP/YUj/wDRUtAHJ6f8Y/iTq9ubjTfC1peW6vsaS20+5kUNwcErIeeR+ddR4e+IXj64t9duNe8Mpp8NhpNxeQSyWE8KvMmCqEu3IIzwMHivN/h74x8deHvDs1p4Y8Pf2nZNdNLJN9hnmxIVUFdyEDoFOOvNemab4o8X+JPAPjX/AISrQv7K8jS5fs/+hzQeZmKXd98nOML09aAIvhZ8Utc8deKLjTdTtdOihhs2uFa1jdW3B0X+JjxhzXslfI/wo11PDWo+I9ZLIr22iStF5illMhliCAgc4LFR+PUda0fAnhW9+L/iK/1DxHrN3JDZqvmsHzKxkLlVjyCqICGOAMDoBzkAH1PRXzF4T1DW/hj8VE8I/b/tenz38MM0K8JJ5qgJIMglGAdCQOu3GSADWZ4P1OP4VfFXUINT3m1gS4tJXMJEkiD5o2Rc8FyiYycYfrjmgD6wor4d0rWptP8AFdjr1x5l3NBepdyb5DumZXDHLHPJ9eetdvCI/Hv7QR8+S2ktX1FjlEEkc8Nup2jBOGDpEAT0+YnGOKAPquiua8ZeIf8AhFfCWpa15ZeS2i/dKVyDIxCpkZHG5hnnOM18+eAfBjfFnVPEGp65q9wLuNUIlRQxaWTdtJz/AAqExtGOMAEYoA7H/hcfiL/haX/CM/Y9L+xf219g3+XJ5nl+d5ec+ZjOPbGe1dd/bHxS/wCEy+zf8I3pf/CP/b/L+1eYPM+zeZjfjzvvbOfu9e3avn/Q7W7sPjFptnqE/wBovYNdiinm3F/MkE4DNuPJycnJ5q5/zcP/ANzT/wC3VAH17RXgPjbwNc6x48aXxX480u30l5TNDBcXginhhP8ADFE3yD7u3fnnbuIJ4rg/A2uyeHviraWvh++nk0i51RbVVkZgtxA0hRWdRtywV8jI4PbtQB9dUV8pXeqX3xg+KNlY3NzJFpr3DLbQ/c8m3XLNgfMPNKryectgfdAxkfEnwjN4M8Tx6Q+oPeWQtxLZGQktHCzv8hHQENvPHBznjJAAPsSivkP4q9PBf/YrWX/s9ejeFvg6qeErDxBo2uXtp4jubDzoZzsEKGWPlcbSw+Vyu8HIPzAdqAPdqK+SNc8I6LpfhTVNU1Xxdp2q+IZbhfssOm3ouBIS2ZGlJG4kjec8AEDklsVoaD4gv9T+CHjDTL64knh097I27SyM7IrSqNgyeEHlDAGMZNAH1PRXyB4Q8Fy+KfBniTVJ7u6gtNGgae1QRloXm2bpOpxnbGoOOfmQngYNr4d+GtR+Ik8vh+61i/g0awt2uERN0kMUxJCfKTtUkszepAYDGSQAfWtFfN37POq36eJtR0j7TIdPeza5MBOVEoeNQw9DhiDjrxnoMfSNABRXypqerat8XPiSNDh1fZpct062i4YQpCgYiXy+8hXcecHLYyo6T+NPDeofBvxRYX/hnWZ1ivYpFiMoVpF27d6uNu11O5SOOvbKgkA9Z+KnxEu/AtnYLZWENxdX/mlJJ3OyPyymcoMFshj3GPfpUvw+8ReO/EFwl14j0bTrPR7iyFxbXFq3zSMxUrx5jEAqSeQOleQfGTT7K4bQPF0ImS58R2ouJ4GkDJFthh2hTtB6NyT19q9e+E/gzTvDHhe31SxmuXn1mztbi4EzqVRvLLYTAGBmQ9c9qAOj8X+IovCfhi/1ya3kuEtFBESEKXZmCqMnoMsMnnAzwelcp4U+Imo+Ivhx4k8TSWVtDLYNc/ZoV3Mu2OESIHOfmOTgkYz6Cq3x18O2epeCn1yeSdbjSP8AUIrAI3myxI24YyeBxgivNvh34M069+HXiLxY89yuoWNvf28UauvlMptMZIxnP7w9/SgDvfhZ8Utc8deKLjTdTtdOihhs2uFa1jdW3B0X+JjxhzXslfIHwr8JweNPE91pNzfXdpafY2luFtiA0yh0wmTkY3FW5B+7+I3fhrc3HhD4yyaCuo7bN7qeyuM4RLgoHEXBJwxYDHOfmxnk5APqKivkXXfFlv8AEPx9HJ4h1WfT/DscjrFtiLGCEZI+Ubv3jYALc8n0AFLoXiy3+Hnj55PDuqz6h4ekkRJt0RUzwnBPynb+8XJAbjkehIoA+uaKK+VPi1qlxf8AxXmsddlnOlWMkSJBauGMcDKjMUyAPMYHPPfAyQBQB9V0V80+EtB0a28fwXngjx9YwWY2RtFqKMs8rNkeT5bCMTKxA6EEZHcAnP8Aij4uk8UePG0K6vXstCsL37M2Ii2xgdskzKD85HzY/wBnsCTkA+pq8H+IHxl8ReEfHOo6JY2ely2tt5Wxp4pC53RqxyQ4HVj2rzefWdO8CeNYNS8Ba7PfWgiBY3ELLuyfmhkBC7wcA5AGMjHK5qH4n6lDrHxEvNThV1gvILSeMOAGCtbxMM4zzg0AfY1FfLPxR8XSeKPHjaFdXr2WhWF79mbERbYwO2SZlB+cj5sf7PYEnOLPrOneBPGsGpeAtdnvrQRAsbiFl3ZPzQyAhd4OAcgDGRjlc0AfYFFfLnjPxxe/EbxtYaDpupzW2gXklvbJGEK5MhQs0q5+dlY4xnHy8dST1i/BTXNA8Uw33hDxKbGywm+Wdz56jILAqq7JV4BwcA9D0yQDf+KXxWm8C3tvpen6clxfzwCfzrhj5UalyB8o5Yna/cY468ium8baj43sTYjwbo9lqJfzPtX2pguzG3ZjMidct69O1fPXxh8NweHPG4CXEk02owfb7lmAC+dJJJu2D+FOOASSPU1q/F7wZp/gfRvD2mabNczW8lxeTs1wys24rAP4QOMKKAPoLwvca3d+HrWfxDaQWmqtv+0QQEFF+c7cfM38OD1PWugr5YvvHOo6D8IfCWh6NfyWdxcpcz3MkO5ZVjFw4Ta46AkPnHPyjoDzb/4Ux/xar/hJ/wC1D/af2T+0PJx+5+z7N/l9M+ZjnPTPGP4qAPpyivma18Z6r4n+CXi+01i5e7n05rPZcyEbmR5UAU4HJBjJ3Ekndz0rI+FvgCH4g2+q217qlxbQaeqtbxxYKiaUEbyD2xEMgYJ45GKAPrCivmf4Da/PZ+LLjQZr91sry3d4bYglWnXByOPlOwPnpnAznAr6YoAKK+VNT1bVvi58SRocOr7NLlunW0XDCFIUDES+X3kK7jzg5bGVHSfxp4b1D4N+KLC/8M6zOsV7FIsRlCtIu3bvVxt2up3KRx17ZUEgHrPxU+Il34Fs7BbKwhuLq/8ANKSTudkfllM5QYLZDHuMe/Spfh94i8d+ILhLrxHo2nWej3FkLi2uLVvmkZipXjzGIBUk8gdK8g+Mmn2Vw2geLoRMlz4jtRcTwNIGSLbDDtCnaD0bknr7V698J/BmneGPC9vqljNcvPrNna3FwJnUqjeWWwmAMDMh657UAdH4v8RReE/DF/rk1vJcJaKCIkIUuzMFUZPQZYZPOBng9Kx/hn4zu/HmgXuqXNtBbeXfyQRRwknEYVGG4nq3z8kAA+grD+Ovh2z1LwU+uTyTrcaR/qEVgEbzZYkbcMZPA4wRXm3w78Gade/DrxF4see5XULG3v7eKNXXymU2mMkYzn94e/pQB9Q15r4k1n4n23iC6g8N+G9KvdJXYILiaVQ7/KN2R5y9GyOg6V4N8L/BVp458US6Ze3M8FrBbPcSeRje+CqgAnIHLZzg9Md8ij8Q/D1p4T8dX2iWMk8lta+V5bzsC53Rq5yQAOrHtQB9o0V4h8VfB2p694mt5NR8Z6Xp2gzbPKtdQuvJ8orw5RPuyN8xOSQfm28AA15LfX9r4H+IM0vg3VJ7mytJYxHMZji4A2l0Ypt3oXBHHBAHXrQB6j8QPjL4i8I+OdR0Sxs9LltbbytjTxSFzujVjkhwOrHtXvFfIfxq/wCSv6z/ANu//oiOtH4tapcX/wAV5rHXZZzpVjJEiQWrhjHAyozFMgDzGBzz3wMkAUAfVdFfNPhLQdGtvH8F54I8fWMFmNkbRaijLPKzZHk+WwjEysQOhBGR3AJ+lqAON8baj43sTYjwbo9lqJfzPtX2pguzG3ZjMidct69O1aXhe41u78PWs/iG0gtNVbf9oggIKL8524+Zv4cHqeteQ/tMfc8M/W6/9o1wHi7/AJJB8O/+4j/6PFAH17RXyhL4DiuPg0PHM+qXUl+CqiKTDRiFZRAqc85GAQc4AAXHeuh8KfEi70T4NarjVBJq9jdR2lgJ4jJ5ccgG0Zxg4CTkZJA2gdMAgH0dXJfELxDeeFfA2o63YxwSXNr5WxJ1JQ7pVQ5AIPRj3rwzwb8N5vib4b1fX73XLltXFx9nt2uG8xSyoh/escsQQwUY+7jPzdK6LW/Cfivwn8GNfste12C/tsW4gtk3yeQomhA2yNghcAjZtwMAgjkEA6z4SfEPWPHp1dtVt7KH7F5Pl/ZUZc79+c7mP90V6lXyF4R/5JB8RP8AuHf+jzXffsz9PFH1tP8A2tQB7/RXxz8MNRh0f4iWepyq7Q2cF3PIEALFVt5WOM45wK3PCen3Hxk+IV1J4lv51VLVpytuANqBgqxpnIQAvnoc4OeSTQB2Xj/4yeIvCXjnUdDsLPS5bW28rY08Uhc7o1Y5IcDqx7V7xXxR400K78N+L73Sb28F5LamONZsn5ovLUx9emE2jHQYwMgV2PxR8XSeKPHjaFdXr2WhWF79mbERbYwO2SZlB+cj5sf7PYEnIB9TUV8fz6zp3gTxrBqXgLXZ760EQLG4hZd2T80MgIXeDgHIAxkY5XNani/xlN8UPGmmaRaXM9pokt3DBbxPGMq0hCtLIoYhmBJxz09CTkA9a+LfxD1jwCdIbS7eym+2+d5n2tGbGzZjG1h/eNdL8PfEN54q8Dadrd9HBHc3Xm70gUhBtlZBgEk9FHevnj4qeAh4EudPgs7+e50i682S3inbLxSAIHzgBefk5AB4wegJ92+Cv/JI9C+k/wD6PkoA1PGV54qstHik8Jafa6hqBuArw3LAKItrZPLrznZ379KXwfe+Kr3R5JPFunWun6gLgqkNswZTFhcHh25zu79ulcT+0Z/yTyx/7Ckf/oqWvIf+beP+5p/9taAPr2ivk/wv4Ci8T/DHXPEN5qdykukrLHZQDBjVY185gc9mMhxjGCSec4rtf2evEUk8Oq6BcXrusKJc2lswJCLkiUg44GTHxnqSQOtAHvdeUeAfivP478a3mmwaattpkFm8yO7FpnYSKoJxwoKt93nBH3jXd+J/Dlp4s8PXeiX8s8drc7N7QEBxtYMMEgjqo7V8ufCjwdp3jbxJdaXqU11FBFZtcK9s6q24Oi85B4w5oA9I/wCFyeIv+Fpf8Iz9j0v7F/bX2Df5cnmeX53l5z5mN2PbGe1e718d6nZzX3xovrO3u5LOe48QSRR3MYO6JmuCA4wRyM56jpV3xx4eb4X+PbT+wNTuwwgS7gmkx5kRJdCpIGGB2ntghsEHuAfW9FfNfxv8eXGoawvhvTbof2TFFFNM0ZBW5dlDqdwJ3IFKEdOcnnCkchq/9geFdT0jU/A3ie6vbyFMzytbtEY5RjkblAKtkjYc8Agk5oA+w6K5nwb4h/4SrwlpmteWY5LqL96oXAEikq+Bk8blOOc4xXk37THTwv8AW7/9o0Ae/wBFfIGu+C57H4aaL4vu727e7vpxbm3uEI2w7CIsEnONsXHYqy4xjmxJ4Z1DxB8MtR8eazq2o3F3azpBbLdlpBJDuCnDsc43yHGOAUYck8AH1vRXzr4a8f6v4f8AgVc3huZJr2LUTpunySIHEC+UrjOeoUb8Zzg7RjAxXnem2nhvVPDusajrniS4h8RMzPawGF5BM2NxMj4OS5JHUYIyc5xQB9darqUej6Ne6pcK7Q2cDzyKgBYqiljjOOcCuI+GnxFu/iBea40unwWdrZeR5EaOXf5g+7c3APKcYAxnv1ryPwvqj+NPh7rXhnW7m6kGhWUmradIhGQIo2XynY5yoLrgYzjIyAAKn+CHgvTvEmrXWqXs90k+i3FrPbrC6hWbczfNkHIzGOhHegD6gor5u1bwDby+Lr278f8AxAsJIbdZGKx3Y+2FeXRREwPljDbtqhuuAOc1k/A/X9RsvHtnpEVxIdPvkmElu0jbAwTf5gXON37sDOOmRQB9T0V5/wD8Ls+Hv/Qwf+SVx/8AG64n4jeHbzxhq2nanL440ux8M6hFFNaW9/cGDaNvLJGcCRsPnJIPz7TgAUAe7UV8bX1/a+B/iDNL4N1Se5srSWMRzGY4uANpdGKbd6FwRxwQB161p/F66ntfjHqtzbzPFPE1u0UiMVZGEMZBBHQg0AfW1FfKHxH8AQfDe40C503VLqWeZWZpGwjJNFsO+MjoCWGByRjqe3pfiNNZ8efCjQtTsfFdppsD24GqS3chtop3K+W4ZwOAJN67cbW3ewyAeyV5b8XPiJrHgE6O2lW9lN9t87zPtSM2NmzGNrD+8a8M8V6HovhKPQ30TxJHqWtbGnvZbGcNFA4K+X5TKOCDu6nPAOFyBWx8Q9YvNe+HfgK/1By900V5E7kkl9jxxhiSSSSFBJ7kmgD6A+HviG88V+B9O1u+jgjubrzd6QKQg2yMowCSeijvXW18c674YMPw48K+JoVjWG4Sa1uCECnzRPKVYnOWJXI6cCIc8gV1vxT8bpr3gbwfZLcpdXF1bi9vXMbK3mqDFxwBgv54IA/hGMDGQD6Zor5U8Zafq/hD4Z+GdCYfZIdTWa91CNXcNLNlCqyKQNuxDGMZwWByMqCaFlofhXUNP0Sfw/4u/snxCMPcxaszQxxOozujmRMJyuRkkkEcgjBAPojxtqPjexNiPBuj2Wol/M+1famC7MbdmMyJ1y3r07VpeF7jW7vw9az+IbSC01Vt/wBoggIKL8524+Zv4cHqeteJfHTzm0Dwg93qUGpzGK4JvYIhGk4Ihw4AJHIweDg9RgcVzPiLVNTtvg34N02KcQ6Zdi8klVH5mdLg4Vhj7oyCOTknkDaDQB9Z0V8i2Wh+FdQ0/RJ/D/i7+yfEIw9zFqzNDHE6jO6OZEwnK5GSSQRyCMH6g0U3J0ixa51KDU5mhBN7BEI0uAejgAkcjB4OD1GBxQBtV5B+0Z/yTyx/7Ckf/oqWvX6KAPIP2c/+Sd33/YUk/wDRUVegeOP+RA8Sf9gu6/8ARTVv0UAfI/wo0JPEuo+I9GKoz3OiSrF5jFVEgliKEkc4DBT+HQ9K0fAniq9+EHiK/wBP8R6Ndxw3ir5qhMSqYy4Vo8kK6ElhkHB6g8YP1PRQB8zeE9M1j4m/E8+L2to7LTrW9hnkk5ZcxbdkKn+JiFXJ4AznAyFMXx90b7F4ztdWjt/Li1C1G+UvnzJoztPGeMIYuwH45r6eooA+P9Q8Ji0+EejeI2eEPcapMihE+dkZABub/ZaCTA5H7zORyK739njQXM+seIJFkChVsoWDDaxJDyZHXIxFg9PmPXt9B0UAcz408Pf8JV4Q1PRTIY3uov3TFsASKQ6ZOD8u5RnjOM189eBfGFx8J9X17Ttc0ucSyxAG3AAcTpnZ82cCMhm+YBv4SMjr9V0UAfGXh3UJNY+LOkanOqJNea3DcOqAhQzThiBntzWh/wA3D/8Ac0/+3VfXtFAHyKbmfw38VnvfiBYz6iFlmNwJbcOLobWjV0WTaDHkDb0AA46YrN0m7hT4oadqU1pHpNrLq0F4IJMIlvC8gkXkgAKEIIOAMYPSvsyigD5Su9Lvvg/8UbK+ubaSXTUuGa2m+/51u2VbB+UeaFbkcYbB+6RnJ+JPi6bxn4nj1h9PezszbiKxEgIaSFXf5yehJbeOOBjHOCT6vrnh74raJ4xutW8O6nJq2nXNxJKtnPcgpEhcP5ZjlYAD+EFDnAP3c4rB1D4f+PviF4yttQ8W2drp1oixxOYZ0wsIblYwpc7zucgtxnvjAoA5X4u2dxp1/wCFrG7j8q5tvDtrDLHkHaylwRkcHkdq9U8S2uv3nwC0aDQDM0rWNmtzDbqWlngaIBkQAE9WUnp8obtwfYKKAPjTTdY0gfDvUfD6aD9s1+4uTNHei3Utb26qjNhuW48t8jgAMTnqKt+FbiFPhd48t2lQTOlhIsZYbmUT4JA9AWXP1HrX2BRQB8//AAs/5N+8Z/8Ab9/6Sx0v7M3/ADNH/bp/7Wr3+igD5i/Z2/5KLqP/AGC5f/R0VfTtFFAHypqek6t8I/iSNch0jfpcV07WjZYwvC4YCLzO0gXcOcnK5ww62/F+v3nxq8W6ZpHh3TZI7a1Vij3BwwDbd8kpBIVBgAYyfqWCj6gooA+cPjnpj6N4d8EaUZfO+xW01t5u3bv2LAucZOM46Zr2/wADf8k/8N/9gq1/9FLXQUUAcB8X7eW5+FWuxwRPIypE5VFJO1ZkZjx2ABJ9ADXj3w88Z6dY/DrxD4SkguDf30F/cxSKi+UFFpnBOc5/dnt6V9QUUAfMP7OP/I/6h/2C5P8A0bFWCP8Ak4X/ALmn/wBuq+vKKAPknUvD6/C34lW0muaP/aOg+bI0AlVZFuICCvcbS67gSpA5A6Ag16H4X8T+FPFvilNN0j4W2sum7wst+bOAGEFScyLs2qMg/wAeSBwCflr3OigArwv4o+K9R03xFBZ+I/BlhdeGwwi+3SwtcSMjk7vJlygilKL93qCuckYNe6UUAfGWq6dY+KfFptvAWhailsyoUt5G8x1PALk5OxMkcsxA65AOB1fxL8K3Hgv4gr4juNP+36LeXwuwJCGV33eZJDJ8uBk7sZByvqQcfUVFAHgGneNvB+veILbTfD/wuh1GN9vnN9it1kiBbBO0KV2jK8s6jJ5x1rz/AOLttDa/FHVLaCNIYYVtkSNFCqiiCMAADoAK+v6KAPl34l+FbjwX8QV8R3Gn/b9FvL4XYEhDK77vMkhk+XAyd2Mg5X1IOOj07xt4P17xBbab4f8AhdDqMb7fOb7FbrJEC2CdoUrtGV5Z1GTzjrXv9FAHzH4/8J3ngL4hQ+JtO0YtoEV1DeoLbPlxFWXcjHB8vL9O2GAHTA6Wf456nrXiqx0/wfoP22CbYrwXke2d23HdtZZCqrtx8xBxyTwK93ooA+Yv2gIbv/hMNLubm28sS6XGpKEtH5gkkLKrkDdjcOwOCOBmovi94y07xzo3h7VNPguoYIri8tytyiq24LA38JPGGFfUVFAHyxfeBtR174Q+Etc0awkvLi2S5guY4dzStGbhym1B1AJfOOfmHUDi3/wuf/i1X/CMf2Wf7T+yf2f52f3P2fZs8zrnzMcY6Z5z/DX05RQB81W/gbU/CfwQ8U3+rKILjVBZstqykPEizDG/0Y7/ALvbAzzkDW/Zn6eKPraf+1q9/ooA+Q/gn/yV7Rf+2/8A6Ikr68oooA+VNT0nVvhH8SRrkOkb9Liuna0bLGF4XDAReZ2kC7hzk5XOGHW34v1+8+NXi3TNI8O6bJHbWqsUe4OGAbbvklIJCoMADGT9SwUfUFFAHzh8c9MfRvDvgjSjL532K2mtvN27d+xYFzjJxnHTNe3+Bv8Akn/hv/sFWv8A6KWugooA4D4v28tz8KtdjgieRlSJyqKSdqzIzHjsACT6AGvHvh54z06x+HXiHwlJBcG/voL+5ikVF8oKLTOCc5z+7Pb0r6gooA+Yf2cf+R/1D/sFyf8Ao2KsH41f8lf1n/t3/wDREdfXlFAHyt8QhqWl/F0al4qhlvNMS/R4N0O6Oa0VlfykDAK2FbBHTcTk85PIeML601XxNcalp2kDS9Lu8NaQCIRqY1+TcABjlkbOMgHIycZr7YooA+QPi7cw3XxS1S5gkSaGZbZ0kQhldTBGQQR1BFel/FHxXqOm+IoLPxH4MsLrw2GEX26WFriRkcnd5MuUEUpRfu9QVzkjBr3SigD4y1XTrHxT4tNt4C0LUUtmVClvI3mOp4BcnJ2JkjlmIHXIBwPs2iigDwH9pj7nhn63X/tGuA8Xf8kg+Hf/AHEf/R4r69ooA8C/5tG/D/2+ri/h54Zn8X+CPGOnWUMcl/G1lPaB3KjzFM2eemSpcDPGSOnUfWNFAHzF4F+Ip+GnhzV9B1XR72LVvNe5thJFgCRolCiVGKsq/KpyMkhj0xzt6r4x8R+MPg14jv8AWdHtrWzDQiC7hdkEx8+IELG2SQOcvuxnAAODj6CooA+W/hfoM/ijwB470izOLmaK0aIYHzsjSOE5IAyVxknjOazfAHjyX4djxBbzaVJJqFwkaRxy5URTRlhiReuPmJPfK44zkfW1FAHxz8MNOh1f4h2emzs6Q3lvdwSlCAwV7eVTjOeea1/DOoXvwf8AiRKviGxbyjA8E3kLuMkR5WSIkqCCyL17bhgEYH1fRQB8S+LvEc3ivxRe65NAlu90ykQoxYKqqFUZPU4UZPGTngdK7j4l+FbjwX8QV8R3Gn/b9FvL4XYEhDK77vMkhk+XAyd2Mg5X1IOPqKigDwDTvG3g/XvEFtpvh/4XQ6jG+3zm+xW6yRAtgnaFK7RleWdRk8461zXxF8K3vw8+IEPiPTbKM6S14t3aNtzHHKCHMTBQNoyDgf3ehyDj6kooA+SPin8RIvHup2YsrN7fT7JWEJnx5rs+3cSASAPlAAGe5zzge8/BX/kkehfSf/0fJXfUUAeQftGf8k8sf+wpH/6KlryH/m3j/uaf/bWvr2igDwP4Wf8AJvvjH/t+/wDSVK539nH/AJH7UP8AsFyf+jYq+nqKACvkT4aeKrT4f+L7641qzvRm2e0eGGMeYkm9DghiMY2Eeua+u6KAPkL/AJuH/wC5p/8Abqt/9o3/AJKBp/8A2C4//RstfT1FAHyh8QPBl9b+H/D3iu3ikn0+60iyW7YHPkSCFVGRjhSAvPPzZzjKg9KvxC8GajNY2+ifCy1v7+ZSZbZbSEFWC5ITbGxcfe5IXgZx6fRVFAGTpNrb2mmW8Fpp8enwBci0jjRBCTyRhMrnJOcEjOeTXi37THTwv9bv/wBo17/RQB4F8Uv+Te/Bn0sf/SV6Qf8AJov4f+31e/UUAfNPgzwhP4y+BWq6fYndfQay1zaoXCLI6wxgqSR3Vmx05xkgZrF8F+LPC/hLStU0vxR4Qi1DU47hniae1iZg20AxPvGUAZe2fvHjjn6wooA8j0M2viL4ceJNRsPAaaBdT6dPBbeRbJuu43h3DYVVWYE47YPGCTnHmHwj8XR+Hv7X0eETpq+t+Ta6dcIivHFP86q0mT90NIh4DcA8ev1XRQB8e+FtWtPCnivVLnxpoU+pXT2zj7JfwKzm4Yq4Z/N5GRn5sE/N0OasfCUf2b8X9JivsWsiSzwuk42MshidQhB6NuIGOueK+uqKAPP/APhSfw9/6F//AMnbj/45XhfjSxu/DXxQtW161nuNEs7mJLNGjLxPZRFSIY9+A+1CFIz94nJJJJ+tKKAPifxhfWmq+JrjUtO0gaXpd3hrSARCNTGvybgAMcsjZxkA5GTjNbPxduYbr4papcwSJNDMts6SIQyupgjIII6givr+igDwD9pjp4X+t3/7Rrg9ftNdk+FvhKeP7RJoMcVwZI4kJjhn+0yDfIQMDIdQuT/exjJz9d0UAfGvivWdI1fw9oEOjaD9iGm2scGo3ogVPtFwyAclev8Aq3ILHJy3Awc3PFFxFN8KPAccciO0LahHIFcEo3mo2D6HBB+hHrX19RQB4donh8+Jv2a4rRE33KQz3FuFg8x/MjnkYBB1ywBXI5+Y9eleQ+CtIk8W+NNC0W5k82280K0UsjBRApaV0GORkb8Yxy3bOa+k/iHN44GnQ2ng7ToLk3UU0V1M0wjkt8gBWjJdcNyxzzggfjzXwc+GOo+EHuta1l/J1C5iNstojKwiTcCSzDILEqMAHAHXJOFANn4q634g0jRV/s/w1Y6vpjjdePdRtcJGFy3zwgD5eAd+SBg5A4J8B8T6h4X8RW2lp4a8O3Vprk7f6akGfJllYD5YYtzHG7O0DbgcYORj7GooA+UPH+mX2j/DfwHY39tJa3SJfO0MhwyhpFYZHY4YcdR0PNdVp2s6/o/wM0L+zvDVlq+lus7Xb3SNcJEFnlb54QB8vAO/JAwcgcE/QtFAHxz4n1Dwv4ittLTw14durTXJ2/01IM+TLKwHywxbmON2doG3A4wcjH0d8LdOvNG+HejWOoW0ltcpHI7QycMoaVmGR2OGHHUdDzXcUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVbm5gtLeS4uZo4YYxueSRgqqPUk9KtV5/wDGw4+EWuY/6Yf+j46AN/8A4Tvwh/0NWh/+DGH/AOKo/wCE78If9DVof/gxh/8Aiq4fwt8JPA+peENFvrvQxLc3VhBNK/2uYbmaMEnAfA5Patn/AIUn8Pf+hf8A/J24/wDjlAG//wAJ34Q/6GrQ/wDwYw//ABVH/Cd+EP8AoatD/wDBjD/8VWB/wpP4e/8AQv8A/k7cf/HKP+FJ/D3/AKF//wAnbj/45QBv/wDCd+EP+hq0P/wYw/8AxVH/AAnfhD/oatD/APBjD/8AFVgf8KT+Hv8A0L//AJO3H/xyj/hSfw9/6F//AMnbj/45QBv/APCd+EP+hq0P/wAGMP8A8VR/wnfhD/oatD/8GMP/AMVWB/wpP4e/9C//AOTtx/8AHKP+FJ/D3/oX/wDyduP/AI5QBv8A/Cd+EP8AoatD/wDBjD/8VR/wnfhD/oatD/8ABjD/APFVgf8ACk/h7/0L/wD5O3H/AMco/wCFJ/D3/oX/APyduP8A45QBv/8ACd+EP+hq0P8A8GMP/wAVR/wnfhD/AKGrQ/8AwYw//FVgf8KT+Hv/AEL/AP5O3H/xyj/hSfw9/wChf/8AJ24/+OUAb/8AwnfhD/oatD/8GMP/AMVR/wAJ34Q/6GrQ/wDwYw//ABVYH/Ck/h7/ANC//wCTtx/8co/4Un8Pf+hf/wDJ24/+OUAb/wDwnfhD/oatD/8ABjD/APFUf8J34Q/6GrQ//BjD/wDFVgf8KT+Hv/Qv/wDk7cf/AByj/hSfw9/6F/8A8nbj/wCOUAb/APwnfhD/AKGrQ/8AwYw//FUf8J34Q/6GrQ//AAYw/wDxVYH/AApP4e/9C/8A+Ttx/wDHKP8AhSfw9/6F/wD8nbj/AOOUAb//AAnfhD/oatD/APBjD/8AFUf8J34Q/wChq0P/AMGMP/xVYH/Ck/h7/wBC/wD+Ttx/8co/4Un8Pf8AoX//ACduP/jlAG//AMJ34Q/6GrQ//BjD/wDFUf8ACd+EP+hq0P8A8GMP/wAVWB/wpP4e/wDQv/8Ak7cf/HKP+FJ/D3/oX/8AyduP/jlAG/8A8J34Q/6GrQ//AAYw/wDxVH/Cd+EP+hq0P/wYw/8AxVYH/Ck/h7/0L/8A5O3H/wAco/4Un8Pf+hf/APJ24/8AjlAG/wD8J34Q/wChq0P/AMGMP/xVH/Cd+EP+hq0P/wAGMP8A8VWB/wAKT+Hv/Qv/APk7cf8Axyj/AIUn8Pf+hf8A/J24/wDjlAG//wAJ34Q/6GrQ/wDwYw//ABVH/Cd+EP8AoatD/wDBjD/8VWB/wpP4e/8AQv8A/k7cf/HKP+FJ/D3/AKF//wAnbj/45QBv/wDCd+EP+hq0P/wYw/8AxVH/AAnfhD/oatD/APBjD/8AFVgf8KT+Hv8A0L//AJO3H/xyj/hSfw9/6F//AMnbj/45QBv/APCd+EP+hq0P/wAGMP8A8VR/wnfhD/oatD/8GMP/AMVWB/wpP4e/9C//AOTtx/8AHKP+FJ/D3/oX/wDyduP/AI5QBv8A/Cd+EP8AoatD/wDBjD/8VR/wnfhD/oatD/8ABjD/APFVgf8ACk/h7/0L/wD5O3H/AMco/wCFJ/D3/oX/APyduP8A45QBv/8ACd+EP+hq0P8A8GMP/wAVR/wnfhD/AKGrQ/8AwYw//FVgf8KT+Hv/AEL/AP5O3H/xyj/hSfw9/wChf/8AJ24/+OUAb/8AwnfhD/oatD/8GMP/AMVR/wAJ34Q/6GrQ/wDwYw//ABVYH/Ck/h7/ANC//wCTtx/8co/4Un8Pf+hf/wDJ24/+OUAb/wDwnfhD/oatD/8ABjD/APFUf8J34Q/6GrQ//BjD/wDFVgf8KT+Hv/Qv/wDk7cf/AByj/hSfw9/6F/8A8nbj/wCOUAb/APwnfhD/AKGrQ/8AwYw//FUf8J34Q/6GrQ//AAYw/wDxVYH/AApP4e/9C/8A+Ttx/wDHKP8AhSfw9/6F/wD8nbj/AOOUAb//AAnfhD/oatD/APBjD/8AFUf8J34Q/wChq0P/AMGMP/xVYH/Ck/h7/wBC/wD+Ttx/8co/4Un8Pf8AoX//ACduP/jlAG//AMJ34Q/6GrQ//BjD/wDFUf8ACd+EP+hq0P8A8GMP/wAVWB/wpP4e/wDQv/8Ak7cf/HKP+FJ/D3/oX/8AyduP/jlAG/8A8J34Q/6GrQ//AAYw/wDxVH/Cd+EP+hq0P/wYw/8AxVYH/Ck/h7/0L/8A5O3H/wAco/4Un8Pf+hf/APJ24/8AjlAG/wD8J34Q/wChq0P/AMGMP/xVH/Cd+EP+hq0P/wAGMP8A8VWB/wAKT+Hv/Qv/APk7cf8Axyj/AIUn8Pf+hf8A/J24/wDjlAG//wAJ34Q/6GrQ/wDwYw//ABVH/Cd+EP8AoatD/wDBjD/8VWB/wpP4e/8AQv8A/k7cf/HKP+FJ/D3/AKF//wAnbj/45QBv/wDCd+EP+hq0P/wYw/8AxVaGnaxpmsQtLpmoWl9Epwz2s6ygH0JUmuQ/4Un8Pf8AoX//ACduP/jlcx8FrK307xd8QLC0i8q2tb+OGFMk7VV5wBk8ngDrQB7PRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef/Gz/kkWu/8AbD/0fHXoFef/ABs/5JFrv/bD/wBHx0Ab/gT/AJJ54a/7BVr/AOilroa57wJ/yTzw1/2CrX/0UtchrPxS1Gx+INx4O03wx/al6gUxN/aCweZmISn7y4GBnv2oA9QoryrVfinrPhiS1m8U+CLvTtPuHMf2i31CK5IYDIGAAMn3YcZIzg16RBcRXtvFcQSpLDMoeORGDKykZBBHUEUAXaKytV1KLSNGvNTuFdobOB55AgBYqqljjOOcCuf+Hvjb/hP/AA7Pqv8AZ/2ExXTW3lef5ucIjZztH97pjtQB2tFFFABRRXnHgz4lHxvb+IZNL0SQNpqhraJ7kB7osJNoPGIydgHUgZ68UAej0Vg+Hb/WNR0+SfW9F/se6ExVbf7WlxuTAw25eBySMe3vW9QAUV4/efGz7HqfiizHh8P/AGHv+b7Zjz9txHB02fL/AKzPfpj3rvPBfiX/AIS/wnY66bP7J9q8z9x5m/btkZOuBn7uenegDpKKKKACiiigAorz7xT8Sf8AhG/iBo3hX+yvtP8Aafk/6T9o2+X5kpj+7tOcYz1Feg0AFFFFABRRRQAUUVwHif4ixeGfG+ieGV0x7mbVHiDTGYRrCskvlggYO45DEjjtzzwAd/RRRQAUVzni7xDF4T8MX2tzW8lwlooIhjYKXYsFUZPQZIyecDPB6U3wX4l/4S/wlY679k+yfa9/7jzN+3bIyfewM/dz070AdLRRRQAUV5pe/Ey5g+JVz4NtdAN1cxws8Uv2wJ5rC384JgpgZPy5J4zn2rrfDt/rGo6fJPrei/2PdCYqtv8Aa0uNyYGG3LwOSRj296AN6iiigAoorB8RX+sadp8c+iaL/bF0ZgrW/wBrS32pg5bc3B5AGPf2oA3qKz7Ga4nsbaa7tvsty8atNAZA/lORym4cHB4yOtcb/wALJP8Awtv/AIQX+yhnH/H79p/6Yed9zb+HX39qAPQqKKKACiivPvDnxDi1/wCIOr+FbfTniTTEl3XckwzI0cixsNgHAyTg56DoM8AHoNFed3vj7VfD/hnU9Z8T+GDpX2bYtrCNSima8dsjaCPu4wCepxkgHFQ2HjjxxqGn217a/Drzba5iWaGT+24RuRhkHBXI4I60AelUUUUAFFc1408S/wDCH+Er7Xfsn2v7Js/ceZs3bpFT72Dj72enal8F+Jf+Ev8ACdjrps/sn2rzP3Hmb9u2Rk64Gfu56d6AOkooooAK8f8AhB/yUP4m/wDYVH/o24r2CvH/AIQf8lD+Jv8A2FR/6NuKAPYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz/wCNn/JItd/7Yf8Ao+OvQK8/+Nn/ACSLXf8Ath/6PjoA3/An/JPPDX/YKtf/AEUteJ65dahY/tNT3OlaZ/aV6gXy7P7QsHmZswD87cDAyfwr2zwJ/wAk88Nf9gq1/wDRS1x//CvNX/4Xj/wmv2ix/s3p5W9vO/49/K6bcdffpQBkeL9I8dfEuLTdEvPC8Gg6et0J7m8kv47krhSBhUIPRm4xySOVGTXLaZo0Pjv4ry+GdTubs6H4atzbW9oZMl0gKQnJAGC5+ZiBnHAPAI+ka8l8Q/D3XLXx/wD8Jf4M1Kysrifm7trsMsTnjIwincHxkg87vmByRgA871aFPDfi3xd4Gsmd/D1zZTXItJnLeVIlr9ojZTkEEOqjnOVADZwDWf4cvV8MfCPU/EOmxvFrV5qJ0hb6OYq0MJjSU4HTPykZGCN2QeK9R074UalqOq6/r/irUbWTXNRt5rW3NireTbK8Ji3YO0sQp2gHsMkknIoeHvhJrUPhTU/CmvXGknTLpzdW9zah5biC6+QK3zKo27VIOME5IyM0AcHNo1td+FIb/S/DPjiXxVM0V6urNbOyNIdpYqynlCdzq2N2cc4qPxOupeKvGXgi38Twz2l/f2sFreL5XkygG7mj3bWHBK4PTHPAxxXo8PgX4m22gReGbfxVp0OkxTgJfoZVvEtweEGBgADnbuz/AA79vFSat8Ktau/GfhPWINUguYNHitVupb2aUz3DxzNJIwyG654BbjpwAKAMJ/B+j+HPjnpnh/TIZotJ1fS5hdWv2hyrI0cysmc7sHyweSeeRjAxyPww0bT7/wALeOdUuLcPe6bpkn2WUOw8vzIJ1fgHByB3Br2zVfBeo33xc0bxZDNbCwsLJreWNmbzWYiYcDGMfvB3HeuN8O/Cvxb4at/EWlQXujTaZrFtLA0khlWcfu5ViIAGF+aQbhluM4z3AOJ8NRaVdfC2K21zxY+iaTJrcpntorcyPe4jgOBt5AXnnBXLKSMgUzWtT8F6D408Pa34Lt9St9PtLoC6nXeI7gKUZliMh3FtrlWBwMFexyem0z4G+I9Jj03VLXUdLOtWN+s4ilaQ2zRptZOQobO4HIxyCOQRze8X/C7x/wCNruG/1bVtE86ImOO1haZYIEwvKZUksxznPoOSMBQDzvWv+Rl+KX/bb/04wVY0AxeDb7wD4w/0eO1vRPHdM29yNs0kUr7R6RSJjHdenr3uofB3xHd6x4xu0u9KCa15n2YGV8rm7imG/wCTj5UI4zzj60/xl4YXw1+z1DpGrzWjX9jOHt3ikO0ytOx+TOCx8t5OMep7ZoAPBzP4x+OuteI98j6fo6NBbOtwJEzgxLj/AGWHnSfLwCevPPafGv8A5JFrv0g/9Hx1W+DWgtoPw4sjMsiTagzX7q7Agb8BMY7FFjODzkn6Db+IXh688V+BtR0SxkgjubrytjzsQg2yKxyQCeintQB4PBpun+FfhBpvjKwhnTxDf3UltHfLcMptQTKjbVHHKRkc8guSCMDDJtGtrvwpDf6X4Z8cS+KpmivV1ZrZ2RpDtLFWU8oTudWxuzjnFewWXw0+0/CKDwXrMsH2iLe63Nuu9YpPNZ1ZdwB6Ng9CQWGRnNYUPgX4m22gReGbfxVp0OkxTgJfoZVvEtweEGBgADnbuz/Dv28UAeceMNf1mLxR4N8QeILF11W0sYZri3kjNuzmK6mxkEfKWCg9Mc5AxxUnhr7D4vgvdW8XaP4x8SahIzwRz6dB5sFupww24I2uCzEL9wBh8tei678J9T1Txd4Yvjf217YaZb28N82oSyPLdlJWeU4YNkMGPBbHOOgpNK+HHjbwReX9v4N13TpdKvFJEepq4aBySAyhAQWC4+bgHuvAoA81utM8XT/D83urx6lYv4WuIW0+W7ikgk8qU7WCsRklGSEryNoJ5+6B1PijX7f4t+JfBXh+wuTFZ3MRu71UuD8j874yNv30WN9pI58wHgHJ9H8NeDL+w8I6jo/iPXr7V7rU42iuJ2ndvJRo9pSPzCRwS53YGcjI4ArA+Fnwr1HwRqt/qWr3drLNLALeBbR2ZQpbc27cg5yqYx7+1AHPeJB8P08aa9feM/Es+u3iAxwabFBKi2oBJEIeM7Sw4X7yjJbdySRw2n6jFZeDviB4diXUY7ffBPb294oDQql0sbCRc/LKQ0QOB/AfQV6fonw48ZeB7zWo/COpaI1jqG0Rzaj5vnxBQ204RduRvPJyDgHA6Viw/A7xREPEazavp1y2p2/lR3EskgkdvtEUu6T5TgkRnOC3J79aAOePgTQv+Gf/APhLtk/9r+Z5nneYcY8/yfL29NuOfXPfHFReItNtNT8feBBfI1w2tabpcmoPJIxadmIjYk5yCVUDjHr15r1c/DvVz8Dv+EJ+0WX9pf8APXe3k/8AHx5vXbnp7daydd+FviG61Dwjqml3uli+0OwtbeSK6MgjaSA7gQVGSpJPGFOB78AHq+n2MGm6fbWNqhjt7eJIYY9xO1FGAMnk8DvXgPjWxmsviVqWtePfDt9q3h4w7IJbJpPKt0yBEd24ANkEMhYDdISM5GfoCw+1/YLb+0PI+3eUv2j7Pny/MwN2zdztznGecV55feFPH2n+NbjWPDfiaG6sLgu50/WZ5nijLHJVVUEAA4KkbSBxyM5APNDb6RP8FdegsvEs+tQ6fJaXdvbTWb250+SSQqw+8Q2QzDAJUEEjk5rP1fR9Psf2f9F1W2t/LvNR1QfapN7HzfL+0qnBOBgegFeg2vwZ1KTQPEkmq6taTeItcUZmSJhFGwm85h2yHKpk7BtwcA93RfCjxHffDZvCer32lxmwkFxpctoZG3SZlLCbcBwfMwCoyOvOMEAy/in/AMm/eDPrY/8ApK9RLAnxP+Nmp6frbSSaRoqzpHYF22tsYRHBUqQSxEhPJ4C8gCptd+F3xF8R6RpWlXuqaBHp+lwRwwW8Ms6qxVdodsxnL449BzgDJz0XiH4e65a+P/8AhL/BmpWVlcT83dtdhlic8ZGEU7g+MkHnd8wOSMAHkd34ai8J/EzWdEt53nittOvjG7gBtjWErAHHcbsZ74zgdKydD8TXi6LZeFIZNSjsLnUWlvU09/390kixx+Uq45OA+AThiwyOBXp9t8H/ABrL4jvdY1nV9Lu7q7tLqKSTzpSWeW3eJePLACgsOB0A4HAFOsPgbqKeFYo21a3stdtL2S5tbq13FWUpHtVmwrqQ8eQRnbk8EngA524sr7w3rmlat8PvCXi+xnt4jFeJqGnuyXQ4+8ATndzuAwBhSoBGar6xYf2Zr/iS4+JGgajNNfuVs9VtPMeCCYhtvl5dQ67cEKWyBGFx1x6jF4T+I+t6xpsviLxRa2lhZKvmQ6PJNE14Qw3eZjZgsAeQcDsoyar2/hD4m6Hqep/2J4qttQ0+5UpAdanlllh9GA2kBhkj+6epXoAAb3wvmtW8HrbWHiCTX7W0nMEVw1q1uYlCKRFhuSBng+hA6Cuf/aK/5J5Yf9hWL/0VLW/8Nfh+PAWj3Mc1xHdaheuj3EqKyqNqcIMnkAl/mwCd3I4pvxT8H6j458M2umadJaxTR3q3DPcuyrtCOP4QefmFAHkHgWBPib4x07T9cMkmk6LpKJHYFztbYkcRwVKkEsRITyeAvIArE1WM/C34p30WmSyXD2Ebi2lfAZTNAdpPBBK+YO2Dt6DPHqCfCnxH4e1nSNa8I6lp1pfxWcMGoQT7lgkdEVXxtTLI5XJyAc/NnJG2hpvwZ8S3fi59Y8Wajp+oQ3STLdNHIzykvEyKVDRbQVJUjsNowOAKAON03TLDxD4OutQv9A8aaz4jvIm8rU0haaFZEJVNr5yy4Cq2QxGDjFVPHeoeI77wf4XXxTb3cV9bXN5AjXcLRSyxBbchm3fePJG7vjnJyT6hY/D/AOJHhvRL7w9oHiXS30qX/UT3Hmx3EGeX8vaGCZJPc+o2kmo/F/wh17XNA0Kwg15dQurF7h7m81SebdKZCm3aPnwAExjIHfqTQBk+J/BOk+BfiB4BfQWu7d7q9SCcmckybXiUsfdhIwYDCkdhznL+HHhrR5vjbrthLZ5t9Ilnmso/Mf8AdNFcIEOc5OB65z3r1Xxv4N1LxN4n8I6nZTWiQ6LffaLhZWYMy74mwuAcnEZ647Vh6N8O/FHh34n3/iXTbvR5rHUZmNwlx5omWGSVZHCgDG8YwCTg9SBnAAPny3s7eXwbqV60ebqG/tIY5MnhXS4LDHTkov5fWut+IfhjR9C8H+B77TbPyLnU7Hzrt/MdvMby4TnBJA5dumOtdRF8C/FEfhy+0w3ej+fcXlvcIwml2hY0nUg/u+v71ccdjXT+OPhbrnibwv4Q0yzudOjm0az+z3DTSOFZtkS/JhTkZjPXHagDgNK1i38f+KNU1TxVo/ijXbWGXfaafpYM0Nsj7htbaVI4VMFcbihJzUI8T+L/AAL4e1fSLax1zT9DupTHptxqNs0Utrls4DYxlkD5A6H5lwc59KHw28R+FvFl3rHgfVdOitb1nefTtQRkgUHkAeWOQCWxjaVGBkgnL7b4YavrPh3Vrfxj4jn1G+1DDQmNmeGxkDFt0asQvPyg4VSBuUEAk0AcDr3wz0jTfgvp3iaCWRdTS3hurhxnbcLMy4QgkhSocAEdcHI549b+Cv8AySPQvpP/AOj5K4O7+GPxLvfClv4XuNe0d9Mt2yqefNuZRjYjHyuVUjIHbPsuPTfh74evPCvgbTtEvpIJLm183e8DEod0rOMEgHow7UAdbRRRQAV4/wDCD/kofxN/7Co/9G3FewV4/wDCD/kofxN/7Co/9G3FAHsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5/wDGz/kkWu/9sP8A0fHXoFef/Gz/AJJFrv8A2w/9Hx0Ab/gT/knnhr/sFWv/AKKWuhrnvAn/ACTzw1/2CrX/ANFLXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAVymt+BPDmv6xb6rq2kpeXduqpG8kr7dqsWAKA7WGSeCDnPNdXRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeP/AAg/5KH8Tf8AsKj/ANG3FewV4/8ACD/kofxN/wCwqP8A0bcUAewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXn/wAbP+SRa7/2w/8AR8degV5/8bP+SRa7/wBsP/R8dAG/4E/5J54a/wCwVa/+ilroa57wJ/yTzw1/2CrX/wBFLXOa58RLix8Zf8Ix4e8PT67qqQ+bcxrcC3SAYBGWYEdCOeB8yjJJwAD0SivLdL+K1zd3niWy1Pw1Ppup6JYS3rWzXQcSCMZI3bRjOUwQGBBz6ZyNP+Neuanot/rFj4DnuNPsT/pE6aiMJ3OB5eWwOTjOBycCgD2mivLdV+Mel6d4D0jxH/Z08lzqu4W9iZMfNG+2TMmCAAehxk5HA5x5R8YvE+q65qum6frPh2TRbuwWRwj3QnEqy7cEMFAwNhHBPORwQaAPqmiqU9xFZW8txPKkUMKl5JHYKqqBkkk9ABXlKfGjUbjQL/xFZeC5JtDs7jyXu31NEbOVAym0nPzp0yOevFAHsdFea+Ivi5oei+DtM8Q2lvPenU9wtLY/uidhxJvbBC7TxxnJxjI5Een/ABOvY/EWk6R4n8K3WhDVlH2Kdrjzw0jEBVYBBtOSAQeVJXIAOQAenUV454c+MWu+LJ5IND8DveNAoaUjVFRUBOBlnjAyecDOTg+hq6vxZv8AWbm8PhPwfqOt6faK5e9837OrFTyEBU7jgqQv3zn7tAHq1FeaxfGHw2/goeJJ2nRllS2nsogHljmYE7ewIwrEMcAgHv8ALVBvizqelHTLzxP4Jv8ARdJvJGi+2PceY0RGfvR7Aw6ZwcEgEgNigD1mivJdX+ME9j40PhjRvDY1qV/KNtLBfhROJI1kDD5CAuG65xgZ4FaHh74nDUda1vStf0afQ7rSLV7u43TeeBEmN54UHoykYBDA5HbIB6VRXkR+L2r3mmXus6P4F1C60K2USG9nuRCWXoxC7W3AENnaTgDJxWhrvxi8Pad4Tstdsd9/JesUgtM+W6su3eJDg7Cu4eucjGQc0Aem0V8rfGLxPquuarpun6z4dk0W7sFkcI90JxKsu3BDBQMDYRwTzkcEGvqmgAor5dWbVPHXxW1ltW8I/wBtXNvE8X9lf2r5C2gjdV4kzg4OcgcEuTivRbb4u32u6pqcHhbwjd6zZ2AMjXIuvJLqO4UoeSQdq53EDp1AAPXaK8nvvjZpkXga38Q2Vj9qnN2lpdae1x5b2zsjtknacr8hwcc+xBA6HwT4r1zxOsV1d+FH0rTLi3M0F298shkOQAPL2hgCMkE8YA9RQB29Fee/Er4lH4e/2XnSft/27zf+XjyvL2bP9k5zv9ulULv4qX+i2EM2u+D72yvdQwul2MVws8l25HIIABjwTGCCC2ZOFODQB6jRXllt8V7mx1nTrLxd4Zn8OwajHvtrye6EqZ4wH+UbOvOeVyMgA5HBfDvVtfm+N2tXL6PJcXc7yw3sL3q5s4/PjBO4/wCsEYCqAOoHFAH0hRXjnhz4xa74snkg0PwO940ChpSNUVFQE4GWeMDJ5wM5OD6GsX4f/EHwd4f0bXNVtfDc+jwpLbQvHBePdvcu3mlQPMwFwFc9Rn64BAPfaK8mb4s6npR0y88T+Cb/AEXSbyRovtj3HmNERn70ewMOmcHBIBIDYra8K/EaHxN401fw7/Zz27WSma3uRMJEuYdwAkHAwGDRsuMghs56ZAO/orzJPi5ZJrnie2udKuotM8Pq4nvwdxeQSCMRhAMAsxbbluQuTjnGZdfFvxHZeGYfEtz4Bmi0ibaUuDqQPDcKxXy9wU9iQAcjnkZAPYKK+dfHGoxaz8ZvAOp26usN5b6fcRhwAwVrhmGcZ5wa+iqACivEPCV2fiZ8V7/xBPcedo3h/CabbscrubIWXaV77GfnDA+WMnbVSL9oWa5laKDwe8jhHcql+WO1QWY8RdAASfQA0Ae9UV5H4d+NC+I9G1WSx8PXc2sWKLNHpkMplNxEXVCyuE4KlskbemMZ5xH/AMLe8Yf9En1z85v/AIxQB7BRXkVz8TPGE2gXl3ZfD7UbbUIriGKGK4jmlDK4kLPtEakgeWBwesg57HzT4dXGrzfHm1bXpXk1UXFyl20jBiJFhkUjjjAxgY4AHHFAH1RRXi3jX4TeC7CHWfFmtahrUcbSPdTrbyRHLu/3VBj7swAye/J715z8Lfhf/wAJ01xqF9NJb6NbsYWaFl82SXAO0ZBAADAkkdwB3IAPq+ivlP4qeCfC3gb7HY6beanPqs+JnS5ZGjWD5hnIUclhx16HOOM9p4b/AGfLGXRIZPEt5ex6k/zPDZSRhIgeiEsrbmHcjjsM4yQD3iivj/SPBln4y8fz6J4Rupzpcfz/AGy9xvWFdoZ8DGcsflGAeRnHJHr2qSHwL8b7C7t4ZE0vxUqwXEaMNpud23cFBGCC0ZLHP+skxkngA9iooooAKKKKACvH/hB/yUP4m/8AYVH/AKNuK9grx/4Qf8lD+Jv/AGFR/wCjbigD2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8/+Nn/JItd/7Yf+j469Arz/AONn/JItd/7Yf+j46AN/wJ/yTzw1/wBgq1/9FLXlt9488Q6p8TNY0B/E9r4Q0+wRhE93bRP5xVgASZccuG3jBxtA4PJPqXgT/knnhr/sFWv/AKKWptQ8NaFqtwtxqWjWF9MF8tZLm2SVlXJOMsDxkn86APlyx1BJfHGsPYaxqGpW8uj3sMl5eMRJdhbJ8kgnO3cgKg8gBc8ivQvhb/yb54y/7fv/AElSvXf+EV8O+b5//CP6X53leRv+xx7vL2eXtzj7uz5cdMcdKsW2haTY2MthZ6XZW9jNnzreG3RI3yMHKgYORwc9qAPl4QPo2m/DrxbPFI+l27GOQxKSytFeyykc4GSrcc87W6Yrc+OHjDQ/FN1odvot39rW0SSWWVBhP3oQqvPO4BeRjjOOoIH0P/Yelf2P/ZP9l2P9mf8APl9mXyfvbvuYx156deap/wDCC+Ef+hV0T/wXw/8AxNAFzVnhj0e8a4snvoVt3MlrHGJGnXacoFP3iRxjvmvnS3n8J2elanr3grxjq/hue2cytpd6QxumHMKoqt8y5LKd3mYBywA5P1BXOT+DPC888s9x4c0iaaVy7yy2MTM7E5JJI5JNAHzpqGsa5d3Pgvx/4iikktI51ha4jClphDcM+doAVCQxUAnJ8pj0r2bUvirpyeMtG8OaJDHrb37p5lxZ3SslupbBPyhtxADMQcYABzzx3F9Y2mp2UlpfWsN1ayY3wzoHR8HIyDweQDVTT/DWhaVcNcabo1hYzFfLaS2tkiZlyDjKgcZA/KgDwr4KafLq3hfx5plsyLNeWkdvGzkhQzpOoJxnjJrM+HI0S3sNW07X/F/iLw3fWkzyvb2959mjcAAN8uCTKCCCvUjGAcHH0ZpmhaRozS/2VpdlYeaB5v2W3WLfjOM7QM4yfzpmo+GtD1e5W41LRtPvZgvliW5tUlZVyTgFgeMk8e9AHyv4g8NaLP4SHiXwpBrTaZb3f2W8k1LyiQ5AKlRF0UZwS2OXQDPOOx1+f4fXHhrT7rUfGfjLV47lty6eb+OaaBgCCZEYYQjOOvOeMjJr6Dt7eG0tooLeJIoYVCRxooVUUDAAA6ADtWbY+E/DtjdR3VhoGl2l1HnZPBZxxuuRg4IGRwSKAPE9EtI9N/aQ02xjSeNLa0ihVJypkULp4ADFflLcc44z0pvjDR73Xfil8QtPsF33TaNDKkYBJfyzaOVAAJJIUgDuSK93/sPSf7X/ALW/sux/tP8A5/Psyed02/fxnpx16cU+PStPh1STU4rG1S/mXZLdLComdeOC+MkfKOPYelAHzp4NufCs/gC4GseM/EmnvaI8c+l21+ESdXLYEMRB3hgcEdjknAOaybnS9M8N6h4U8aaPbau3hp7xWL3vltOXhly33PlAIBCgkElH7YJ+lb3wn4dv7uS6v9B0u7upMb5p7OOR2wMDJIyeAB+FaF9Y2mp2UlpfWsN1ayY3wzoHR8HIyDweQDQB85/HDxhofim60O30W7+1raJJLLKgwn70IVXnncAvIxxnHUED6crnv+EF8I/9Cron/gvh/wDia6GgD5t8LWE2rfFX4j6bblBNeWWpwI0hIUM84UZxnjJrU+DXjDRPC3h7WND1+6/su9trqS6dbobMrsVSoHUuCh+TGTkYB5x7PaaHpdlfz39rpdlBeXBbzbiK3RZJcnJ3MBk5PJz3qrfeE/Dt7dSXV/oGl3d1JjfNPZxyO2BgZJGTwAKAPlSLS763+F99qU9s8Vne6varbSuMCQxxXO7HsCwGemcjscfVvgf/AJEDw3/2C7X/ANFLVi50LSb6xisLzS7K4sYceTbzW6PGmBgYUjAwOBjtVqC3isreK3giSKGFQkcaKFVVAwAAOgAoA8P/AGluvhb63X/tGo/jhp8tn408PeIblruPSwsdvJPZEiaFklMhKsRgMVfK89UPpXtWp6FpGstF/aml2V/5QPlfardZdmcZxuBxnA/KrNxbw3dtLBcRJLDMpSSN1DK6kYIIPUEdqAPAPENj8P8AU9Q0axl8W+LfEl1ekfZUivop/JMhAAYyACMk4yOoxyBxVj4fXtrZfHvxZ9ruYrfz5buGLzpQvmSG5TCLnqT2A5r2vTvDWh6RctPpmj6fZTFdjS21qkTMuQcEqBxkDj2pJvDeiXOqf2nNo+nyX+5XF29qhmDLjadxGcjAx6YFAHjv7NHTxR9bX/2tXjFpo91daHe6tCm61sZ4Y7jaCSnm7trdMAZTGSerKO9fZumaFpGjNL/ZWl2Vh5oHm/ZbdYt+M4ztAzjJ/OjTNC0jRml/srS7Kw80DzfstusW/GcZ2gZxk/nQB4Lr8/w+uPDWn3Wo+M/GWrx3Lbl0838c00DAEEyIwwhGcdec8ZGTVj4lafc/D7WfCfinQ4ZIHt7JLJ1uIFYho02gTOh2szRsU47RnaeBj2mx8J+HbG6jurDQNLtLqPOyeCzjjdcjBwQMjgkVc1HR9O1iBYdTsLW9gR96xXMKyKGwRnDA88n86APD/D91qfw4+Bp8QadYbtS1e63PNJb4NrEcqjt/eX5crnAzMOv8WJ421ubUPA9nPqvxCfWLy9gRk0iygiiSJyY3f7RsPIUAgBgDuwRjDV9IfYrb+z/sH2WD7F5Xk/Z/LHl+Xtxs29MY4x0xWVH4N8MQrKkXhzSI0mXy5VWxjAkXIbB45GQDj1A9KAPm3TZ5bjxV8MZJ5XkYJbRhnJJCrfzKo57AAAegAr62rn18KeH4pbWRNA0tZLTH2ZhZxgwYYuNhx8vzEnjuSa6CgDxH9nW5tG0LW7VIcXsV0kks2wDdGyYRc9TgpIcdBu46muQ/Zy/5KDqP/YLf/wBGxV6Za+Etc8MfFufW9Gg+06DrWf7RhWUBoJDz5mGcbvmycjJAaQBeme10/wANaFo9w1xpujafZTMuxpba1SJiuQcEqBxkD8qAPmf4PaVea5r2tabYapNpd1Nph2XsGd8eLiEnGCDyAR1716p/wqHxh/0VjXPym/8Aj9eiaf4a0LR7hrjTdG0+ymZdjS21qkTFcg4JUDjIH5VuUAcV4H8I6x4W+2/2r4pvde+0eX5X2oP+427s43O3XI9OleL+D/8Ak6C5/wCwpqP/AKDNX07WJD4b0S21Q6nDo+nx3+5nN2lqgmLNncdwGcnJz65NAHkf7ROrFNO0XREkhJlle7lUt+8XaNiHGeAd8nbkrx0Neo+CNE/4R7wVo2lNbtbywWqefF5m7ExG6TnJ/jLdDj04q1qHhrQtYuFuNS0bT72ZV2LLc2qSsFyTgFgeMk/nW5QB81aAo8b/ALQ91qBigurS0uZZ/Mgk+TZANkMgOfm+YRHjIOemK9Y+LGr/ANkfDrV5Q8IluIfsiLKfv+adjADIyQhcj6Z6A10Nh4b0LR7hrjTdF0+ynZdjSWtqkTFcg4JUDjIH5VY1HSdO1iFYNT0+2vYUfeIrmJZFDYIzgg84J/OgDzP4AaL9i8GXWqyQGOXUbo7Jd+fMhjG1eM8YfzewP4YrK/aAsp9T1HwhY2iCS5uZ54YUJA3uxhAGTwOT3r2WxsbTTLKOzsbWC1tY87IYIwiLk5OAOBySa4FfCWp698Y38S61pyQaVpduIdNDsjPO4JPmFQW4BZyM7SP3fGQaAPTqKKKACiiigArx/wCEH/JQ/ib/ANhUf+jbivYK8f8AhB/yUP4m/wDYVH/o24oA9gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP/AI2f8ki13/th/wCj469Arz/42f8AJItd/wC2H/o+OgDf8Cf8k88Nf9gq1/8ARS10Nc94E/5J54a/7BVr/wCilroaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArx/4Qf8lD+Jv/AGFR/wCjbivYK8f+EH/JQ/ib/wBhUf8Ao24oA9gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsPxLoFp4o8O3Wj6gZFtboKHMLYcYYMCCQe4HatyigDx/8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGq9gooA8f/4Zy8H/APQS1z/v/D/8ao/4Zy8H/wDQS1z/AL/w/wDxqvYKKAPH/wDhnLwf/wBBLXP+/wDD/wDGqP8AhnLwf/0Etc/7/wAP/wAar2CigDx//hnLwf8A9BLXP+/8P/xqj/hnLwf/ANBLXP8Av/D/APGq9gooA8f/AOGcvB//AEEtc/7/AMP/AMao/wCGcvB//QS1z/v/AA//ABqvYKKAPH/+GcvB/wD0Etc/7/w//GqP+GcvB/8A0Etc/wC/8P8A8ar2CigDx/8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGq9gooA8f/4Zy8H/APQS1z/v/D/8ao/4Zy8H/wDQS1z/AL/w/wDxqvYKKAPH/wDhnLwf/wBBLXP+/wDD/wDGqP8AhnLwf/0Etc/7/wAP/wAar2CigDx//hnLwf8A9BLXP+/8P/xqj/hnLwf/ANBLXP8Av/D/APGq9gooA8f/AOGcvB//AEEtc/7/AMP/AMao/wCGcvB//QS1z/v/AA//ABqvYKKAPH/+GcvB/wD0Etc/7/w//GqP+GcvB/8A0Etc/wC/8P8A8ar2CigDx/8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGq9gooA+U/Hnw90fwr480HQrKa9lttQ8rzXndS67pdp2kKB09Qa9M/4Zy8H/APQS1z/v/D/8arA+Mn/JZPB3/bv/AOlBr3+gDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8f8A+GcvB/8A0Etc/wC/8P8A8ao/4Zy8H/8AQS1z/v8Aw/8AxqvYKKAPH/8AhnLwf/0Etc/7/wAP/wAao/4Zy8H/APQS1z/v/D/8ar2CigDx/wD4Zy8H/wDQS1z/AL/w/wDxqj/hnLwf/wBBLXP+/wDD/wDGq9gooA8f/wCGcvB//QS1z/v/AA//ABqj/hnLwf8A9BLXP+/8P/xqvYKKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8f8A+GcvB/8A0Etc/wC/8P8A8ao/4Zy8H/8AQS1z/v8Aw/8AxqvYKKAPH/8AhnLwf/0Etc/7/wAP/wAao/4Zy8H/APQS1z/v/D/8ar2CigDx/wD4Zy8H/wDQS1z/AL/w/wDxqj/hnLwf/wBBLXP+/wDD/wDGq9gooA8f/wCGcvB//QS1z/v/AA//ABqj/hnLwf8A9BLXP+/8P/xqvYKKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGq67wT8PNJ8AR3i6VNeS/bChla6dWPy5wBtUf3jXZUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc740mki8C+IZ4XZJI9NuXR1OCpETEEGuirnvHf/ACTzxL/2Crr/ANFNQB434A+Dnh3xb4I03XNQvdVjurnzd6wTRhPklZBjchPRR3rpf+GcvB//AEEtc/7/AMP/AMaroPgn/wAki0L/ALb/APo+SvQKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8f8A+GcvB/8A0Etc/wC/8P8A8ao/4Zy8H/8AQS1z/v8Aw/8AxqvYKKAPH/8AhnLwf/0Etc/7/wAP/wAao/4Zy8H/APQS1z/v/D/8ar2CigDx/wD4Zy8H/wDQS1z/AL/w/wDxqj/hnLwf/wBBLXP+/wDD/wDGq9gooA8f/wCGcvB//QS1z/v/AA//ABqj/hnLwf8A9BLXP+/8P/xqvYKKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8f8A+GcvB/8A0Etc/wC/8P8A8ao/4Zy8H/8AQS1z/v8Aw/8AxqvYKKAPH/8AhnLwf/0Etc/7/wAP/wAao/4Zy8H/APQS1z/v/D/8ar2CigDx/wD4Zy8H/wDQS1z/AL/w/wDxqj/hnLwf/wBBLXP+/wDD/wDGq9gooA8f/wCGcvB//QS1z/v/AA//ABqj/hnLwf8A9BLXP+/8P/xqvYKKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8f8A+GcvB/8A0Etc/wC/8P8A8ao/4Zy8H/8AQS1z/v8Aw/8AxqvYKKAPH/8AhnLwf/0Etc/7/wAP/wAao/4Zy8H/APQS1z/v/D/8ar2CigDx/wD4Zy8H/wDQS1z/AL/w/wDxqj/hnLwf/wBBLXP+/wDD/wDGq9gooA8f/wCGcvB//QS1z/v/AA//ABqj/hnLwf8A9BLXP+/8P/xqvYKKAPH/APhnLwf/ANBLXP8Av/D/APGqP+GcvB//AEEtc/7/AMP/AMar2CigDx//AIZy8H/9BLXP+/8AD/8AGqP+GcvB/wD0Etc/7/w//Gq9gooA8i/Z7mll+H10ru7LHqUiIGOdo8qI4HoMkn8a9drx/wDZy/5J7f8A/YVk/wDRUNewUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B8ZP8Aksng7/t3/wDSg17/AF4B8ZP+SyeDv+3f/wBKDXv9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3jv/knniX/sFXX/AKKauhrnvHf/ACTzxL/2Crr/ANFNQBgfBP8A5JFoX/bf/wBHyV6BXn/wT/5JFoX/AG3/APR8legUAFcDYfFPw3f+NJ/DD/a7W/iuJLZJLlFWKWVW27VYMeTg4yBnp1IB76vkm58Nah4h+JvjFtJuJItQ024u9QgEYbfI0c4+VSvIf5sjHcAcZyAD6D8b/ETSvAH2H+1ra9m+27/K+yorY2bc53MP7wrs6+TvH3jOHxt4V8LTzShdRszcQXqlly8m2H96AMYVuT0HIYDOM13l5rGu/ET4vXnh3T9dvtG0fSN4m+ySmGWQIypIcqeSXOATwF5xnIIB7LqF9Bpun3N9dOY7e3ieaaTaTtRRknA5PA7VjeDvGeneN9Il1TTYLmKCO4MBFwqqxYBTngnj5hXi+ratrGja94u+H17repalp8tlNPBdzzn7REUt/tAXcc7lIXy2XgEEkbckHov2e9Lx4dvtXW/vv+PqS1+xed/o/wB2JvM2Y/1nbOenFAHpfiXxQfDTWv8AxItc1UXG7/kF2nn+XjH3+RjOePoa6SvEPj9rmr6K3hz+y9VvrHzjceb9luHj348rGdpGcZP51i6EmueMPi/4j0Sfxbr1lYWc93KI7S9dTtWbYqrk4UDcOx4GPcAH0TRXzbZ+PvEHhHQ/G9nPq11qd1YalFYWNxdDzdkhMwaQ7iSBthyBkgNjjBNdHongjxtqHgzTNcs/HWqDWbjyryGG4vJGtfKYBgrg5JODk8Efw4I+agDvf+FiaT/wsX/hCPs17/afXzdi+T/qvN67s/d9utdlXy/4huNRtvjPq1xcyJDqcOkTPJLZsyqkw0skmMnkAN0PXpXXfDvXNYvvgr4r1G71O9uL2H7X5VzLcM0seLdSNrE5GDyMd6APcq4zxv8AEXSvAP2AarbXs/23zPK+yorY2bc53MP7wrxp/G/iS98GeDfDOm6vdxarrDObi/lmbzCGuniiHm5LAZU54zgKAcZFZ/xk8L6j4a1PTTP4g1DV7C4EhtRqFw00sLLt8wZPGDlTkY9COMkA+qKK+aU+I0fjDxLf3Ov+NdU8OaNbzH7DaafC6SSxnI+Z492GG1Cd24ZY7cVX034z6voOia1oqajJqsiMw0rVrhCXwXxlw5yRtyy5yQcAgjgAH0F4n8R2vhTw9da3fxTyWtts3rAAXO5gowCQOrDvR4Y8R2vivw9a63YRTx2tzv2LOAHG1ipyASOqnvXg3inwp4iX4O2fiO78WareGaKOe9s7m9eWF45XXytoPcZjyDkZyQeBn1f4K/8AJI9C+k//AKPkoA1fEPjLT/DGraJpl7BcyT6zcfZ7doUUqrbkXL5IwMyDpnvXU14b8eYr241nwZBphkTUZLidLUxybGEpaEJhsjBzjnPFVvFieKfhbc6Nrdr4p1jWdPkdbfUIb+cOruCGIQPnaHCsAQCVwfmOaAPe6K8N8H+KL3wh448Y6H4i1HUbyGyt3u7U3l950piiBkCqCcF2iYMcEfd5Hps/BO413WNG1PX9c1S9u/t11tt47jdsQLks0fOACWK4UADy8ewAOn8Z/EHR/BEFnLqsd1I127rFFbRh2ITG5uSAAMjvnnp1xd1TxN/Z+v2Wkf2Jrl39q2f6ba2e+3h3MV/ePn5cYyeOAQa8e/aPtNl/4eu/OnPmJNF5Jf8AdLtKHcB2Y7sE9wq+lL45XWNF+IvhbwraeKfEIs7iGCKWY6i3nP5tzICxIwCwBwCR0UelAHpOjfE7QfEOn+IL6xhvHt9EiMs7tGq+amJDmMbs8iM/e29RWj4L8Y6f430eXU9LguooIpzAVuVVW3BVP8JPGGFfP/w00r7V4X8cagL++i+xaZJ/o8M22G43wTj96uPmx1HoazfDPju90bwpB4b0/UX0lL3UZJL6/WDe0UDJGmUwc5GHJwAeFwRzQB9e0V8xXPxBTwfrOlX/AId8aap4nhaMpqNpqZlCE8ZK7x8ue2MldvJYHFfTtABRXg97C6vreoeMvit9g1FZSkVpoWosY7Y/dwYB85wcAqADhSSxJJHHnx3rlz8I8HxDqP8AatpriIZkndZRBJDIVBkHLAssnUkjA7YoA+qKK+bvEUPiLwt8PfDviy28a6/cXl28Lywz3bNFmRDKmFJPAC4IbIbPbpW/LrOsfEH4wXnh201vUNK0bR1mWRbGc28shQiNjkZDHzCMZ42joCTkA9A/4WJpP/Cxf+EI+zXv9p9fN2L5P+q83ruz932612VfNPhjS77RP2i7XT9U1B9SvITKDdSOzNIptWKkluc7SBjJxjGT1r6WoAKKKKACiiigAooooA8f/Zy/5J7f/wDYVk/9FQ17BXj/AOzl/wAk9v8A/sKyf+ioa9goAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwD4yf8lk8Hf9u/8A6UGvf68A+Mn/ACWTwd/27/8ApQa9/oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5fxp4sg8F+H5NZubWe6jSRY/LhxnJPUk9B/wDWoA6iue8d/wDJPPEv/YKuv/RTVT8I+P8AQfGlsG0y7C3QXL2cxCyp+Hce4yKueO/+SeeJf+wVdf8AopqAMD4J/wDJItC/7b/+j5K9Arz/AOCf/JItC/7b/wDo+SvQKACvH/Ang7xBo/xd8T67eaf5Gm332r7PP5yNv3Tqy8AkjIBPIr2CigD55+Jnwg1i/wDFMmq+FrD7TBf7prqJrlFMc5JLEbyPlbOeCed3QYFb+q+C/FXhX4nTeLPB+nw6ha6huN5ZtOsZG4gyLukP8TDeGHQ8YwMN7PRQB4ja/DfxF4n8R+I/FWv28Gj393az2thZLOJQC9uYQ0jrngKe3JOTgAAHU+Duh+KfCen3ei61oH2S1eV7tb37ZE+XIjUR+WhJ6KTnPtXrVFAHkHxq8Ga/4w/sH+w7D7X9kM/nfvo49u7y8feIz909PSk8CeDvEGj/ABd8T67eaf5Gm332r7PP5yNv3Tqy8AkjIBPIr2CigDw4fCvVtabx7b39slmdR1FbzSrl5QyllkmOSEbIBWTHI43ZwSKb9i+K0/gfS/Ctvo0mmTQMkL6smpwofJUkKu2P5lAGzJUkkIeu417nRQB4JcfC7xLc/E6W4uN8umS6abGTVpJEZnY2HkGUxmTeSX7fr3qrp/hf4jeHvA+qeDtO8OwOt9dSGTUVvoSrQsoRlRGIIyF6nnBPAPI+haKAPny4+FniVPBvha9023S38U6I8m+3eVCXX7Q0sZVixjypbOD1DHJ4ANTx54a+KXjy6s5b/wAMwW8NnHtihhu4MbmA3tkvnkgYHYADk5J+jqKAPFNK8GeLvhv4s1C78MaZa6zoN+5JshcrBJEo5jBaTupYgEFsgHIBIxYn8D+OfHPhbU4fGV/a29xK4m0yyjCGO1lDNnzCgyQV+UfO+A5JBYDHsdFAHzxqej/FbU/h5a+EpvDsItodsclwLq33ywpjykxvwMEdRycL77vVPhjo1/4e+Hul6Vqtv5F7b+b5se9W25lZhypI6Ed67OigDyL4xeFPE/ia58O3Hhq1klnsHmcypcJC0THyypBZgc5U9OmKoa34X8bfEjUtKsvE2lJoOjWa+bdNBdpMbiXgHaoJwccLkHaC3LZwfbKKAPnT4+aBEPEehXtnbO2oamslu8USgmZkKhOAMlz5m3vwFA6V7j4d0aHw/wCHLDSINhS0hWLdHGEDsB8zYHQsck+5NYEHw30f/hMD4qvrrUdTv1dmt4r6cSRWxLFh5a44C5O0EkDOeuCO5oA8i+NHgnXvGNvo0uh2iXElm8wkhMqxth9uCNxAx8hzznkcdcZviLwx4v8AE3xI8JeJpvDn2KK1+z/bIvt0MnkeXcux5yN3yYbgd8dRXt9FAHz74P8ABHjXwzp/ivQ5vD6XEGr2U0CX0d9GFVlimCYUnJDM4HO3Gcms/Svg14qg8P22q28EFh4m06/eeKKWVH86NVRo8EFkDB1bAOAd3JAAr6SooA8qjn+LGvaxpqS2Vr4b0+FFN9Kk8Nw053Df5eRJtOM7QRgc5Y8V6BrFpNf6Pe2VvdSWk1xA8SXEed0LMpAcYI5BOeo6Vq0UAfP3hrwR4x8MadPplv4L0i61Nr0va+ILmaCQWo+UB1UgvgbSw7gn7p6Hm7f4WeOI/Cmpae2if6VNf2syJ9qg+ZES4DHO/HBkT8/rX1LRQB47478Ha/rXwk8NaFp2n+fqVl9l+0QebGuzZAyNySAcEgcGotV8F+KvCvxOm8WeD9Ph1C11DcbyzadYyNxBkXdIf4mG8MOh4xgYb2eigDwXwp4S8ezfF228XeJNJjhV2lM8iTQlUBhaNVCq5OB8o7n1PU171RRQAUUUUAFFFFABRRRQB4/+zl/yT2//AOwrJ/6Khr2CvH/2cv8Aknt//wBhWT/0VDXsFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAfGT/ksng7/t3/APSg0f8AC5PiP/0I/wD5JXH+NHxd/efGrwZGen+jc/W4Ne/0AeAf8Lk+I/8A0I//AJJXH+NH/C5PiP8A9CP/AOSVx/jXv9FAHgH/AAuT4j/9CP8A+SVx/jR/wuT4j/8AQj/+SVx/jXv9FAHgH/C5PiP/ANCP/wCSVx/jR/wuT4j/APQj/wDklcf417/RQB4B/wALk+I//Qj/APklcf40f8Lk+I//AEI//klcf417/RQB4B/wuT4j/wDQj/8Aklcf40f8Lk+I/wD0I/8A5JXH+Ne/0UAeAf8AC5PiP/0I/wD5JXH+NH/C5PiP/wBCP/5JXH+Ne/0UAeAf8Lk+I/8A0I//AJJXH+NH/C5PiP8A9CP/AOSVx/jXv9FAHgH/AAuT4j/9CP8A+SVx/jR/wuT4j/8AQj/+SVx/jXv9FAHgH/C5PiP/ANCP/wCSVx/jR/wuT4j/APQj/wDklcf417/RQB4B/wALk+I//Qj/APklcf40f8Lk+I//AEI//klcf417/RQB4B/wuT4j/wDQj/8Aklcf40f8Lk+I/wD0I/8A5JXH+Ne/0UAeAf8AC5PiP/0I/wD5JXH+NH/C5PiP/wBCP/5JXH+Ne/0UAeAf8Lk+I/8A0I//AJJXH+NH/C5PiP8A9CP/AOSVx/jXv9FAHgH/AAuT4j/9CP8A+SVx/jR/wuT4j/8AQj/+SVx/jXv9FAHgH/C5PiP/ANCP/wCSVx/jR/wuT4j/APQj/wDklcf417/RQB4B/wALk+I//Qj/APklcf40f8Lk+I//AEI//klcf417/RQB4B/wuT4j/wDQj/8Aklcf40f8Lk+I/wD0I/8A5JXH+Ne/0UAeAf8AC5PiP/0I/wD5JXH+NH/C5PiP/wBCP/5JXH+Ne/0UAeAf8Lk+I/8A0I//AJJXH+NH/C5PiP8A9CP/AOSVx/jXv9FAHgH/AAuT4j/9CP8A+SVx/jR/wuT4j/8AQj/+SVx/jXv9FAHgH/C5PiP/ANCP/wCSVx/jR/wuT4j/APQj/wDklcf417/RQB4B/wALk+I//Qj/APklcf41Fc/Ffx/d28lvc+AUmhkG145bCdlYehB619CVyvjx/EyeGJ/+ETjV9UZlVclQVU9Su7jP1oA+Ttcmu7PW0vE0eTw/P/rI4ovNi2nP3l3HI/A16b4a+I3i3xB4K8RadqOmS6naR6VchtTQBDF+5b75OA34fN9a3PC3wPlu7z+2fHF5Je3kh3taLKWyf+mknU/Qfma9I8WWVrp3wy8Q2ljbRW1tHpNyEihUKqjym6AUAZPwT/5JFoX/AG3/APR8legV5/8ABP8A5JFoX/bf/wBHyV6BQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/7OX/JPb//ALCsn/oqGvYK8f8A2cv+Se3/AP2FZP8A0VDXsFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfP/wAW/wDkungz/t0/9KWr6Ar5/wDi3/yXTwZ/26f+lLV9AUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeO/8AknniX/sFXX/opq6Gue8d/wDJPPEv/YKuv/RTUAYHwT/5JFoX/bf/ANHyV6BXn/wT/wCSRaF/23/9HyV6BQAV59qfxQ0jT/EVxoNlpusa1fW6brhdKtROImzghvmHIJGccAnGc5A9BrwjQPGGv+KLzxTeeDLDwzoVlFtkuLy/iaO4IYORM7LlCRh2+YEDP8XJIBo+JPiXY+K/hd4kv/DlzqWn3dg1urs/7mVA8yAEMrHggMODng5HIy7w58adHt/DWk/2pY67sjSGyudVktxJAZwg3EvvJJ6t0LEc4ryOHVLiaz+IMC6j9ut7yJbqS58kRfaWW9iCy7cZTIlY7f8Aa9hXqX9reGP+GafLx/o32T7L9n80b/tu7d03Z/1n73Gfuc4xxQB2OsfFDR9Ku9KtILTVNVudUtReW0On2pkkaEjKttJB5AY46jac4rMm+KNhqXhHxNPpEWpW+saXbyD7DPbKLiJvuiXZkgqjH5v7oU5HTPlPhbQ9FuV8OTaX4pk8P+NURiLe4tpQk7sWaD5yNqh4yo/iDhh8pJIbYtPEN/baj4v8M6vYaLeaiuj3xudY0izUSNJ5fmN5zgKMZ+Q/KDvCg880Aafwx+Jc+meBtXvfEEeu6ktpOZjfMDMgUmGMRCR2+9l9230ya7DSPi9oOqo92NO1u202LcJtSuLUC2iKruwzqx+Y8ADGSWUDrXlnh7/k1/xV/wBhRP8A0K2rp9O8T2nhf9nXSbq70qDU/tEstvDbXMYeEuZpWBkB6qNucdSQOnUAHRyfHDQodNi1OXw/4kj0+Vtkd21mgidueA3mYJ4P5H0rV8SfFDwz4WsdNvLmea6/tGJZ7aK1jBkMLDIkKsV2g9OeSe3Bx5j441PxRc/DWyk1e/8AD2m6VfWsLWemabA/mXIzEyqQ4OxY15ypxnC87hXNeA7y4k+I/g+78RyebbSRLDYtModQqh4YQqjO3Eq8cDn5j1zQB67qnxc02bR9ftrWz1jTddsrJpILS9tFSYsV4YISchcq7A/wgnBANZ/wL8S6jrOj3ljqTaveXCXDzDULndLCFxEPKEjE/NyTt9Dmrfj3xV4Uk1PWPD8mm+d4jTRrpVvfsqH7OPs0smzzD8w+Un7oI+f64i/Zz/5J5e/9hWT/ANFRUAdB8UPGz+DPCDz2ksa6tdv5FmGAbaf4pNpPIUd8EbiuRg1kf8JbH8KfCeh2viyTV9S1TUEklmlVxMyyDaWUl5OAodVG04O0njNY/wAdvsH9veB/7X/5Bn2yX7X97/U7oN/3eemenPpWd+0x08L/AFu//aNAHR2/7QHg+e4jikt9WgV2CmaSBCqAn7x2uTgewJ9qva/8bfDPhzVpdOng1G6eNUcT2iRvFIroHUqxcZGGFeU/FSwtbXwL8Opbe2t4ZJNLO9o4wrN8kLckdfmdj9WY9zXd6fo/xQudB0abw14k0yz0ltMszBBPEpdf3Ee7P7lv4snqetAFoftGeECcf2drnP8A0wh/+O1yvxP+K2sXE2o6HoEV3pttYXptrrUI3IeRwThQR/qwSjnrlgvYbhXVDw98cs8+MtDx/wBcV/8Akel/aM/5J7Y/9hSP/wBFS0AL4W0vXfG/wZ0JYvFOo6dqBnlllvkd3llUSyrtY71JHI7/AMIrznx5D4m8IaxZaNYfEDW9Z1ObiS3immV4iceWMCRsltxwOvT1Fex/BT/kkWhf9t//AEfJXlPwuiPjj4vah4k1C2nkSDfeRhz5qRSFwsSFiP4VJ29D+7BHTFAC+K/Fvi7w7omheCm1YprLxCXUbwX+ZleSVikTTE/JhdhJz0I52/e1PB8/jfR/GcsqeJIfEvhi2lH2+8/teCVEhIbEp3uzRbcliBjOwjJHNc18bNIlsvig97f700/U1hkWeKIsQqKsbgA4Bcbc4z0ZeRmsrXtFs7n4pS6F4Gkj+y3LpBbSWtw0yBZIQJcuCxKcybuuBu7cUAaUvjLxR4+1jVtQh8VR+HYraDdaWZ1MWsch3cRAll3MRuJcjGQAdoIx6DpNn481X4V6rDrNxfRajbRLd6TqFjerJJcoI8iMeQ2ZMhcZYnd5oPJUV494X03Q2/4SePxF/o17Z6XcGzt7hjDi5XgDO4HeDwI8HOTnpz6j+zj9r/s7xB5nn/YfNg8nOfL8za+/b23Y8vOOfu57UAeifDXxZ/wmXgiz1GVi19F/o95x/wAtlAyegHzAq2BwN2O1dpXhX7O32r7B4hz532LzofKzny/Mw2/HbOPLzjnG3PavdaACiiigAooooAKKKKACiiigAooooAKKKKACiiigDx/9nL/knt//ANhWT/0VDXsFeP8A7OX/ACT2/wD+wrJ/6Khr2CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPn/wCLf/JdPBn/AG6f+lLV9AV8/wDxb/5Lp4M/7dP/AEpavoCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK57x3/AMk88S/9gq6/9FNXQ1z3jv8A5J54l/7BV1/6KagDA+Cf/JItC/7b/wDo+SvQK8/+Cf8AySLQv+2//o+SvQKACuI1P4XeDdY1C4v77Qke7uG8yV0nkjDN3OFYDJ6k45PJ5rt6KAOJX4W+DAb/AGaGka367LhI5pEVl3rJgANhRuVT8uOmOnFU4PhF4EtrlJ4vDsZaNgwElxNIpI55VmII9iCDXoVFAHJeIfAvhrxdcQT65pKXU0KFElEkkbhc5wSpBIz0B6ZOOpqXRvAvhjw7b3EGmaLaxJcq0cxkUys8bAAoWcklTgfLnHtXUUUAcHB8I/BFrDcwwaHsju4xFOPtUx3oHV8ff4+ZFPHpWzD4S0G38Mt4aGnJ/YpVk+yu7OMMxY8kk53HIOcg4xjAro6KAOAi+D/gOJJFHh9CJU2PuuJmIGQeCX+U8DkYOMjoSKu3Xw58J3mgWOhXOjxyafYu720Zlk3RFiS2H3bsEnJGcdPQV2VFAHI6J8PvCnhtrr+y9FhQXcXkz+YzTb4+6fOT8p7jocDPQUeHfh54X8K6i1/oml/ZLmSIwu/2iV8qSCRhmI6qK66igDgPih4Jfxn4QeC0ijbVrR/PsyxC7j/FHuI4DDtkDcFycCq+naFYfEbwho9z410G6/tO0VopYrnzbZhJwGfA2ZDBVbgEDOB0Nej0UAclq/w+8Ma7p+mafqWl+fbaZH5Non2iRfKTCjGQwJ4Veuelbun2MGm6fbWNqhjt7eJIYY9xO1FGAMnk8DvWhRQAVh+IvDGkeLLGOw1q0+1WscomWPzWTDgEA5Ug9GNblFAGDaeF9GsPDLeHba0KaU0UkJtvNY/K+dw3E7udx796g8NeCvD/AIQ+1f2FYfZDdbPO/fO+7bnH3icfePT1rpaKAOe1/wALaJ4msha61psN5GoyhcYdMkE7WGGXO0ZwRnHNU/D/AMP/AAr4Yuzd6RokEF0RxM5aV04I+UuSVyCQcYz3rraKAOI1j4ZeENe1Nr6/0KB7p8l5IZHh3kkklghAJJJyTyaZ4os4/CHw6v7Pwro06zyw+RbQadC/mCRl2+aSgJ3KBu3HklQM5IruqKAOL+GvhP8A4Q3wRZ6dKpW+l/0i85/5bMBkdSPlAVcjg7c967SiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8f8A2cv+Se3/AP2FZP8A0VDXsFeP/s5f8k9v/wDsKyf+ioa9goAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqdzd21qI/tFxFCJGEaea4Xcx6AZ6n2q5XmPxo8JS+JvB5u7TcbvSma4VAfvpj5x9cDI+nvQBxvxb/5Lp4M/7dP/AEpavdvtVv8Aavs3nx/aSu/ytw3bfXHXFfI+o+OjrPiPwjrOoCR59JSCO6YHmXypi24e5Uj8c16H8I9O1Dxh491H4haoWVI5Gjt1zkF2XbtH+yiHH4j0NAHv9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeO/+SeeJf+wVdf8Aopq6Gs3WdNTWdDv9LkcxpeW0tuzqOVDqVJH50Acj8E/+SRaF/wBt/wD0fJXoFeMW3we8RWFnHa2PxJ1S0to87IYIpERMnJwBPgckn8an/wCFQ+MP+isa5+U3/wAfoA9gorx//hUPjD/orGuflN/8fo/4VD4w/wCisa5+U3/x+gD2CivH/wDhUPjD/orGuflN/wDH6P8AhUPjD/orGuflN/8AH6APYKK8f/4VD4w/6Kxrn5Tf/H6P+FQ+MP8AorGuflN/8foA9gorx/8A4VD4w/6Kxrn5Tf8Ax+j/AIVD4w/6Kxrn5Tf/AB+gD2CivH/+FQ+MP+isa5+U3/x+j/hUPjD/AKKxrn5Tf/H6APYKK8f/AOFQ+MP+isa5+U3/AMfo/wCFQ+MP+isa5+U3/wAfoA9gorx//hUPjD/orGuflN/8fo/4VD4w/wCisa5+U3/x+gD2CivH/wDhUPjD/orGuflN/wDH6P8AhUPjD/orGuflN/8AH6APYKK8f/4VD4w/6Kxrn5Tf/H6P+FQ+MP8AorGuflN/8foA9gorx/8A4VD4w/6Kxrn5Tf8Ax+j/AIVD4w/6Kxrn5Tf/AB+gD2CivH/+FQ+MP+isa5+U3/x+j/hUPjD/AKKxrn5Tf/H6APYKK8f/AOFQ+MP+isa5+U3/AMfo/wCFQ+MP+isa5+U3/wAfoA9gorx//hUPjD/orGuflN/8fo/4VD4w/wCisa5+U3/x+gD2CivH/wDhUPjD/orGuflN/wDH6P8AhUPjD/orGuflN/8AH6APYKK8f/4VD4w/6Kxrn5Tf/H6P+FQ+MP8AorGuflN/8foA9gorx/8A4VD4w/6Kxrn5Tf8Ax+j/AIVD4w/6Kxrn5Tf/AB+gD2CivH/+FQ+MP+isa5+U3/x+j/hUPjD/AKKxrn5Tf/H6APYKK8f/AOFQ+MP+isa5+U3/AMfo/wCFQ+MP+isa5+U3/wAfoA9gorx//hUPjD/orGuflN/8fo/4VD4w/wCisa5+U3/x+gD2CivH/wDhUPjD/orGuflN/wDH6P8AhUPjD/orGuflN/8AH6AD9nL/AJJ7f/8AYVk/9FQ17BXG/D3wQvgHw/LpK35vjLctcNKYvL5KquAMnso712VABRRXB/GKeW3+FmuSQSNG+2FdynBwZkBH4gkfjQB3lFeF+HvgV4Y1nwxpWqXF/q6zXllDcOsc0YUM6BiBmM8ZNan/AAzl4P8A+glrn/f+H/41QB7BRXj/APwzl4P/AOglrn/f+H/41R/wzl4P/wCglrn/AH/h/wDjVAHsFFeP/wDDOXg//oJa5/3/AIf/AI1R/wAM5eD/APoJa5/3/h/+NUAewUV4/wD8M5eD/wDoJa5/3/h/+NUf8M5eD/8AoJa5/wB/4f8A41QB7BRXj/8Awzl4P/6CWuf9/wCH/wCNUf8ADOXg/wD6CWuf9/4f/jVAHsFFeP8A/DOXg/8A6CWuf9/4f/jVH/DOXg//AKCWuf8Af+H/AONUAewUV4//AMM5eD/+glrn/f8Ah/8AjVH/AAzl4P8A+glrn/f+H/41QB7BRXj/APwzl4P/AOglrn/f+H/41R/wzl4P/wCglrn/AH/h/wDjVAHsFFeP/wDDOXg//oJa5/3/AIf/AI1R/wAM5eD/APoJa5/3/h/+NUAewUV4/wD8M5eD/wDoJa5/3/h/+NUf8M5eD/8AoJa5/wB/4f8A41QB7BRXj/8Awzl4P/6CWuf9/wCH/wCNUf8ADOXg/wD6CWuf9/4f/jVAHsFFeP8A/DOXg/8A6CWuf9/4f/jVH/DOXg//AKCWuf8Af+H/AONUAewUV4//AMM5eD/+glrn/f8Ah/8AjVH/AAzl4P8A+glrn/f+H/41QB5p49+Gd3YfE220vSIP9E1iXfZcfLHz86n2Tr/u4r6T8OaHaeG9Bs9IslxDaxhAccse7H3Jyfxrzf8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGqAPYKK8f/4Zy8H/APQS1z/v/D/8ao/4Zy8H/wDQS1z/AL/w/wDxqgD2CivH/wDhnLwf/wBBLXP+/wDD/wDGqP8AhnLwf/0Etc/7/wAP/wAaoA9gorx//hnLwf8A9BLXP+/8P/xqj/hnLwf/ANBLXP8Av/D/APGqAPYKK8f/AOGcvB//AEEtc/7/AMP/AMao/wCGcvB//QS1z/v/AA//ABqgD2CivH/+GcvB/wD0Etc/7/w//GqP+GcvB/8A0Etc/wC/8P8A8aoA9gorx/8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGqAPYKK8f/4Zy8H/APQS1z/v/D/8ao/4Zy8H/wDQS1z/AL/w/wDxqgD2CivH/wDhnLwf/wBBLXP+/wDD/wDGqP8AhnLwf/0Etc/7/wAP/wAaoA9gorx//hnLwf8A9BLXP+/8P/xqj/hnLwf/ANBLXP8Av/D/APGqAPYKK8f/AOGcvB//AEEtc/7/AMP/AMao/wCGcvB//QS1z/v/AA//ABqgD2CivH/+GcvB/wD0Etc/7/w//GqP+GcvB/8A0Etc/wC/8P8A8aoA9gorx/8A4Zy8H/8AQS1z/v8Aw/8Axqj/AIZy8H/9BLXP+/8AD/8AGqAPYKK8f/4Zy8H/APQS1z/v/D/8aqt8FbNdL8QeONFgmme2sL9IYRI+TgPOuTjjJCjOAOlAHtNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5/8bP+SRa7/wBsP/R8degV5/8AGz/kkWu/9sP/AEfHQBv+BP8Aknnhr/sFWv8A6KWuhrnvAn/JPPDX/YKtf/RS10NABRRXmsvxh0keItQ0O10LxFqF7YyyRTJZWazfcbaWAD5257kdxQB6VRXmSfGHQ49dtdM1bSta0Wa5xtfVbUQIoJIDH5iQCQRnGPUgAmtzxf4/0DwPHGuq3LNdyL5kdnbrvldc4zjgAdeWIztOMkYoA7GivOF+LOj2+p2djq+j6/oYvGKRXGq2YgiBHqdx4yQM4wMjOBzV/XviBD4e1C8guPDniS5htVEkl7aWAe327QxIcsOADz6YNAHcUV5jp/xj07V4PtGm+FvFd7ArbGkttPWVQ2AcZVzg4I49672wuft2n2t2YZ7czxLL5M6bJI8jO117EZwR60AaNFFFABRRWD4i12y8N6HdaxqO9bW1Te/lruYksAAB6kkD055IHNAG9RWH4Y8R2vivw9a63YRTx2tzv2LOAHG1ipyASOqnvTPEWv8A/CPafFd/2Vqmph5RF5OmW3nyDIJ3EZHy8Yz6kUAb9FZ1hc/btPtbswz25niWXyZ02SR5Gdrr2Izgj1rRoAKKKKACiiigAori/BHxF0vx/wDbv7Jtr2H7F5fm/akVc792MbWP901reItdsvDeh3WsaiXW1tU3v5a7mJLAAAepJA9OeSBzQBvUVy3hPxhF4tgkuLfSNXsYVWN0l1C2EazK4JBjIJ3DA6+49a6mgAooooAKKKKACiiigAooooAKKKKACiuU8aeNLDwRo8Op6nBcywy3Atwtsqs24qx/iI4+U1raVqUWr6NZ6nbq6w3kCTxhwAwVlDDOM84NAGrRWfqF9Bpun3N9dOY7e3ieaaTaTtRRknA5PA7VjeDvGeneN9Il1TTYLmKCO4MBFwqqxYBTngnj5hQB1NFFc1qnib+z9fstI/sTXLv7Vs/021s99vDuYr+8fPy4xk8cAg0AdLRXF+CPiLpfj/7d/ZNtew/YvL837Uirnfuxjax/umu0oAKKK43/AIWJpP8AwsX/AIQj7Ne/2n183Yvk/wCq83ruz93260AdlRRRQAUUUUAFFFFABXj/AMIP+Sh/E3/sKj/0bcV7BXj/AMIP+Sh/E3/sKj/0bcUAewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXn/AMbP+SRa7/2w/wDR8degV5/8bP8AkkWu/wDbD/0fHQBv+BP+SeeGv+wVa/8Aopa6Gue8Cf8AJPPDX/YKtf8A0UtdDQAV81eEtQ1nTvjf4vm0TQ/7XuGlvEa3+1pb7V+0D5tzcHkAY9/avpWvH/Ang7xBo/xd8T67eaf5Gm332r7PP5yNv3Tqy8AkjIBPIoA43VJtY+N/imDSltLXQl0ZXM6XE5knUs6rJhMAkjaOMAAjlhuFafhNIPEv7RHiO61S1gkksPONqNp2o8MkcMb4J5baM/XkYwMdB8QvAmtt4v0zxl4OtvN1aOYG7ia5EYk2ABTyR8pUFGAYZBHHLGmeJPCHi7/hJ7Lx54WihtdZltYxqOlSTZ8xvlBTfnYw24B5X/VhhyeAD0fX/DuleJ9PNhrFil3alw/lsSCrDoQQQQeoyD0JHQmsfxHpVvovwv1rTbFZEtrfSblIUeVpCi+U+BliTgdBzwMDoK43xhb/ABJ8daXH4f8A+EatdCsbh913PcahHcBguGVflGVG4DoCSccgZz158Kf2P8LbrwtpS+bKulzW0fO3zpmRsn5jxudicZwM+lAHnXwru9WsPgp4iudDtJLnVEvZvs8cZG7d5UQ3AEHcV+9tx82Md65bQ9fm1TRNPa1+Iuqab4qW6Jmi1m/lFkY13MCDtZf7gw55IYY5GfRfh74P8X6B8NNW0tXTRdclvGmtZX8udQNsWM43DB2MvcjOcHiuf1fw/wDEfxX4fTSte8I6ZLqkkqxnXppbcSRQbt2MIcjBzkr/AA5G0k5oA9r0qaa50iyuZZLaaeWBHkltGLQuxUEmMnqhPQ+mK8K0JNb8YfF3xJok/i3X7Kws57uUR2d66nas2xVXJwoG4djwMe49m8IaLN4e8JaVpFxcvcTWlusckjOXG7qQpIHyAnC8cKAK4LwJ4O8QaP8AF3xPrt5p/kabffavs8/nI2/dOrLwCSMgE8igDg9O8eReIdWkj1zx7rOiaLY4isordXFxcx7Su6WWMH958qMxbcCXbbis258X3+u+C/Evhu81i61K00x1vLPUC7JJcoLhItsobJZD5okAJypUdQAB6HpXgzxd8N/FmoXfhjTLXWdBv3JNkLlYJIlHMYLSd1LEAgtkA5AJGLF34a+I/iTwJ4ig8Q3dqLu9RGsdLiMQWIrMHYFgvXCAJ85HzfMc8gA4GQ6n4d+BOkavpevaxBNf6iFMcd2yRwqpuBiMDG0McFhk5IBrQ8WWWu+HfhbofiWLxp4lmv8AUXhMitqDiJUkiaTAGc5GAM5554GcC1eeDPHGo/Cex8JHwx5VzpmoLNG5voG89W88scbsLtLqOpzn2NdL478G6/rXwj8NaFp2n+fqVn9l+0QebGuzZAyNySAcEgcGgDg4PiLceJLyx03VvGGoaBotlaW++e2jdri6nVVEmZEy2WJkIJyPlUlc1LpvirXNS1nWfBfh3xPqOr21/G0mmajPK8dzHJHH520MxBw2wxHOBzuGBkHf0v4d+MvAes6b4i8M2drdmWzgg1HS3nVXDFF84b2O3G9NwZTwSBtKg57bwrF8QNQ8UXWp+Jmg0zSPmFvpULRSMDwFLOFJIwWOdwO4dAOKAOA/4Wjdv8CnkXU7o6/HOumtchl8xSxLhyc5wYlZQ/3twJ6jdWbrHi3XdJvNL8Fap4qvdHW2tFbVtTMbTz+fIPOChlYsQuUjypGfmzkYFaH/AApjVv8Ahbn2j7DB/wAIv9v+1eZti8vy/wDWeT5O/OM/uumMc4xxXUeOPAniBPG1t488H/ZJNSiRRPaTtgzMBsyCx24MZwRlcBcgkmgDhrf4nReDvG6HS/E2qeJvDdxGnnrqDOZoWyQdhkA5HXoAQ2DyAw1PCFh4t+Juka94ibxdqWm3TXHlWUFndvFbo4UEqyDouDGAQc9Sdx69lbWvxA8V6+8eu2cGheF2i8m605LiKaS5QqwYeYqk8nAOCmFPHPNcpoPh34n+ALbWdD0HTLXUrG4YvaXhmiTypDgeYFZs52jBQ5AYAgkZ3ADf2aOnijPra/8Atatb9oi23+ENMu/PnXyr/wAryVfEb7kY7mHcjbgHtub1qf4K+DNf8H/27/bmn/ZTdGDyf3ySbtvm5+6Tj7w6+ta3xn8Max4r8H2mn6LZ/arlL9Jmj8xUwojkBOWIHVhQB5jf32taJpvhPwv4e8Rast54hsrKaWS7uiY7YN8iRwMOYl3FtwAzhUAPUHa8WXmvfCHWtAvovE2q67b3kUiXlpqc5dJCm3cUyTszuGOpXHJYEitPxZ8NtevvDfhLVtFjSPxLoVnbQSQNIuWMYUrgk+XlH3H0IJ5OADFrnhLxl8UNa0SHxPo0Gg6bYRsbiWG5SZ5WbbvCAE7c7RgHO3kktwKAMbQk1vxh8XfEmiT+LdfsrCznu5RHZ3rqdqzbFVcnCgbh2PAx7j3mwtfsen21mZ55zBEsXnTvvkk2jG5m7scZJ9a8v8CeDvEGj/F3xPrt5p/kabffavs8/nI2/dOrLwCSMgE8ivYKAPmLwknjLxP4F8Q65ceL9ctrbSY5JbUx3TEyzBA7qx3btoVVAHQGTI6MDb0M+KvFfwv1nxPL4w1iK80lTDbQQ3JgQxwqsjmQrzI5ViATzkDJOeOw8C+DNf0X4SeJtC1Gw8jUr03X2eDzY2374FRfmBIGSCOTR4F8F6/ovwj8S6DqNh5GpXv2r7PAJY2374FRfmBIGSCOTQByWp/ETxNrnhjwloFnqklvrGtuxuL9QIiQbloogGj+6Mqd2BnAHJyQdHxZea98Ida0C+i8TarrtveRSJeWmpzl0kKbdxTJOzO4Y6lcclgSKiuPhZ4lTwb4WvdNt0t/FOiPJvt3lQl1+0NLGVYsY8qWzg9QxyeADp654S8ZfFDWtEh8T6NBoOm2EbG4lhuUmeVm27wgBO3O0YBzt5JLcCgDG0JNb8YfF3xJok/i3X7Kws57uUR2d66nas2xVXJwoG4djwMe4zNO8eReIdWkj1zx7rOiaLY4isordXFxcx7Su6WWMH958qMxbcCXbbiu88CeDvEGj/F3xPrt5p/kabffavs8/nI2/dOrLwCSMgE8iqmleDPF3w38Wahd+GNMtdZ0G/ck2QuVgkiUcxgtJ3UsQCC2QDkAkYAD4O+OdQ1TW9U8L3WovrNtbLJcWmpz7hK8YkVcMG5IO8EZOV5HIxjW+NHjW+8J+HLW00qSSC91OR0FwoGY40A3bTnhjuUA4PGehwa2vAdv47ae91DxndwIJv8Aj2063EeIPmOdxVcngLt+duCc89Kfxa8DTeNfDsf2EJ/atg7S2wdiBIpHzx5zgE4UgnuoHAJNAHl3xX8H6x4f8K6VeX3ibUtThdkiura8u3mVbrYx3xZx8vDjkZHvk4pWPxCbWbjTNGvfFd74a8P6dYWyB7OBvOnljRVcbo8sM5kwfu4Vcrmug8Y6N8WvGei6bpeoeHoUjtMPM8d1bg3EwyA5+f5flPQcZJPoFt6X8O/GXgPWdN8ReGbO1uzLZwQajpbzqrhii+cN7Hbjem4Mp4JA2lQcgHMx+MZ7iXxP4TtvEmo61oV5ZXFxaX88jrcRGOAzbcsMlT5ZjZcAEZI25IO38JLLVI/hzr2taNqws78SyW6JfT4sYAFhZp2XBxIFz8xyOBkYzXX2+m/EjxMPEH9tyWul6beWlxbWmlK8cm12TaheRUYlfmJJDA7h0A4rh9N+HXjtvh1qXhGTSBZZujqKzG+jK3RARRblVJxnG8MTjKAHHUAFfxRPHoHg23nt/ilqt/4kbDNBaaq81vJyNyjacpgMCCx+bacDni1f+N9W1Pxx8PJLfXL3yb62sftkUMrwxzTfaHjm3IMA/MpHTBA9MVLqng3xlqHhGHQ9N8B6ZpEkdrHFeXi3Fs0+obSnyhhjbll8w5PO3r2aHTfhv4wt9d8EXMuj7YtLEX21vtMJ8vF7LKf4ufkYHjPX1oA4Pwn461DwdoOsQ6RJ5GoX81vtnMauI4080tgHjJLKOQRjd0OK6nUfF0PhyDTNR8P/ABJ1jxBqcM5+02t8k4t5UOedj9ABwRkk7sgripdG+BviO+0TU4tQtINN1JZoJLKSecOjr+8Eqny2bHWM5IPTA6k13cl38ZNUsNM01NMs9Gukz9r1WSeCVZcA4/djdsz3wDk4xtGRQBzmk+LNa+LPxDis7TVdQ0TRrWzM8kNlcmGYnCBvmAIc+YwAyANo6Ak5zPDGl32iftF2un6pqD6leQmUG6kdmaRTasVJLc52kDGTjGMnrXVah4J8V+EPiUfEvhK1TV4L5D9uhnljididplyzEAF2G8FQADkbdowaPhTwl49m+Ltt4u8SaTHCrtKZ5EmhKoDC0aqFVycD5R3PqepoA96ooooAKKKKACiiigArx/4Qf8lD+Jv/AGFR/wCjbivYK8f+EH/JQ/ib/wBhUf8Ao24oA9gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP/jZ/ySLXf+2H/o+OvQK8/wDjZ/ySLXf+2H/o+OgDf8Cf8k88Nf8AYKtf/RS10Nc94E/5J54a/wCwVa/+ilroaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArx/4Qf8AJQ/ib/2FR/6NuK9grx/4Qf8AJQ/ib/2FR/6NuKAPYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz/42f8AJItd/wC2H/o+OvQK8/8AjZ/ySLXf+2H/AKPjoA3/AAJ/yTzw1/2CrX/0UtdDXPeBP+SeeGv+wVa/+ilroaACiivPtZ+Kfh/SfEX9iW0OpaxqgZkkttMtvOaNlGSDkjJxnIXONpzjFAHoNFeZt8ZPDC+Fxr6C+lhF2LSW1RE8+FiGZSylgMEIcEE+nUHG/r/jvRvDvha28RXMk09ld+V9mEEWXm8wblwDjHygnnHT14oA62ivPLz4s6DZzaZbW9nqup32oWq3SWVhAs00SMgcB13cHac4BPAz0IJzpPidpviXQPFVlpsWq6dqunaXdTGO7j8qRCqkEgqx2srY64OSMdDgA9Uor56+H/xWh8M+CVufE8+sanPd6lOkMgYTMqxxQEgmRxgfvOMe9eueIfGWn+GNW0TTL2C5kn1m4+z27QopVW3IuXyRgZkHTPegDqaK8+1P4oaRp/iK40Gy03WNavrdN1wulWonETZwQ3zDkEjOOATjOcgcz4k+LNprXwz1u/8ADP8AaltewyxWrsYQGtxIf9YSCQqkK6gg5DEdMg0Aez0V8+ad44im+EenN4hu/GNs8F4EOp2Egje7ZjOQFldvnVQuG9CFrt5fiv4a8PWuhaYp1fVLq7s4HjijRZ7nDqvl+b8wzIwIOBknr3GQD0yiuF0n4naDrNjrU8cV7bXWjRSz3Wn3MQS4CIMsQu7B5BHXg4zjIzgRfHXw9cWdzdxaJ4iktrbb9omjtYykW44XcfMwMngZ60Aes0VheHddsvEuh2msaYXNpdJvTzF2sCCVYEeoKkenHBIrnfih42fwZ4Qee0ljXVrt/IswwDbT/FJtJ5CjvgjcVyMGgDv6K8p/4S2P4U+E9DtfFkmr6lqmoJJLNKriZlkG0spLycBQ6qNpwdpPGaht/wBoDwfPcRxSW+rQK7BTNJAhVAT947XJwPYE+1AHrlFeY6/8bfDPhzVpdOng1G6eNUcT2iRvFIroHUqxcZGGFZw/aM8IE4/s7XOf+mEP/wAdoA9for52+J/xW1i4m1HQ9Aiu9NtrC9NtdahG5DyOCcKCP9WCUc9csF7DcK6TRPiJN4X+COieIdSW71a8nneBTLOd0jebL95zk4Coex6Ae4APZaK+avAnjPxVrnxntItZ1G9jE0twJtN8x0iiKwvhPKzgYIHXnIyeea7zx3rl/wCCPiDoWvveXp0C/wB1nqNsWdoIjxiQD5gGwc4UAnym/vGgD1miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArx/4Qf8AJQ/ib/2FR/6NuK9grx/4Qf8AJQ/ib/2FR/6NuKAPYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz/42f8AJItd/wC2H/o+OvQK8/8AjZ/ySLXf+2H/AKPjoA3/AAJ/yTzw1/2CrX/0UtdDXPeBP+SeeGv+wVa/+ilroaACvmL4XweIT4p17R4/F40PW5JsTxzWiXb3UkZff8zHG5SSTgknJPQE19O1yXiD4feFfE92LzVtEgmugOZULRO/AHzFCC2AoAznHagDyzw94I0TxBqPi9LPxXH4h1C9s5orgiwkt4EnaVZFkMqkoR5iZAXqAcZANcb4a1S+8fXng/wRf5ksrG5dpN9xIBPAAG2sB3VFkVSMYDAcYJP0joHhXRPDFk1roumw2aNzIUGXfBJG5jlmxuOMk4zxUel+DdB0bXr3XdO0/wAnU73f58/nO2/cwZuCSBkgHgUAeeJ4x1XWfinrOl+D9F8P219ZxvHc32qQuJrjy3VG+aLnbnbgHPC546DzWLV9Qfx14i87XINVmu9FvLe8vbeFVjn22TEqvA4V4lAYAbgmehr3/Xvhx4T8T6o2o6vo6z3bKEaVZZIywHTdsYZOOMnnAA7Cq8Hwr8G290bmDREila3a2JWeUAxtEYmGA2MlScnqSSc55oA+YLr/AJJ7of8A2Fb7/wBFWle3/FLU7C5+KHgLTYbmN7yz1JHuIl5MYklh259CdpOOuMHuM93H8OPCSeG5fD8ejxnS5Z/tLQPJIxEuANwYtuU4AHBHGR3NU7L4S+CdOvre+s9E8u5tpVmhf7XOdrqcg4L4PI70AcJoHjDX/FF54pvPBlh4Z0Kyi2yXF5fxNHcEMHImdlyhIw7fMCBn+LknzaHVLia0+IUC6j9ut7yFbmS58gRfaWW9iCy7cZTIlY7f9r2FfROp/C7wbrGoXF/faEj3dw3mSuk8kYZu5wrAZPUnHJ5PNPt/hj4NtZNQeHQYE/tCJoblBI+xlZgxCrnC4KgjaBjAxigDxXxD/wAmxeFP+wo3/oVzTfg9cw6X8T4k8QzRrdz6dGlg9ywcgusRhCtztJhOAMjg7epxXsSfCbwNFZTWC6GRbTSpM8f2qflkDBTnfngSP+f0q3qfw48K67Bp8WoaQkyafALa2ImkVliAACllYFgMcZJ6n1NAHi3iz/TfjT4qnsx9oit9LvPOki+dY8aeUO4jphztOe/HWug+Fv8Ayb54y/7fv/SVK9S0vwJ4a0bSL7SdN0uOCzv0ZLpRI5aVSpXBcktjBOOeMnHU07S/Bnh7RvD95odhp/kabe7/AD4POdt+9QjfMSSMgAcGgDH+Cf8AySLQ/wDtv/6Pkrkfjt9g/t7wP/a//IM+2S/a/vf6ndBv+7z0z059K9Y0PQ9P8O6RDpelwmCyg3eXFvZ9uWLHliT1J71y3xQ8Ev4z8IPBaRRtq1o/n2ZYhdx/ij3EcBh2yBuC5OBQB5/+0x08L/W7/wDaNc18VLC1tfAvw6lt7a3hkk0s72jjCs3yQtyR1+Z2P1Zj3Neu6doVh8RvCGj3PjXQbr+07RWiliufNtmEnAZ8DZkMFVuAQM4HQ1tav8PvDGu6fpmn6lpfn22mR+TaJ9okXykwoxkMCeFXrnpQBwen6P8AFC50HRpvDXiTTLPSW0yzMEE8Sl1/cR7s/uW/iyep61aHh745Z58ZaHj/AK4r/wDI9en6fYwabp9tY2qGO3t4khhj3E7UUYAyeTwO9aFAHkP7Rn/JPbH/ALCkf/oqWt74Kf8AJItC/wC2/wD6PkrpPEXhjSPFljHYa1afarWOUTLH5rJhwCAcqQejGptD0PT/AA7pEOl6XCYLKDd5cW9n25YseWJPUnvQB88eD/8Ak6C5/wCwpqP/AKDNXfftF/8AJO7H/sKRf+ipa7K0+H3hew8TN4jttL8vV3llmNx9okPzvkMdpbbzuPbvXJ+O9Dv/ABv8QdC0B7O9GgWG681G5KusEp4xGD8oLYGMqSR5rf3TQB3nhX7Z/wAInon9ofaPtn2CD7R5+fM8zy13bs85znOec1u0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeP8Awg/5KH8Tf+wqP/RtxXsFeP8Awg/5KH8Tf+wqP/RtxQB7BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef8Axs/5JFrv/bD/ANHx16BXn/xs/wCSRa7/ANsP/R8dAG/4E/5J54a/7BVr/wCilroa57wJ/wAk88Nf9gq1/wDRS10NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/8ACD/kofxN/wCwqP8A0bcV7BXj/wAIP+Sh/E3/ALCo/wDRtxQB7BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4m1CbSfCmsalbhTPZ2U1xGGGRuRCwz+IrYrnvHf/ACTzxL/2Crr/ANFNQB5T4Zb4w+LPDtrrlh4s0uK1ud+xJ4Iww2sVOQICOqnvWv8A8I98cv8AoctD/wC/K/8AyPXQfBP/AJJFoX/bf/0fJXoFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHj/APwj3xy/6HLQ/wDvyv8A8j0f8I98cv8AoctD/wC/K/8AyPXsFFAHj/8Awj3xy/6HLQ/+/K//ACPR/wAI98cv+hy0P/vyv/yPXsFFAHnPwg8T6t4u8I3F7rFytxdQ3r24lWMJuUJGwyAAM/Me1ejV4/8As5f8k9v/APsKyf8AoqGvYKACud8ZeG18X+Fb7QnuTbC6Cfvgm7aVYMOMjPKjvXRUUAeNwfCDxPb20cFv8TNXhgiURxxRxyIqKBgAAT8ADtUn/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9VNS+GXi3StJvdQb4o65MLW3km8v8Aeru2qTjPn8dK9rrF8V/8idrf/YPn/wDRZoA8H+HegeLfiBo91qC/EPXNP+z3HklPOml3fKDnPmj1rsv+FQ+MP+isa5+U3/x+q/7N/wDyJuq/9hD/ANppXtFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P10Xw+8AP4Il1a4n1uXVbrU3jkllki2HK7jk5ZixJcknNd9RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3jv/AJJ54l/7BV1/6KauhrnvHf8AyTzxL/2Crr/0U1AGB8E/+SRaF/23/wDR8legV5/8E/8AkkWhf9t//R8legUAFFeUfHXU9R0bwRZ3Omahd2U7aikZktpWjYr5cpxlSOOB+VQaV4Hm1HwVZa1ceP8AxZaTXGmpdSSvqp8mFmjDEkED5ATn7w4HXvQB69RXzr4H+Kms6Z8PfEN3qV0uo3GmvAtgbyU75HmZhtLZy4XaWx1wGGQMY6bwh4Q8U+K9ITX/ABP4x162lv0jmtrfTLwQKsRXhmCjaCwwcADHfJJAAPZKK8o8PaJ46ii1Dwl4gu9RuNKds2fiKzvUjuYwGDYO5i+DjHQkZIyVIK8V4ystX8P/ABK0DwzZ+MPFD2Wo/Z/Okm1RjKvmTMh2kYHQcZB5oA+jKK8ml1PTPhx4rt7KTVvGniPUr21YpYNL9rCrnO8KdvPyP0zgBs44rp/CPxA0fxbNfWlot1aahZMVmsr2MRzqAcE7QTwDwe4PUDIyAdlRWHr/AIi0rwzp51DWb9LS1DhPMYFizHoAACSepwB0BPQGuNsfjV4cvLnT1urLVtNtNQZlt76+t1S3cg4PzhzwDgE9BnnA5oA9OorjLfx/pFz47m8HS297barHnaZkUxy4Xf8AKVY9U+bkDjg4PFVtG+JWh6zbarqMKXtvo+m583U7mNUgc54VPm3MTkEDbnkA4JAIB3lFeVW/xx8OTW0V4+l67Bp73AtzfSWi+SkhGcFg55A5wMnHauXv/Gl5ZfHa5kGr3k+gwWj3fkW9yXheMWJlyq52nOMjtnmgD32iuJ0P4iaR4j8J6l4mtLa9Sy0/zfOSZEEh8tBIcAMR0PGSOarXPxU8O2fgqx8VXJuo7e+ZltrUov2iUq5VsLuxgYyTnGMdyBQB39FfNXxT+J13qF5p1poz+ItBurQyfa4bjNq7bghTIVsngE8+vHWvVNZ+Kfh/SfEX9iW0OpaxqgZkkttMtvOaNlGSDkjJxnIXONpzjFAHoNFcNoXxH8O674fu9fjvvs9nZf8AH2l0AskHplQTnd2xnJ4HOQOA8cfGKy1HwTPHpNl4g024vsfYb94RCj7JV8zbIr5PAIOPXBoA94orhvhPf3mpfDLR7y/up7q5k87fNO5d2xM4GSeTwAKh+KHjZ/BnhB57SWNdWu38izDANtP8Um0nkKO+CNxXIwaAO/oryn/hLY/hT4T0O18WSavqWqagkks0quJmWQbSykvJwFDqo2nB2k8ZqG3/AGgPB89xHFJb6tArsFM0kCFUBP3jtcnA9gT7UAeuUV5jr/xt8M+HNWl06eDUbp41RxPaJG8UiugdSrFxkYYVnD9ozwgTj+ztc5/6YQ//AB2gD1+ivmfSNd8YfFnxpqcNj4jutCENk89tbW8zrEArKFVihHJL5MmCfQYwBu/CvxfrHjrS9Y8J6nqd0t6LPzLPUYiyTQgYXLOrKWIYxn1b5txOaAPe6K81+Efiy88R+G59O1Z5zrWkS/ZrvzwfMYc7S2QPm4ZSDk5TJ616VQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/AOzl/wAk9v8A/sKyf+ioa9grx/8AZy/5J7f/APYVk/8ARUNewUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWL4r/5E7W/+wfP/AOizW1WL4r/5E7W/+wfP/wCizQB5j+zf/wAibqv/AGEP/aaV7RXi/wCzf/yJuq/9hD/2mle0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeO/wDknniX/sFXX/opq6Gue8d/8k88S/8AYKuv/RTUAYHwT/5JFoX/AG3/APR8legV5/8ABP8A5JFoX/bf/wBHyV6BQB5B+0Z/yTyx/wCwpH/6Klrl9b+Een3/AMLdL13w/YzLrQsILmaGORpPte5FL8MeGHLDb15GDkY9r8ReGNI8W2EdhrVp9rtUlEyx+ayYcAgHKkHoxq5p9jBpun21jaoY7e3iSGGPcTtRRgDJ5PA70AeDXv8AZ/jn4GSjQdNtdMudDuEubyytwuHKRlWkyTuwUJbc2WJjK/Mea9O+F/iXTNe8EaXDYTbp9PtYbW6gbh43VQuSPQ4JB7/UEC9pHgTw3oGsXOraTpKWd5cKySPHK+3azBiAhO1RkDoBjHFZ978JPAmo3L3M3h+AO+MiGaWFOBjhUYKOnYUAVNE+JsXiP4g3PhjRtPS8sLdWeXVIrobdoAyQhX5hvITIJzncOK4v4pf8nA+CvrZf+lT167oHhbRPC1obXRdOhs1b75Rcu/JI3Mcs2MnGScZqLU/Bug6zrtjruo6f52p2Wz7PP5zrs2sWXgEA4JJ5FAHmnjTRtBvvipFPovi/+xfGabR5MkMhjnl8seWPMPyrlcKR8wIIG0nIZPh9r+oW3xNvfDWrabol5qSxS/adY0myUSNJkSHznAUbc/IflB3hQeea9D8Q+BfDXi64gn1zSUupoUKJKJJI3C5zglSCRnoD0ycdTU/h3wV4c8JtI2iaXBaPJndLy8pBxld7Ett+UHGcZ5oA8y/aKivW0nRJ13/2elxKkwD/AC+YVXy8rnk4EuDjjn15qeMbFdV8K6bdeJfitb3GkXcgmsyujLl3AIJAiO/5ckHPQnBwcV7dfWNpqdlJaX1rDdWsmN8M6B0fByMg8HkA1yVl8JPAmnXKXMPh+AumcCaaWZORjlXYqevcUAeSfFS3srr/AIRTwto9rdahr1jpyRtLDBtd4vLGEeLBkDYUvtONoY8HdkQ3uoWmp/s/RwaFbfYxp19CNYhSYZlyCPObnLK7mPAI4K4HEea960zwboOja9e69p2n+Tqd7v8AtE3nO2/cwZuCSBkgHgVDaeAvDNhrGoarb6WgvdRWRLt5JHdZlkbc4ZGJXBI9KAOTsPEnhPQPgroV7qdol3pEtvDbtaJahxLOPvjY2FyHSRiT1Kk5JIz5Vrd1a33xQ1K7sLfyLOfw/LLbw7AvlIdKJVcDgYBAwOK9rg+EPgO2u4p4vDyF43DgSXEzrkHPKsxBHsRg1uf8IV4e/wCEu/4Sn+z/APidf8/XnSf3PL+7nb93jpQB4z4D1Sx0n4CeKWv7mOH7RNdW0O7rJLJbxhVA7kn9AT0BNcfkW1r8Nr3VudAXfvWX95H8t65m/d8/wlM8cjA5xXvM/wAIfAdzdSzy+HkDyOWIjuJkUEnPCqwAHsBgVryeA/DT+FovDEmlI+kxP5kcDSOSjbi2Q+dwOWPOehI6cUAeNfH7U9G1HUtDWwubW4vI4Hed4MMfKfY0WWHUH5yBno2f4hmj8L4PEJ8U69o8fi8aHrck2J45rRLt7qSMvv8AmY43KSScEk5J6AmvXB8FPh8Onh7/AMnbj/4utTxB8PvCvie7F5q2iQTXQHMqFonfgD5ihBbAUAZzjtQB86+KtAtVtNe1nR/Fza/cLOP7X8iwa3iCyS/eL52MDKEwq5z94cLkdz4m1jw5N+zrplvbXFkbhoreKCFUG9bpCpnwMZVsGQluM7+p3jPrej+ENA0HTZdN03SLWG0nUpOhTeZlOeHLZLj5iPmJ4OOlYX/Ck/h7/wBC/wD+Ttx/8coAd8Ff+SR6F9J//R8lcf8AHb7B/b3gf+1/+QZ9sl+1/e/1O6Df93npnpz6V6vomiaf4d0mDS9Mg+z2UG7y4t7PtySx5Yk9Se9cv8UPBL+M/CDwWkUbataP59mWIXcf4o9xHAYdsgbguTgUAef/ALTHTwv9bv8A9o1zXxUsLW18C/DqW3treGSTSzvaOMKzfJC3JHX5nY/VmPc167p2hWHxG8IaPc+NdBuv7TtFaKWK5822YScBnwNmQwVW4BAzgdDW1q/w+8Ma7p+mafqWl+fbaZH5Non2iRfKTCjGQwJ4VeuelAHB6fo/xQudB0abw14k0yz0ltMszBBPEpdf3Ee7P7lv4snqetWh4e+OWefGWh4/64r/API9en6fYwabp9tY2qGO3t4khhj3E7UUYAyeTwO9aFAHypf6T4Lu/Gmqw22u6p4Wkj+0i4ju7OJo0bLCSGNoZeBtJULg5AIycgVrfs62U7+LdVvlXNrDYeS75HDPIpUY68iNvy+lexa98OPCfifVG1HV9HWe7ZQjSrLJGWA6btjDJxxk84AHYVcNpY+C/CdydD0UeXbQmSOys4WL3EgUBQdoLFjhQXIJ7npQB5h8Lvtf/C7fHPl+d9i86583GfL3/aPk3dt2PMxnnG7Hevdq8m+HHw7i/wCEEvY/FdrPPe6/MLi/inkdZMK26MMQ2c5y5PBy+D0r0PQ9D0/w7pEOl6XCYLKDd5cW9n25YseWJPUnvQBrUUUUAFFFFABRRRQAUUUUAFFFFAHj/wCzl/yT2/8A+wrJ/wCioa9grx/9nL/knt//ANhWT/0VDXsFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi+K/+RO1v/sHz/8Aos1tVi+K/wDkTtb/AOwfP/6LNAHmP7N//Im6r/2EP/aaV7RXi/7N/wDyJuq/9hD/ANppXtFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWF4l8T6b4R0ltT1aV47YOIxsQsSx6AAfj+VAG7XPeO/8AknniX/sFXX/opqn8P+I9I8UaeLzR76K6hI52n5kPoynkH61B47/5J54l/wCwVdf+imoAwPgn/wAki0L/ALb/APo+SvQK8/8Agn/ySLQv+2//AKPkr0CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPH/2cv+Se3/8A2FZP/RUNewV4/wDs5f8AJPb/AP7Csn/oqGvYKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArF8V/wDIna3/ANg+f/0Wa2qw/GLbPBOvNjO3Trg/+QmoA8z/AGb/APkTdV/7CH/tNKz/APhpWz/6Fmf/AMDB/wDE1pfs5J/xRWqNnrqJH/kJP8a9d+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJo/4aVs/+hZn/APAwf/E17f8AYLT/AJ9YP+/Yo+wWn/PrB/37FAHiH/DStn/0LM//AIGD/wCJqjqnx60XW9OnsNT8IvdWsow0b3YwfT+Hg+4r337Baf8APrB/37Fct46vb3QPC099oWhx6hfhlRIlt9+3P8RUcnHoPWgD5WXxANF1/wDtPwpNf6WB91ZJxIw9iQAGX2I/OvWtM+ME/ivwV4g0XVtMm+3nSrnF1aRFoiPJblx/B9en0qDQfhN4k8bX41rxxdzWsT8i2AAmI9Ao+WIe2M+w616frXh7SPDXww8R2WkWEVpANKud2xfmc+S3LE8sfc0AQfBP/kkWhf8Abf8A9HyV6BXn/wAE/wDkkWhf9t//AEfJXoFAGHr/AIi0rwzp51DWb9LS1DhPMYFizHoAACSepwB0BPQGuK/4XVpH9l/2r/wjXij+zM/8fv2BfJ+9t+/vx97j68Vq/E/wZeeOPC0el2VzBBcw3KXCGfOxsBlIJGSOGJzg9Md8ji4fEvi7wv4Tg0Pxd4CnutJW1NpNc6fcbtlokYRi4Qtg7cnJZAe2ME0Ad/rXxD8P6H4Ug8Tvcvd6bdMqW5tV3NKxzwAcYI2tkMRjaR14rc0rUotX0az1O3V1hvIEnjDgBgrKGGcZ5wa+fPHsHhG4+FOnX/g03dvpy6tsmtGeTaJngy28OTl1CIAQSBubGc1H4yuNX8I+AfAw0vxJrcf2+1a5kzfMNmYrfEa7cYjXnA5xk+tAH05RXlPxO1TUtP8AG3w/t7S/u7aG71Ly544ZmRZl82AYcA/MME8H1Ncv4bvfEHxb8UeIbuLxJqmj6VZxBLKKxnMJVnJ8ougJDcKxb5gckAEDoAd4vxV0ubWtZ0m00jWru80nf50VrbLI0m2ZYj5YD5PLZ5A4BNdXoeqHWdJgv/sN7Y+du/0e9h8qaPBI+ZcnGcZHsRXytp0mr+H9Q8c51KZdWtLVopb2KZg7OL2BWYPw3PPPU5rVs/iZq+o6bovh+68VXmkWawy/2hqhjaadpPMd1wwO8rgRrwQeWzkYoA+q6K+bdP8AiJceH/H8Nn4Y17UvFulaikcS2+pTOsizklQqvIBg5wc4AIbB5AYZeneI73VrDVLbWvHGuaN4rF6I4Y7m6lgsxlgGDBFPlkfvM52qPl7A4APqaiua8I3N9e+GbKfUdRsNRumUiS70990MpDFcqeOcDnAAznAFeVfFjUdcPxb0DQ9N1/UdNgv4LeJhbXDoqs87pv2ggE4x+VAHvVFeEzX2q/D74sWtjN4j1nVNEk0ue9mgvJ/Pk2JFKxAycZzDkEbeuPXNfwNp3iv4nRax4hvvGGq6ZG0rQW1vp1w8aRSBVIOzONgBXgHLc5YHkgHrHi3xdpng3RP7W1YTmIyrDHHAm53c5OBkgdATyR09cCtHStSi1fRrPU7dXWG8gSeMOAGCsoYZxnnBr5b17xXqni34awJq11PJcaPfxQCUy8XCyxykGVccyJ5OA2ejnPOSfoX4a6W2l+AtIX7de3guraG5/wBLm8zyd0Sfu044jGOB2zQBf1TxN/Z+v2Wkf2Jrl39q2f6ba2e+3h3MV/ePn5cYyeOAQa6WvEPiHrmq2Xxu8J2Frql5b2U/2QS28NwyxyZuGB3KDg5HHPaua+Fll4j+IP8AbP2vxv4itfscaCLyb6Q5kfdhmy3Kjb90YznqMcgH0pRXy/D8UvEOn/ChLdtTuZdTvNRntor2Vt7xwLHEzYkJzv3SjBOcAnBGFx6JH8P/ABzpFto9/pfje7u9XhbN9b6ndSvZygjoowTgdORk5yChAFAHU6B8QNI1/wAYan4ZtLe9S907zfOeWNRG2yQRnaQxPU8ZA4rs6+TLu+u9M8Y/Eq8sLue2uY/P2TQSFHXOoQg4I5HBIr0U65q//DMf9rf2re/2lj/j8+0N53/H5t/1mc9OOvTigD26uL134h6R4f8AGGmeGbu3vHvdR8ryXiRTGvmSGMbiWB6jsDxXlsvijX/FHiLwZ4MsNYvrGNrC1n1C6inMU87tbiVz5gyT+7PGRy5Oc4BHNeM7K88DfFjSJtX1e+1i2t5YL6Ca4lMs4txKT5ZLHGQVboQDnPGcAA+q6K+Y9M8cJ4nW81DxZ8RdU0O5O+O1sdNilSJBwVc+WCGAJYYPzEAfNVT/AIXT4gHgKTRTLJ/aokWFNU/jMGDnJzxIPlAfnIJPDDcQD3zxp40sPBGjw6nqcFzLDLcC3C2yqzbirH+Ijj5TWtpWpRavo1nqdurrDeQJPGHADBWUMM4zzg18+fFfwfrHh/wrpV5feJtS1OF2SK6try7eZVutjHfFnHy8OORke+Tj3nwP/wAiB4b/AOwXa/8AopaAN+ivCPipd+I7r4s6H4f0fWtUsEvbWFWFlNIAuZZQ0hVSM4UZPsvXiprufxD8O/ifoWnf25qusaFrUscITUrgSuHzsI3EEjaZEfgLnIHOM0Ae41zPi3xdpng3RP7W1YTmIyrDHHAm53c5OBkgdATyR09cCvLb2F1fW9Q8ZfFb7BqKylIrTQtRYx2x+7gwD5zg4BUAHCkliSSPPdV1678R/CqF9S1m+vL7TdX8vypXLAwzRFlZyR8xDRygEkkAkdCKAPonUPHMVnpOlanbaBr2owanCJ4xp9mJmiUqrDzAG+UkN79DXY18x+MrjV/CPgHwMNL8Sa3H9vtWuZM3zDZmK3xGu3GI15wOcZPrUyfEaPxh4lv7nX/GuqeHNGt5j9htNPhdJJYzkfM8e7DDahO7cMsduKAPpaivl60+IWtN4Q8V6KmuXV+LBFuLDWRI8VwY/tUSEEn5sMHyMnK8jkYxdNh4h/4Uv/wm/wDwnPiP7b5mfI+3SeVs87ydv3s7s/NuzjtjvQB7Jr/j7SPDnijS/D12tzJqGpsixCFAVQM+xS5JHBOemTweOmewr5c8UxXGsfEPwLLealffaNYsdMnlnSUK8DyNtJhwMJyN3A+8Sa1tc166074kT6L4p8Q+J9E0e3tVhsprS7O+RVACzOVX5/Mw5JAJDEA/dOAD6NorzP4UXWrz6JcW+qeKdM16NNktvLa3LTTxK+SVm3gMOnAYZHzA9AB6ZQB4/wDs5f8AJPb/AP7Csn/oqGvYK8f/AGcv+Se3/wD2FZP/AEVDXsFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheM/+RF8Qf9gy5/8ARTVu1heM/wDkRfEH/YMuf/RTUAecfs4f8iLqX/YTb/0VHXsleN/s4f8AIi6l/wBhNv8A0VHXslABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3jv8A5J54l/7BV1/6KauhrnvHf/JPPEv/AGCrr/0U1AGB8E/+SRaF/wBt/wD0fJXoFef/AAT/AOSRaF/23/8AR8legUAee/FD4fyeOtFt47SaGHUbOXdBJOW2FW4dTjOM4U5wfu44yTWT/b3xb/4Rr7F/wh8P9r+V5f8Aaf8AaNvtz/f8nOM498Z5xj5a9YooA8D1D4Q+ILT4Tf2DbSWt9qY1X+0HiifauPL8rarPjJxhudvcc4GX+JvAHjDxP8PdAh/shLLVNBX7Itk11G5uovLiXzQ4O1TlD8hPTPPQH3migDwzWdJ+Iniv4ieHdV1Lw0lhpWm3sMqQreQSGJd6GViwbLE7RwB0AwM5JWz8H+Ofh54s1eXwdpNrqWjX6lkiknRPKPzeWDvcNmMn1IZT1BPy+5UUAfMdt8NPH88Xim51LRw17qtrw32m3HmTG6hlbo2BwrnsOPpWnpnwq8YeGrTQfEuhW9rHr9lG4u9PnlUmVjK4BDbihBiYAjK4C5B3Hj6JooA8ut1+KHiHxDJNOIPCukRxbUgRoLuRn2Nhs7W3YfbkfJ8vA5ya5nUdL+Jup6Jqela/4T0vX7lt8Vlqsklsptw3ys0a8HkAFThSDyc9B7vRQBxfw28LXfg3wfb6PfXf2m6Ekkr7JS0SZPCx5AIXGCRj7zMe9cn448HeINX+LnhjXbDT/O02yFr9on85F2bZ2ZvlJBOAQeBXsFFAHlniXwZqOufGHSNVlsPN0FdKls7yXzVX76zqVxkNz5g5A71z/hbQfiP8OpNU0jStGtdc0yVmktZzcxwASkACQgsGxgAMnqOG7n3OigD52l+C2u2vw1ktrdUuNcur2C6ntPNVVRESRQiseCw80kkkDjAzjLeu+AxrEHhGysdb0g6bc2Mcdokf2hJvNRI1AkyvAyc8dsV1lFAHj/jjwd4g1f4ueGNdsNP87TbIWv2ifzkXZtnZm+UkE4BB4FHwV8Ga/wCD/wC3f7c0/wCym6MHk/vkk3bfNz90nH3h19a9gooA+drX4Ra9d/C+awu7JLTXrTUpbu0jeZWE0bRRhkyrFQSUGCe6AcAk10Oo2fxX8VR6JpT20/h2OAj+0NTh1GNjOQoG/bEQw6N8gOCWGcYyPaKKAPn3/hVXibVPFfjZp7ZLKz1dJ/sl1JKjqzfao5kBVWLAEJ1xx6dqr3Hhv4mSfDWy8EweF0gtonc3M5v7d2nHmmRVA3fIATz1JwOQMg/RVFAHhOqfDnxXo174W8U+F7WF9atNPt7a+s5JV/1iQhCcs20gqNhCkYwCM5JGZrXgvx142+Iljq3iLw6IdME8UUkCXkJENoJMlcq25jgsSRzk8Y4A+iaKAPEPDOgfET4a/wBpaXo+lWWvadc7praQXCQeVKflDMGIJ4VcoMjphxzlNd+GvjHxZ4HEviHUYLrxHbz+faQgIqJEVG6ElVUeYT3O5fkUAgEmvcKKAPnrxjo3xa8Z6Lpul6h4ehSO0w8zx3VuDcTDIDn5/l+U9Bxkk+gX2jwrZ3GneEdEsLuPyrm2sYIZUyDtZYwCMjg8jtW7RQB4D8UV1o/HLw83h2LzdVj0+OWCMybA+x5mZScjgqCCMjIJHetPUPBXjD4jeLV1XxCknhi00+3xYRW92tw6zckSAqcAhsEn5SQqgf3h6Fe+DtPvvHdh4sea6XULC3NvFGrL5RUiQcjGc/vD3HaupoA+fvDXgjxj4Y06fTLfwXpF1qbXpe18QXM0EgtR8oDqpBfA2lh3BP3T0OBZ/CPxp/whmr2UmmRx3b3lpcRRPcRkzKqzq+CGIBHmqeSOM9+K+oKKAPnrxd4J8a+J/CXhWxXwwbe70iOS0kT7fA25AkIWTO4AZKvxzjHuK2tK8GeLvhv4s1C78MaZa6zoN+5JshcrBJEo5jBaTupYgEFsgHIBIx7XRQB4tqfhv4l+JfAfiCLX3gkvL3yvsOkwNCoixOGbc2OyqNv7w8E55qwfBuv/APDO/wDwin9n/wDE6x/x7ean/P35n3s7fu89a9hooA8E8QeAfFi6x4E1nTtHS9k0bTbKG5tRdRxsssDbipZjjBzgEZ6H2ztX0fxP/tp2vtCsfEfh69iEsmlXElsgtmPzCIsR8zRsAN2GDAZ4J+X2GigDyj4VeBdb8PalrOuavHBp8mpfc0yykHlRfOxOVGV442YY4DMDXq9FFAHj/wCzl/yT2/8A+wrJ/wCioa9grx/9nL/knt//ANhWT/0VDXsFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheM/+RF8Qf8AYMuf/RTVu1heM/8AkRfEH/YMuf8A0U1AHnH7OH/Ii6l/2E2/9FR17JXjf7OH/Ii6l/2E2/8ARUdeyUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeO/8AknniX/sFXX/opq6Gue8d/wDJPPEv/YKuv/RTUAYHwT/5JFoX/bf/ANHyV6BXn/wT/wCSRaF/23/9HyV6BQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/AOzl/wAk9v8A/sKyf+ioa9grx/8AZy/5J7f/APYVk/8ARUNewUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWF4z/5EXxB/2DLn/wBFNW7XzJda5q3gDxN4u8N65dzz2Oq2dyYZZGLZZ0by5B9fun3+lAHb/s4f8iLqX/YTb/0VHXslfH+jeL7rS/htP4b0lpV1LVNSJdoshhFsjAUY7sePoD619PeC9JvdD8Iabpmo3Ul1eQRfvpZGLHcSSRk9QM4HsBQB0VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeO/+SeeJf8AsFXX/opq6Gue8d/8k88S/wDYKuv/AEU1AGB8E/8AkkWhf9t//R8legV5/wDBP/kkWhf9t/8A0fJXoFAHn/jj4hL4G1jRYL7TkksNQcq90tyQ0AVlDkxhDuADgjByeRgd87V/itFpHxKtvCK6O87yz28Et01wECNLt6LtO4AMO45yPcyfGvSf7W+Gt44juJJrGSO7jEQznB2MWGOgR3J6YxnoDXhE+m6p4l8Ga/42vke6uE1K3R72SUAhdriQbc9MvbgADgYA4BoA9b8efEnT7m68TeGrvw9Bq2m6bFFJdONSaHzf3sI2jYhIKyOARu/hP0rzK51ue68T+CJdH0B7OxtnifTNMOoeakz/AGp9xDt90s4Kkkfwg9MVq2djNqHwo8c+Mb6BEu9XvItmICoVftCM5jYkkoWfGPWLqSOMPTp47XXfhtc3EscUEUcUjyyMFVFGoTkkk9ABQB0upavq1l+0OmowaC91qrJDnTEuBkSPaKrJ5mCMLuJLYxhc8DmvV/CPxEbxD4j1Dw7qOhXWkazYhpZYHkEibAUGd3HJLgjAIIwQTmvPYJ4b79qeK4t5UlhmQOkkbBldTY5BBHUEV0nh/wD5Oe8Wf9glP/QbagA/aM/5J5Y/9hSP/wBFS03Q/hZ4GvvAunalf6b5Es2mRT3F6byVPLJiBaTltoxyeRj2xTv2jP8Aknlj/wBhSP8A9FS1P4W+EvgfUvCOiX93oYluLmxgmlf7XMNzNGCTgPgcntQB4s+savqXwgms75557Gz1m3W0mmLNjMEwaIEnGFCoQo6bvcV7Bofws8DX3gXTtSv9N8iWbTIp7i9N5KnlkxAtJy20Y5PIx7Yql8bNJs9E+Fmlabp1ultZ2+oxLHEo4A8qX8yTySeSSSa1vC3wl8D6l4R0S/u9DEtxc2ME0r/a5huZowScB8Dk9qAPFn1jV9S+EE1nfPPPY2es262k0xZsZgmDRAk4woVCFHTd7ivVPgD4ke88O3vh6d08zT3822BYBmickuoXGSFbknn/AFoHHFJ8bNJs9E+Fmlabp1ultZ2+oxLHEo4A8qX8yTySeSSSa8319LzwS+nX+nJGtt4h8NQxTA2+IzvgWOVQe75CykjBy4zkE5AI08Qt4r+Nmna2I9iXOs2ohXGGEayIq5GTztAzzjOa6K6utM1f4x6tY/EPULldMtp5o7G3uJHihUl1WMfL9xDHht3yg4BJPfNbQD4c8efDixkhCXMkVlcXO6HynDyXUjEMOu5QQuTz8o6dK77SvG9lqvi7UPDvxK0rQIbuyYpZyzWv7jvu+aYnAYBCpwAR7kAgFrw94MfSPGUWt/DvWdMbw3MY4dRszeNcKxB+YLgH5gpDDLZBJ/hOK9ir5tuYvDWlfFvwzZfDy4uQzXESal9guXlgki8xXI3ZJYbAS4yVAUdw1fSVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/AOzl/wAk9v8A/sKyf+ioa9grx/8AZy/5J7f/APYVk/8ARUNewUAFFFcR8VtTvdF+G2r3+n3D290giVJY2wy7pUU4PY4J5oA7eivDtC+HHi7W/Dum6r/ws3XIPttrFceVmZtm9Q2M+cM4z1xWj/wqHxh/0VjXPym/+P0AewUV4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/QB7BRXj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9AHsFFeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP0AewUV4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/QB7BRXj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9AHsFFeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P0AewUV4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/QB7BRXj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9AHsFFeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP0AewUV4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/QB7BRXj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9AHsFeV/GfwYfE3hY6lZoG1LTFaRcDmSL+Nf0yPoR3qn/wqHxh/0VjXPym/+P0v/CofF/8A0VjXPym/+P0AcX8BfBP9pau/ia9jza2LbLVSOHmxy3/AQfzI9K+k68Xtfg74isrVLWx+JGqWtumdkMEMkaLk5OAJ8dTmrH/CofGH/RWNc/Kb/wCP0AewUV4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/QB7BRXj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9AHsFFeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P0AewUV4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/QB7BRXj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9AHsFFeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP0AewUV4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/QB7BRXj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9AHsFFeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P0AewUV4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/QB7BRXj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9AHsFFeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP0AewUV4//wAKh8Yf9FY1z8pv/j9O+EF9rJ1rxdourazdaoulXaW8U1y5cnDTKSMkkZ2A4ycUAevUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3jv/knniX/sFXX/AKKauhrnvHf/ACTzxL/2Crr/ANFNQBgfBP8A5JFoX/bf/wBHyV6BXn/wT/5JFoX/AG3/APR8legUAUri3hvbaW3niSWGZSkkbqGV1IwQQeoIqjF4b0OHT5dMi0jTk0+V98lotoghduOSuME8D8h6Vt0UAZP9h6T/AGR/ZP8AZdj/AGZ/z5fZl8nru+5jHXnp15qrN4V8OzWdvaTaBpclrbbvIhksoykW45baCMDJ5OOtdBRQBhweG9Etr2K+ttG0+K8iUJHcJaosiqF2gBgMgBflx6cVYj0rT4dUk1OKxtUv5l2S3SwqJnXjgvjJHyjj2HpWpRQBl6jo+naxAsOp2FrewI+9YrmFZFDYIzhgeeT+dTwW8VlbxW8ESRQwqEjjRQqqoGAAB0AFXaKAMvUdH07WIFh1Owtb2BH3rFcwrIobBGcMDzyfzqeC3isreK3giSKGFQkcaKFVVAwAAOgAq7RQBl6jo+naxAsOp2FrewI+9YrmFZFDYIzhgeeT+dV7zw3od/b2tveaPp1zBarst45rZHWFcAYQEfKMAdPQVuUUAZF1omk31/Df3em2dxe25HlXEturSR7TkbWIyMHnjvRqeg6RrLRf2rpVlfmIHyvtdusuzOM43A4zgflWvRQBk6ZoOkaM8v8AZelWNgZQPM+yW6xb8ZxnaBnGT+da1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/7OX/JPb//ALCsn/oqGvYK8f8A2cv+Se3/AP2FZP8A0VDXsFABXn/xs/5JFrv/AGw/9Hx16BXn/wAbP+SRa7/2w/8AR8dAG/4E/wCSeeGv+wVa/wDopa6Gue8Cf8k88Nf9gq1/9FLXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj/AMIP+Sh/E3/sKj/0bcV7BXj/AMIP+Sh/E3/sKj/0bcUAewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVm6zpqazod/pcjmNLy2lt2dRyodSpI/OtKigDxi2+D3iKws47Wx+JOqWltHnZDBFIiJk5OAJ8Dkk/jU/8AwqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHj//AAqHxh/0VjXPym/+P0f8Kh8Yf9FY1z8pv/j9ewUUAeP/APCofGH/AEVjXPym/wDj9H/CofGH/RWNc/Kb/wCP17BRQB4//wAKh8Yf9FY1z8pv/j9H/CofGH/RWNc/Kb/4/XsFFAHj/wDwqHxh/wBFY1z8pv8A4/R/wqHxh/0VjXPym/8Aj9ewUUAeP/8ACofGH/RWNc/Kb/4/R/wqHxh/0VjXPym/+P17BRQB4/8A8Kh8Yf8ARWNc/Kb/AOP0f8Kh8Yf9FY1z8pv/AI/XsFFAHG/D3wQvgHw/LpK35vjLctcNKYvL5KquAMnso712VFFABXn/AMbP+SRa7/2w/wDR8degV5/8bP8AkkWu/wDbD/0fHQBv+BP+SeeGv+wVa/8Aopa6Gue8Cf8AJPPDX/YKtf8A0UtdDQB5ND8WdZ1Lxjq3hzQ/B39oXOnSzIx/tNIdyRybN3zJgckcZPWjUPi3qPhvXbGx8WeEZ9GtrvpdLfLchR0zhFwcHGQDkA5wcgHg/Cn/AAkX/C7/ABf/AMIz/ZP2zzbzf/afm+X5f2kZxs53Zx7YzUjQa18VvHyeH/Gd7aaHcaUp2WEEBEk5JBfYWJBJQA5yRgAhSNxoA9P8Y/FLTfCN+mkW1pNq2uSlRHZWx6FiMBjyQSDkAAk8cAEGs+/+J+r+G7yy/wCEt8G3Gj6dcy+Ub6O/S6ERx3CL+OM5wCQDjFcz4HE91+0P4rk1OHNzDFP5DSwgMiCSNIyvHH7ogA9we+a9j1z+yv7In/tz7F/Zvy+d9u2eT1GN2/5euMZ74oA5PxD4y8RaV9rv9N8HR6pocNuLpdTTV4kWSLYHLBcE4HPTOcZHWsjw98T/ABV4s0577RfAP2u2SUwu/wDbMSbXABIwyA9GFdNrf9lf8Kp1z+xPsX9m/wBmXfk/Ydvk/cfO3Zx1znHfNea/CqHWrj4L+Irfw+UXVJLyZbdmcx4JiiB2sCMNjO05wGxnigD2yxmuJ7G2mu7b7LcvGrTQGQP5TkcpuHBweMjrWhXyPZ2fhzT9M07TNetdW8JeJopzcHV3tpZA8Q3FD5e9Sp3YAKqeYwc8nH1Dodx9q8P6bcm++3ebaRSfa/K8r7RlQfM2fw5647ZoApaVqniC68Q3tne+G/sOmQ7/ALPqH29JftGGAX92BlcjJ56YxXSV8ia1/wAjL8Uv+23/AKcYK2D4E0L/AIZ//wCEu2T/ANr+Z5nneYcY8/yfL29NuOfXPfHFAH1HWNrupHRvD+o6qIfO+xWslz5W7bv2KWxnBxnHXFeAXt1e/Efxj4U8HajqN1FYx6bbSzMH3tPKbUTPKc/xEHaCc45Pcg9xrPwzt/Ctj4k1XQNUnstKl0a5S50kqZUkIhcAh2bIwcHoT94Zw2KAOs+Hvjf/AIT7w7Pqv9n/AGHyrprfyvP83OFVs52j+90x2rtK+Jbr/knuh/8AYVvv/RVpXvfxe/5KF8Mv+wsf/RtvQB6/Xn3hb4k/8JJ4/wBZ8K/2V9m/szzv9J+0bvM8uUR/d2jGc56mvM/BekW/xj8U+JdZ8SPNJFFGsNrbiUg2wkLbNjDA+QKeCpDFiSM5zwEOp3vw+8QeJrHTrqT7WFm0xb2P92yATLlwOcEiMjrkbsg5FAH2ZRXyvNo1td+FIb/S/DPjiXxVM0V6urNbOyNIdpYqynlCdzq2N2cc4q8msa38SfHXhvwp4sinsktxuu7V42j+0OqtIXZPlKlkAX2ySuM4oA9Z8U/En/hG/iBo3hX+yvtP9p+T/pP2jb5fmSmP7u05xjPUV6DXzBr/AIRsfBvxv8N2Omu5s7i9tLmOOQZMIM+NmepAK8E84IBzjJ+n6AOb0rVPEF14hvbO98N/YdMh3/Z9Q+3pL9owwC/uwMrkZPPTGK6SvkTWv+Rl+KX/AG2/9OMFbB8CaF/wz/8A8Jdsn/tfzPM87zDjHn+T5e3ptxz65744oA+o64DxP8RYvDPjfRPDK6Y9zNqjxBpjMI1hWSXywQMHcchiRx25543fBs8tz4I0G5uJZJppdOt5HldizOxjUkknqSa8U+KejaddfHLw/bS24aLU/sf2xd7DzczGI9+PkQDjHT1oA9L/AOFkn/hbf/CC/wBlDOP+P37T/wBMPO+5t/Dr7+1ehV8zah4T0rU/2hF8N3EUg0qNIU8pJCCY4rNSqbuuPlAJznHfPNWWvpfhn4x8dafoU90NPstNE9ravOWSGaZrdQ+CCCV83jIJIUAnvQB9IUV8p6bplh4h8HXWoX+geNNZ8R3kTeVqaQtNCsiEqm185ZcBVbIYjBxivbvhTqHiS/8ABm3xRBdxX1rcNBG13A0UskYVSrNu+8eSN3fHOTkkA76ivBPiXok3iH43eH9Hjuntlu9OCTSRyFH8ndOZQDg8mMMORg5weK52PwnYQ/HO58DwzX0Xh+5kWS4tEuGAlVYPPVGPdQ3AzyB3zzQB9O0V81x3158MfFnjrT9JupzZWVg09pbCQ+XC80luEfa24MyCUDJ5YLzjNY+m6ZYeIfB11qF/oHjTWfEd5E3lamkLTQrIhKptfOWXAVWyGIwcYoA9r+IvxFh+H0OmtJpkl9NevIFQTCNVVMZJODz8y4GPXkY59Br5B8cPrd34b8PXviiyuodYR7ix827ieOWa3jETIWDdSDLIN2MnvkjNep+OfD/grRLzQNJ1nxI+meHrNGmj0KOKWUzOWctIzqSwBLY5HQOFIycAHtdFfLeneIfCnhL4tadq2hRanY+HJYWjl81G2yg+ZH5iAks8W5UbnJyrcZAFe02fxa8EalfW9hZa35t1dSrDEn2SYbnY4AyUwOT3oA7uivm2a2+HEl5rD+IfEGo+LfEF7P5cb2FtIkm4nYBCAfLYgnjJK4VQo7Hj11g3XwXl0p3mZ7HXY5F8xsoscsMuFTnj5kkJGMfNnuaAPsKivl7xd4L0rwv8MfCfijSmu4NXme3eS4E5yzSRGXP+yVKgLtxx1yea7Xx3F4Kk+IXmeN/FjzW1vbgQ6IlvLtt9wHLSR5OTgtjhuV52gAgHqeu6kdG8P6jqoh877FayXPlbtu/YpbGcHGcdcVifD3xv/wAJ94dn1X+z/sPlXTW/lef5ucKrZztH97pjtXhGg6npmmeJfF+n6TBqdppWqaBdG1tbrhlP2fzlZhnldok2nk4cepNYGnWUmj+D9H8a2iwG5sNdaFvNLHeRHFLENo4wCsueQfmH4AH2VRXz7qt9L8RvjTp/9hTJcWuj2S3ltK058kyhRKjsuMgGV4Y3AG7C9sccT/Zem6dZX+nePtI1fTddvLzNvr0kbzKBuXzSV3qJAOTuXeT5mewyAfSfiTVvEOmNbf2F4Z/toyBhN/p8dt5WMY++Pmzk9OmPeulr5f8AivdJeeC/A8ya3Jran7Yo1B4GhaYK8a8qecjGMnk4z3qLWLD+zNf8SXHxI0DUZpr9ytnqtp5jwQTENt8vLqHXbghS2QIwuOuAD6H8RX+sadp8c+iaL/bF0ZgrW/2tLfamDltzcHkAY9/ar1jNcT2NtNd232W5eNWmgMgfynI5TcODg8ZHWvnjxjPan4IWNtY+Im161tNZSCK5e1aAxKIGIiw3JAzwfQgdBXvHgf8A5EDw3/2C7X/0UtAG/RRRQAV4/wDCD/kofxN/7Co/9G3FewV4/wDCD/kofxN/7Co/9G3FAHsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5/wDGz/kkWu/9sP8A0fHXoFef/Gz/AJJFrv8A2w/9Hx0Ab/gT/knnhr/sFWv/AKKWuhrnvAn/ACTzw1/2CrX/ANFLXQ0AeXeDvh5q3h/4n+IfE13cWT2Wo/aPJSF2Mi+ZMsg3AqB0HYnmm/Eb4aXfiHW9N8R+G57LT9btJVaSaZSBLtwY3OAwJUjHK8g8nCgV6nRQB5V4s+HOs61qum+KtH1W10vxVbW8a3BjQi3llGMndjdjBYfMG3KFUgDNQeIvBvxF8b28Wl69q+g6fpW4tONMWdmkI5Xcr43AEdNwHOeSBXrlFAHKXHhlLbwBc+FtIVIkOnSWcJlwo3MhXc+0dSTkkDkkmuY8GfDrV9B+Hmp+GbrV/sd7eXbTxXumTNui+WPByQp6pyB1BxkZ49SooA8Sm8BfE7U/C6+F9X8Q6RNpks6vPdO8s1zsDBtuWUbgCNwyQeANwHFem+FtBt/DPhnT9GtW3R2kQUvgje55ZsEnGWLHGeM4roKKAPCdQ+DviO71jxjdpd6UE1rzPswMr5XN3FMN/wAnHyoRxnnH1rpT8O9XPwO/4Qn7RZf2l/z13t5P/Hx5vXbnp7da9RooA8g1H4Vask3hXWtAvrO217SbW3trkSllguPKQDO5F3HONhz1TA4xgxv8L/E2ueINX1/xJqen/b5dNms7G3snlMEbSQvFzvGVQbicDOSxPHQ+x0UAeAf8KL1afwLFpj6lZJq1rfy3MBRnMDxyJErBjsDA/u8ggEdu+Rr3fgDx94g8c6Lr2u6johg066hlW1tZZgkaI6s2xSn3jt6k88DOAMe0UUAeNP8ADXxb4Z8WanqvgfV9NtLK/Ri9rdgqsbNngKqFSEJyp4x0IIzux9D+Beqy3WsN4m1Gym+3WzLHcws80yXBkRxKfMUZ+6wPOSGIzzmvfaKAPGofAvxNttAi8M2/irTodJinAS/QyreJbg8IMDAAHO3dn+Hft4p+vfCrV5LvQ9b8Na35PiCwiSK4ur13/wBKYA5lLfMxY5IKtkbcLwFwfYqKAPC2+GPjrVfiFp/ijXdV0idre9hmaOGWTEcSOG2RgpwMZxz1OSckmvdKKKAPCdQ+DviO71jxjdpd6UE1rzPswMr5XN3FMN/ycfKhHGecfWulPw71c/A7/hCftFl/aX/PXe3k/wDHx5vXbnp7da9RooAwvDenzaR4W0rTZ2RprOzht5GQkqWRApxnHGRXEfED4ea5r/jjRvFGhXenrPpyxjyL3eq7o5DIpygJIJYgjjp1549UooA8msvh74h/4W9b+NdQutL8kRL9oit3k3eZ9m8ptgK/d35xk5x71Zn+G02pfEPxNrOpNbPo+s6aLIRKS06NiEbsFdoIMRIOTg4NeoUUAeMWPw/+JHhvRL7w9oHiXS30qX/UT3Hmx3EGeX8vaGCZJPc+o2kmvRvCeiXXhzQY9PvdVu9Wug7PJe3Ujs0hJ44Zm2gDAwDjjPUmuhooA8/1XwXqN98XNG8WQzWwsLCya3ljZm81mImHAxjH7wdx3rO/4V5q/wDwvH/hNftFj/ZvTyt7ed/x7+V0246+/SvUaKAPL5/htNqXxD8TazqTWz6PrOmiyESktOjYhG7BXaCDESDk4ODWRY/D/wCJHhvRL7w9oHiXS30qX/UT3Hmx3EGeX8vaGCZJPc+o2kmvZ6KAPGPF/wAIda1zwxo1jB4i/tDUbCadprnUpJf34kI6HLldoRRtHB5PB6vuvh54yHjOx8bWl5oLa/5bi8t5fO+yhtpiUx4G4gx4yDjDAnJBwPZKKAPEJvhj4x1T4gaT4o1nVtLuZILqGeeGMyqsCxy5EcIK8jaAecck5z94+tarpsWr6NeaZcM6w3kDwSFCAwVlKnGc84NatFAHjGhfD3x94a0W+8O6PrWh2+mXd0ztqCib7ZGh2qWUY2htqdM8EnDDgjm4PgX4mi0C+0s32kGW5vLe4RxNLtCxpOpz8nXMq4+hr6LooA8r8ZfDzVvEPwz0LwxaXFkl7p32fzpJnYRHy4WQ7SFJ6njIHFV/+FfeJ9A+IWp+KPCd5pEiakkhki1XzcxtI4kYDyxyNyjBz0OMHGT65RQB4NF8H/Fz+I73WNT1qwvp7yzuIpJndwxlltnixjZgIrPgY/hAwB92tG28EP4N+CXinSfEU9lIH866jaGZgm/y4/KGSFOfNQYHfgc5xXtFc14l8FeH/F/2X+3bD7WbXf5P75027sZ+6Rn7o6+lAHm/wO8MMvgHVr+Wa6tW1pzAk0EqqyxICgkQjlXDNLyf7oOPWUeCfinbaRq+gr4k03ULG/3xi51CWZ51jPBwSp27l4IywHbB5PrVvbw2ltFBbxJFDCoSONFCqigYAAHQAdqvUAeE+IPgbfv4Z0XSNG1Cxke0muZrq4ui8XnNKY8EKA+MLGB17Z7mtq38IfE3Q9T1P+xPFVtqGn3KlIDrU8sssPowG0gMMkf3T1K9APXKKAPB5/gbfx+BP7Hsb2yk1W41CK8uZ5t8cQRInURrgNnDSMQcDIPOMAV634c0+bSPC+labOUaezs4bdyhJUsiBTjOOMit2igAooooAK8f+EH/ACUP4m/9hUf+jbivYK8f+EH/ACUP4m/9hUf+jbigD2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8/+Nn/ACSLXf8Ath/6Pjr0CvP/AI2f8ki13/th/wCj46AN/wACf8k88Nf9gq1/9FLXQ1z3gT/knnhr/sFWv/opa6GgDx7XNe1Txl8XbTwjo2o3FppWl/6RqstpNsaQr95N6OG2/MseBghmYkHaMW9V+O3hnRtXvtLurDVWns53gkMcUZUsrFTjMg44rF+Ff9n/APC3/H3nZ/tP7VN5H3v9T57eb7dfJ68+neuP8LwQ3P7Sdyk8aSKurXzqHUMAyiVlPPcEAg9iBQB6vofxl8Ka5FftAt7BNZWr3fkXCIrzoilmEeHIJAHQkevQEjI/4aN8H/8AQN1z/vxD/wDHa818O2VxH8ddTs9EaCzuVudTisjtAjhfy5gnGCMA44weB0r0r/hHfjl/0OWh/wDflf8A5HoAr33xqj17Sb608G6NrU2tGHdFmyWURDcoLkK5PAPHBGcZ4rhNRh+IPhfwXp3i3UPFetW9zNfCFNOuZZsoAHIaQSHHJjPylSCCDnnFeoadc+NvBcN/r3j3xBY32i21q2IrKEeZ5pdQuMRJ1yRycZIz6jzFLhfi74kl1XxX4l07QtItW8u2snu4w+3IJVAxHJHWUjk4ABAwoB1ereLPEDeBvB/xBt7m83wSiDVLOKRvJuowzIXcD5EyVIzs4Mq8/KtezaffQalp9tfWr+Zb3ESTQybSNyMMg4PI4PevPfiWdL/4UZqMeizwT6ZFFbw27QTeYmxZ41ADZOcYx17Vs/Cf7X/wq3Qvtnn+Z5L7fOzu8vzG8v73bZtx2xjHFAHc0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/8IP8AkofxN/7Co/8ARtxXsFeP/CD/AJKH8Tf+wqP/AEbcUAewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXn/xs/wCSRa7/ANsP/R8degV5/wDGz/kkWu/9sP8A0fHQBv8AgT/knnhr/sFWv/opa6Gue8Cf8k88Nf8AYKtf/RS10NAHj2uaDqng34u2ni7RtOuLvStU/wBH1WK0h3tGW+8+xELbflWTIySysCRuGe2s/h94WsPEreI7bS9mrtLJMbj7RIcs+dx2ltvO49u9dXRQByln8PvC1h4lbxHbaXs1dpZJjcfaJDlnzuO0tt53Ht3rq6KKAMPxF4X0jxbYR2OtWn2q1jkEyx+a6YcAgHKkHoxrm/8AhSfw9/6F/wD8nbj/AOOV6BRQB4/4/wDDE02kaB8P/DGm31vp01z5t1cRea0NtCGJIdm4fJZn2ls5ReOVr1DT7GDTdPtrG1Ty7e3iSGGPcTtRRgDJ5PA71oUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeP/CD/AJKH8Tf+wqP/AEbcV7BXj/wg/wCSh/E3/sKj/wBG3FAHsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5/8bP8AkkWu/wDbD/0fHXoFef8Axs/5JFrv/bD/ANHx0Ab/AIE/5J54a/7BVr/6KWuhrnvAn/JPPDX/AGCrX/0UtdDQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeP/CD/kofxN/7Co/9G3FewV4/8IP+Sh/E3/sKj/0bcUAewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFZ99fWmmWUl3fXUNrax43zTuERMnAyTwOSBWd/wAJ34Q/6GrQ/wDwYw//ABVAHQ0Vl6drGnaxA02mX9rewI+xpbaZZFDYBxlSeeR+dQah4l0LSrhbfUtZsLGYr5ix3NykTMuSM4YjjIP5UAbdFZmnavp2sQtPpl/bXsCNsaW2lWRQ2AcZUnnBH51R/wCE78If9DVof/gxh/8AiqAOhornLfxn4XuLiK3tvEWkTTSuEjiivY2Z2JwAoB5JNdHQAUUUUAFFFFABRRWRqeu6RozRf2pqllYeaD5X2q4WLfjGcbiM4yPzoA16KKKACiiigAorI/tzSf7X/sn+1LH+0/8Anz+0p53Td9zOenPTpzWvQAUUUUAFFFZGma7pGstL/ZWqWV/5QHm/ZbhZdmc4ztJxnB/KgDXooooAKKKKACiisvUdW07SYFn1LULWygZ9iy3MyxqW5OMkjng8e1AGpRRRQAUUVzi+MfDBgaYeItIMCMEeUX0W1WbJUE7uCdrYH+yfSgDo6KpQXEV7bxXEEqSwzKHjkRgyspGQQR1BFXaACiqVxcQ2VtLcTypFDCpeSR2CqigZJJPQAVDp2r6drELT6Zf217AjbGltpVkUNgHGVJ5wR+dAGnRWffX1ppdlJeX11Da20eN808gRFycDJPA5IFPguIr23iuIJUlhmUPHIjBlZSMggjqCKALtFZGp67pGjNF/amqWVh5oPlfarhYt+MZxuIzjI/OtegAorPvr600uykvL66htbaPG+aeQIi5OBkngckCixvrTU7KO7sbqG6tZM7JoHDo+Dg4I4PIIoA0KKKKACiiigAooooAK5Tx54cuPFfgrUtDtpYoZ7kR7HlztBWRX5xk87cV1dFAHi9l4S+MWnafbWNl4r0WG1t4lihj8sHaijAGTb5PA71Y/4R745f8AQ5aH/wB+V/8AkevYKKAPH/8AhHvjl/0OWh/9+V/+R6P+Ee+OX/Q5aH/35X/5Hr2CigDx/wD4R745f9Dlof8A35X/AOR6P+Ee+OX/AEOWh/8Aflf/AJHr2CigDx//AIR745f9Dlof/flf/kej/hHvjl/0OWh/9+V/+R69gooA8f8A+Ee+OX/Q5aH/AN+V/wDkej/hHvjl/wBDlof/AH5X/wCR69gooA8f/wCEe+OX/Q5aH/35X/5Ho/4R745f9Dlof/flf/kevYKKAPH/APhHvjl/0OWh/wDflf8A5Ho/4R745f8AQ5aH/wB+V/8AkevYKKAPH/8AhHvjl/0OWh/9+V/+R6P+Ee+OX/Q5aH/35X/5Hr2CigDx/wD4R745f9Dlof8A35X/AOR6P+Ee+OX/AEOWh/8Aflf/AJHr2CigDx//AIR745f9Dlof/flf/kej/hHvjl/0OWh/9+V/+R69gooA8f8A+Ee+OX/Q5aH/AN+V/wDkej/hHvjl/wBDlof/AH5X/wCR69gooA8f/wCEe+OX/Q5aH/35X/5Ho/4R745f9Dlof/flf/kevYKKAPH/APhHvjl/0OWh/wDflf8A5Ho/4R745f8AQ5aH/wB+V/8AkevYKKAPH/8AhHvjl/0OWh/9+V/+R6P+Ee+OX/Q5aH/35X/5Hr2CigDx/wD4R745f9Dlof8A35X/AOR6P+Ee+OX/AEOWh/8Aflf/AJHr2CigDx//AIR745f9Dlof/flf/kej/hHvjl/0OWh/9+V/+R69gooA8f8A+Ee+OX/Q5aH/AN+V/wDkej/hHvjl/wBDlof/AH5X/wCR69gooA8f/wCEe+OX/Q5aH/35X/5Ho/4R745f9Dlof/flf/kevYKKAPH/APhHvjl/0OWh/wDflf8A5Ho/4R745f8AQ5aH/wB+V/8AkevYKKAPH/8AhHvjl/0OWh/9+V/+R6P+Ee+OX/Q5aH/35X/5Hr2CigDx/wD4R745f9Dlof8A35X/AOR6P+Ee+OX/AEOWh/8Aflf/AJHr2CigDx//AIR745f9Dlof/flf/kej/hHvjl/0OWh/9+V/+R69gooA8f8A+Ee+OX/Q5aH/AN+V/wDkej/hHvjl/wBDlof/AH5X/wCR69gooA8f/wCEe+OX/Q5aH/35X/5Ho/4R745f9Dlof/flf/kevYKKAPH/APhHvjl/0OWh/wDflf8A5Ho/4R745f8AQ5aH/wB+V/8AkevYKKAPH/8AhHvjl/0OWh/9+V/+R6P+Ee+OX/Q5aH/35X/5Hr2CigDx/wD4R745f9Dlof8A35X/AOR62Phn4I13wpf6/f8AiG9s7u81aZJme1JwWBdmJyq4yX6AYr0iigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4H41f8kj136Qf+j468Q+Hf8Awq3/AIR6f/hNv+Qn9qby/wDj5/1O1cf6r5eu/wB/0r2/41f8kj136Qf+j468r+HfgGw8cfCPVYlhtotXXUW+yXrp8yFY4iFZhztOWGOQN2cEgUAc98KvEN34TXxNrcUc8trbaX90AmE3DSxrDvGQOrN3zjfitn4R+ALDx0+p674kju7uGO4CITcYFxKVJk8wj58jdG2cjJPfkVN4D8SPr2k3nww8WTiBJoTb2M11uEtvMpG2EjjOGAKgkfd2c5AFTwJ4zvfhHql/o3iTR9RjguWEhj3YMZXcpeNT8rhiANwYDCdWwKAPTfDnwhtPC/jSTXtL1u+trXkR2EaDgEgmN5Gzvj4PGAfundkZPF/GXwB4X8J+D7bUNE0r7Lcy36QvJ9olkypSQkYZiOqiup8H/E3xJ428WzR6f4cT/hGg5UXchZGiA25LvyjNg/6sDPzDnALU39oz/knll/2FY/8A0VLQByvhnwWf+FceG/FHhvwza6l4mF4ZGe5uZFVVSSXa2PNRcgrGMfoa900mW/l0eyl1OJIb97eNrmJOVjlKjcByeAc9z9a8v8GeMdP8DfBDw9qWowXU0Ek81uFtkVm3GWZv4iOMKa9R0nUo9Y0ay1S3R1hvIEuI1cAMFdQwzjPODQB5fr3xG8Xx/FKbwb4fsdJlYtGIXvFcEAxCRixEg4AJPAzgdCa1J/EXxKl1m30Gy0LSxdwxNJfancRTixYnlRC2QTgFQep3E8AKTXJf83cn6f8AtjVfX/EF6Pilqtl408Sa14e0iKJjYDTJJI1kTeBGfkDbty7yT6jHGNoAOk074j+Ko9W8WaNr+m6XHf6Lpk1/C9rv8tjGoIyCxJVg6HqpAyCMnjJ0j4lfEbXvCmqeJLHStA+w6bnzRIsod9o3PtHmfwqQTkjPbJ4rzGwSxXxtfHTbG7srFtIvWt47s5maP+z5cSN7v9/jj5uOMV6P8Lv+Te/GX0vv/SVaANbUvjLdxeCfD95YaZDP4j1ksEtUJdE2SGMttB3HcQQo+vJ288B8Y77xbNqunWPiuy02FbdZHtbiwWTypw23dyxJyCoGMAjPoQahfTL3S/CXgPx1b2z3NnpzMlzEvATy7ySRctzgOWK5xgED1Apfi54/0rxve6SmlxTi3so2ZpphtJaUKSu3/Z24Jzyc44AJAPTIviN4p8V+M7/R/BOm6XLZWRKy3+ob2jJBI3bo2xhiMKBkkDPTO2mnxlvx4V8Qpd6fbW3ivRWAktyrNbyL56xMRhsgqXwRu9CCRkDnfA2rW/wg8Z69ofiVJ4La7KNBfeWSrLGX2NtXJIYMehOCMHuRz8+m3uqaD4+8brbSQaNqLFLUzjbJIXvYn4AzwAuCc4zwM4OADs7r4ueNbPw9pniq40LSRoV7OLfAkfzWZR85B3fKGKy7eDjbzngtb1X4p+NNBsdK8RapoGlNoeq7ngggkk86NSMxiSXlAxBDDjkK3CnpR+KP/Jvfg36WP/pK1L8U/wDk3/wZ9bH/ANJXoAseKfiFb+Gfi1qEV3oGiNHaQ7xffZiLx2NtlV84ZxliEzjgGptP+I3xCvvDNl4ks9H0bVLKW68iay06O4e6jwTncASE4HU5+8pxzXN+J7me0/aNv57XSBrEiw4On7gPtCmywy8g5+Uk4wc4x3rnrm98GT6VDqXhGHWtE8XeattbabZXEkoJLYLiQjcdykrgEHOBtxkkA9h8S/E7Uo9V07w94X0P7Zr9/arc+RfSLH9lyu/ZIm4fPsDEgsuMr1ziobb4lav4d8aJ4c8eQaXaLcxK9rf2DMIRkkfPvJIBIIycYI5GDuHmOu+G9T0rV9E8T+N9IutV0y6soG1MRCVGiIQRASvncJQPLY7toZiVB6mtm20fwF4t8QyaF4O8Izz27R7X11rq6WK0YoxDbDnOMcBiu5hjpzQB0Vh8SvHfiuHW9V8KaHpz6VYMBFFeRStcTjuF2MFZgBuKjkbgBuJGc79mjp4o+tr/AO1qyvA/j6H4aaVrfh7xFpl1HqdtO1xDGv8Ay2chF8sn+EcBg/IKk47BtX9mjp4o+tr/AO1qAPVfGPiu08GeHLnWbxPN8vCxQCQK00h4CjP5nGSACcHFcBZeOPinceGrbxKPDGl3NhJKp+xwRzC7lhP8aruPynoDgn+LaV5roPjB4YvvE/gOSHT1kmurOdbpLeNdzSgBlKjnrhye5O3AGTXF2Pxjt9O+HWh6folst34mVIbEWDxyyBdnyB+ANxYKuFByC464OQDa1L4o67q3jK08OeCtGgkuBEsl4+pI2ICQCwcI37vy87Wzk7sqBkDc20+Kur6fd+IvD/iKws7fxDp1rNc2bWoZrafZCZQG+YkZA3ZyMgkHaRzyOm3l78MvixJrHiu0eOHXbdnlngX5InlKSSbQC24RyZUjOcYbnIBr3cM3jXxz4v8AGmjwyHQbTTbqNrqZSnmt9iaIBR3Ofm7YXGcEgEA6LSPiV8Rte8Kap4ksdK0D7DpufNEiyh32jc+0eZ/CpBOSM9sniuP+KfiLUPFnhrwbrd5b2sEFzBcgRxFiwmWUJIef4TtQgdRlgSeDXU/C7/k3vxl9L7/0lWuH8SwSt8HPAVyYZGgjkv0eQKdqsZ8gE+pCtj6H0oA9L8XfEXx14Z8Q6N4eFlodzq19bozLEsvltK80iKFLOuBgJ1755xT9b+I/jXRNTs/C0enaLqfii5l3lbMyNDHER8qkFgwfhmJJAC7Tzkkcz401vT/EXxn8Datpc3n2UxtPLl8tl3YvJFPDAHqD2rQ8fRXHgL4zWHju6tp7rSLjCu0agGNvJMJTOeTtG8ZxnkdiaAOp0/4h67o/jqHwn41s9PhmvljNjdaZvMbMxIAYMScFgVzgYI6EHcPnq0/5J5rX/YWsf/RV3XrF5OnxN+Nmjan4ZMlxpujrbvdXkqGOMBZWk4yM5OdoBAJIPYFq8ntP+Sea1/2FrH/0Vd0Ae16F8QNa1G20Pwl4M0uzvL2z0uza7vLyf91GPLQONqkE7Sy55zkMNhxmtLT/AIsz6RrGsaF44t7Wz1OwjeaJ7Akw3ChNwQbm4ZhgrkjOcHaeD5Npfh3S/C2sabe+M9Gu7zw1qdnA8d8m9EjeWNXzlDklcOpXOSMsB0B6GLw14Z8cLrVj4J8Iz28dvE7W2szXc22WRNp8pUf5MtkD5mBCtuIyMUAa2o+PPiD4m+HGr63baHpY0KYT2roElNykBUhpQdwVgucFgOoJ2gA46H9nP/knt9/2FJP/AEVFXC6X8TbHQ/hHqPhC9sLqLWIUnsVhYYBEpfczZHylNxBU8k49Tt7r9nP/AJJ7ff8AYUk/9FRUAVf2iftn/CHaZs+z/Yvt377fnzPM8ttm3tjHmZzz93Hesm+8f+LPAfgPwjug0Sc3tr+4wkzYt0ih8vd8w/efM2ccdMV0X7QFvLP8PYXjikdItRikkKqSEXZIuT6DJA+pHrXmHxG1zT9a8CeAv7Pn877FbyWdx8jJsmSK33LyBnGRyOKAOp+IHivxfoNvpEvi7w54OvnuhIYIpLR7hrcgJvB3NgHlfukg469K7i78RfEHVvFeoaf4c0GxstNsvk+2a7FMouHBIJj2nlTg4wDwMkjcBXGftLdfC31uv/aNYDeIWvdX8TW3xI8SeItJuUwkelabKyxygq26MJhkwRsAJIDBsknJNAGzrnjfW/Ffwy8cafrthaWmoaRPbQy/ZmO3JnAK4JbkGM8g4Ofbml4F+I2qWmk+F/BvhsaQt1Ik3n3GqGQRrK0sjLGNuOSMYxuyXA4INcFbqsaeOESxfT1WywtnISWgH263/dktySvTnniuh03U/Dn/AAinhrTfGPhicWcsNxHba7BcEOqmZ8kIo+bYx+6Scddp3YIB7b4H8UeJ9T1jU9H8T6G9tNaM3k39tbypazqrBSFL9TnkEdRngY57+vAfhMb7/hPbu28N3ep3Pgq2hkiSTUS+zPyk+WAAgkLndggHYTkZr36gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-09-16 10:56:32 +0200" MODIFIED_BY="Liliana Coco" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQcAAAEmCAIAAADgOcJjAAAJu0lEQVR42u3dv3LUSBCA8X0ABw78KA79bg4dEBD6dagyhC4/AgUURUDgGAh0W+e6Y+3V6s/u9Oy09PuKgPJxjZD6m+keSaPNBsA+HYD/YAXACoAVACsAVgCsAFgBsAJgBcAKNJ8Nq88HZwF/U6H396wAK15lxjoNYQXMD6zAWDY4D6wAWAGwAvNSwUtprMBw273O3GAFDiqxWjFYAVawAjMbDBUUAFYArMD0CqqzBgXsarD/G1aAFawAWMEKjPYVVmYBsAJgBY5oLVRQgG6bFWAFK8AKVuD4nFitEqwAWAGwAie2FiooQLfNCrCCFWAFK3B8TqxWCVYArABYgeNzwm4GUgG6bVaAFawAK1iB0/sKT3wAYAUGKyhWOBEgBiswranwXTwArABYgbm1kwoKeNttu18B+IYqK8AKVuCIBkMFBYAVACswsXCyMssK9LfX+grAGhQrwApW4IgGQwUFgBUAKzC3gtJXgBKvNrwplRu5BGMFhqwoIka6GyCsQFUrup0vATSbeKzAkBhFciNdgrEC9fKMFUBuh1kBsALnSrUMN0NYgTP08V3bXwJgBcYH9eJK7P6EFUgznBdPWVZgIVYUF2N/CmIFVm1FshpSNqBXDG8dIaRndSqi+3hWJBtu01Ugce9te+KDFcmeEu3i94NiBSs2jjzvaWFF7Jl1HobnIlZAT6yCkl4JdxyLu7fNCj5k3ck47g1VFRSy9tzubbMCI2JUeDqQFUqpjZOggjLoIt/ZYIU8qDSiswJLaLiLH7972+hSr8wWT2V9BZYzuVmZBXzriBW1MqyzJJXHN1bUqEbWfJ84Y23GClawghWsYAUrVNLOBitghYAVUPWxInXNsM63jlRQSNBNnsUK3TYS1x5BIzorkFuMCmdDBaWvsDib6Y08VpgomMwKVij5WCHJ2jngiPuDERMaK2pX0qsVI27/teKHzQpU6iuirejKfRGBFahUQVWwwlyRr3ZKuptB3GkpGJMVsEJQZVCTCoheIbBLGmI7V7PQQNNSpF1hRVfhUqlMKsxCpfp4VtSzIosYeW+wsIIVlYqcFb4pxYp6Fyzpje1E81upA2YFlmBFSA0pG5C3r2BF1gzr3B2LPBtlV7dYodtOfzaKr4CzghVDrUXEbgbRVnTWoFiRpdtmBbJ2rqFrUHFnwxMfYHKVMyAVUCfVWIE0+4LVqaC60psP/L/oZGU2pRLti1H5/UFfFmZFmuki+ghTtCus0Lkuoa8oe55dLYzXUWubk1mB8IIqqCdmxXKG3nWKUfMgVVDyKc2/ImLtIWjdjBWsCJ/c0u0ZxwpiOBWsOOu461SzAkuQudmemBU4W53T/peF7b5s3GVFuBisSJlhSY857kveVmZZYX7TV7ACrNBXLP5sdJEvM3niA/lmTnt8AKzA4UbCW0esQPo1qC54N9hmI7OCFZVG9HyrAjI4etxd7de0WAHV//jQUOf2NitgfjNXAKzAMlYIQle3WIHwwqn9b8V3djNYTKqtrRoJtSL2qknfRBmW9FnDCve2S515ViSzosIjJInubaugiNETsHj6LuNbfiqoZP1rs3V/Xiv0FQjf8j7OirLfdIyrzViB8Opft40aGZa6xWKFVjukK8i1mTErUMOK7sAS7Snxqz3ZGtHE6ytYcTCyS1nSMSciaefKClZgxLeIG8asANlCvtNV7WhZ0Xpu+UpvdHUXFJkVC6mgole3ih9t9AOCrFjRuFuhJgnK4ER1FCuS5VZ0hoEVteeKLMHrDBbNRmbFcuaixjuWRN8WY0XWnjjdFMQKvLo2iW48s4IVVa3oiq7911mZ1VcggRWqvnpnQAZXEGPlFRQrUG8gdyeEFehJ35b3bGUFKuVu5XdfWYEuRe5mHOB9bxuVdr33bTHfUM3dHK/5mFkB8xsrcO4RPUXH4t42alQjuXqhZFdN+iatRvRCrGBF7iHcyizca9NtYynVSPT9eFbA/MYKVMnams/MWplFyEVK92iGNShW4Dy1WbORWWEWIgYr5O78g487J21GZgUqDef6Chw81wWHxje/ZwUr8lVTxbO22uuv6+mzWVFPhgofl2i5+q+z8UL5+yqSOHQMS2RF9Nlghbki31zBClak7CvivkUkMivOo4fzkGYgcyIAVgCsAFgBsAJgRSMnDplhRXkrRF5qZFbIA5FZIQ9EZoU8EJkVrBCZFawQmRVZrHj+83z35e7m6eby4+Xmw+bi4eL68fr28+3P3z9FbjwyK0KsuP9+f/XpanuR9n9tL977b+9FbjkyK8pbsR2oeq/T7q/tnxG52cisKGzFdvQavVQvvw6NZCKfN/LZrKjzN/be2D/xh8P/hG2Ne2hC753if/z6IXJTkRduRe8bvSf+cPSfsG37Jl6qgfld5DNGbtGKiWP27gZhE/+RxQXo/eHN003PVXmh72pdP16L3FTk5qyYNZDv753RghUvi4PTr9bFw4XITUXOYcXE5J6ixBFWzO0r+q/TLnsXTOSmIrdoRe+z7/s/rGaFucJc0dBcMTePJ47o+gqRF9VXHJorpithDUrk1q3orZcG1qC6w1/IPK4ec79C5LasyHhPcOJf6j5x9shLsOJcB++ZogVH9hxUiI3bkax/neTfCf3d13citxyZFVFz1KHn/ntrXJGbisyK5io3kc8emRXyQGRWyAORWSEPRGYFK0RmBStEZkU7VsCe5DDumisgw1gBGSYyK+SByKyQByKzghUis6ItK+zvvcuf5+cvd3dPNzcfLy8/bDYPFxeP19efb29//7Qn+WqssL/3Lt/v7z9dXfW+F7SV5Nt7e5KvwArvte2ynRBGXyPd/pmmjpkVha3wDvSbWWLiRhyHZox239se3kKmSMlxaP+OExP39O087PFxdORtL3GocOotpX79SLXHR+/mMY1bUWTrp7k739hbaZdtez0ncH8d1e5+UMNWTNkzfHTfpzc5evTO5NOVi7DCPny7PN3czLLi8TrV3oG7m5QNbFg2vM/fxNQc/n+7absJFrFi1l6dL9izdZeXRdjpvx4uUu0ze4QVE0ujiQJMT/GJpVSQFfb33mU/P69GAqfak7y4FQPbjA/k6OjO5AWtGJ2FzBXmipJWnPJf584VR+9JPvp6ir5CX7EpmMSjLcTc/6WbvG34EXZZg7IGNduK4QWlgYQ+NOcMr0HNyuYT9yR3v8L9Cri37d42K2Ks6DwH9RrPQbHi70hmf+/dGePQetT251/f2ZN8HVZ09vfe6zF636/o7SXOfsysiLJC5LyRWSEPRGaFPBCZFfJAZFawQmRWsEJkVrRjBexJDqxsyHMiAFYArABYAbACYAXACqC2FQB2+QfKbLRmIfNliAAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-09-16 10:56:28 +0200" MODIFIED_BY="Liliana Coco" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-09-21 09:33:14 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-05-04 14:55:21 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-05-04 14:54:53 +0200" MODIFIED_BY="[Empty name]">Expanded Disability Status Scale (EDSS)</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-04 14:55:21 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="20">
<TR>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>Normal neurological examination</P>
</TD>
</TR>
<TR>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>No disability, minimal signs in one FS</P>
</TD>
</TR>
<TR>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>No disability, minimal signs in more than one FS</P>
</TD>
</TR>
<TR>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>Minimal disability in one FS</P>
</TD>
</TR>
<TR>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>Mild disability in one FS or minimal disability in two FS</P>
</TD>
</TR>
<TR>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>Moderate disability in one FS, or mild disability in three or four FS. Fully ambulatory</P>
</TD>
</TR>
<TR>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>Fully ambulatory but with moderate disability in one FS and more than minimal disability in several others</P>
</TD>
</TR>
<TR>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe disability; able to walk without aid or rest some 500 meters</P>
</TD>
</TR>
<TR>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance; characterized by relatively severe disability; able to walk without aid or rest some 300 meters.</P>
</TD>
</TR>
<TR>
<TD>
<P>5.0</P>
</TD>
<TD>
<P>Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily activities (work a full day without special provisions)</P>
</TD>
</TR>
<TR>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude full daily activities</P>
</TD>
</TR>
<TR>
<TD>
<P>6.0</P>
</TD>
<TD>
<P>Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 meters with or without resting</P>
</TD>
</TR>
<TR>
<TD>
<P>6.5</P>
</TD>
<TD>
<P>Constant bilateral assistance (canes, crutches, braces) required to walk about 20 meters without resting</P>
</TD>
</TR>
<TR>
<TD>
<P>7.0</P>
</TD>
<TD>
<P>Unable to walk beyond approximately five meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day</P>
</TD>
</TR>
<TR>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot carry on in standard wheelchair a full day; May require motorized wheelchair</P>
</TD>
</TR>
<TR>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; retains many self-care functions; generally has effective use of arms</P>
</TD>
</TR>
<TR>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>Essentially restricted to bed much of day; has some effective use of arms retains some self care functions</P>
</TD>
</TR>
<TR>
<TD>
<P>9.0</P>
</TD>
<TD>
<P>Confined to bed; can still communicate and eat.</P>
</TD>
</TR>
<TR>
<TD>
<P>9.5</P>
</TD>
<TD>
<P>Totally helpless bed patient; unable to communicate effectively or eat/swallow</P>
</TD>
</TR>
<TR>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>Death due to MS</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-09-21 09:28:09 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-12 14:17:55 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-09-21 09:28:09 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">#1"multiple sclerosis"#2MeSH descriptor Multiple Sclerosis explode all trees#3"Demyelinating disease*"#4MeSH descriptor Demyelinating Diseases, this term only#5"transverse myelitis"#6MeSH descriptor Myelitis, Transverse, this term only#7"neuromyelitis optica"#8"optic neuritis"#9MeSH descriptor Optic Neuritis explode all trees#10"encephalomyelitis acute disseminated"#11MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only#12"devic"#13MeSH descriptor Interferon-beta explode all trees#14"interferon beta*"#15rebif#16betaferon#17betaseron#18avonex#19(#13 OR #14 OR #15 OR #16 OR #17 OR #18)#20(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)#21(#19 AND #20)</HEADING>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-12 14:20:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-11-12 14:17:36 +0100" MODIFIED_BY="[Empty name]">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-12 14:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>(((("Multiple Sclerosis"[mh]) OR ("Myelitis, Transverse"[mh:noexp]) OR ("Demyelinating Diseases"[mh:noexp]) OR ("Encephalomyelitis, Acute Disseminated"[mh:noexp]) OR ("Optic Neuritis"[mh])) OR ((("multiple sclerosis") OR ("neuromyelitis optica") OR ("transverse myelitis") OR (encephalomyelitis) OR (devic) OR ("optic neuritis")) OR ("demyelinating disease*") OR ("acute disseminated encephalomyelitis"))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh]))))) AND (("Interferon-beta"[Mesh]) OR ("Interferon-beta*") OR (rebif OR avonex OR betaseron OR betaferon))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-09-21 09:33:14 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-09-21 09:26:31 +0200" MODIFIED_BY="[Empty name]">EMBASE (EMBASE.com) strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-09-21 09:33:14 +0200" MODIFIED_BY="[Empty name]">
<P>'encephalomyelitis'<B>/</B>exp OR 'demyelinating disease'/exp OR 'multiple sclerosis'/exp OR 'myelooptic neuropathy'/exp OR 'multiple sclerosis':ab,ti OR 'neuromyelitis optica':ab,ti OR encephalomyelitis:ab,ti OR devic:ab,ti AND ('crossover procedure'/exp OR 'double blind procedure'/exp OR 'controlled clinical trial'/exp OR 'clinical trial'/exp OR 'single blind procedure'/exp OR 'randomized controlled trial'/exp OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti) OR placebo:ab,ti OR 'double blind':ab,ti OR 'single blind':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti) AND ('beta interferon'/exp OR 'rebif'/exp OR 'interferon beta'/exp OR 'betaferon'<B>/</B>exp OR 'betaseron'/exp OR 'avonex'/exp) AND [humans]/lim AND [embase]/lim</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-09-21 09:23:55 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-10-15 11:06:16 +0200" MODIFIED_BY="Deirdre Beecher">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-09-21 09:23:55 +0200" MODIFIED_BY="[Empty name]">
<P>(pt randomized controlled trial or pt controlled clinical trial or mh randomized controlled trials or mh random allocation or mh double-blind method or mh single-blind method) and not (ct animal and not (ct human and ct animal)) or (pt clinical trial or (tw clin$ and (tw trial$ or tw ensa$ or tw estud$ or tw experim$ or tw investiga$)) or ((tw singl$ or tw simple$ or tw doubl$ or tw doble$ or tw duplo$ or tw trebl$ or tw trip$) and (tw blind$ or tw cego$ or tw ciego$ or tw mask$ or tw mascar$)) or mh placebos or tw placebo$ or (tw random$ or tw randon$ or tw casual$ or tw acaso$ or tw azar or tw aleator$) or mh research design) and not (ct animal and not (ct human and ct animal)) or (ct comparative study or mh follow-up studies or mh prospective studies or tw control$ or tw prospectiv$ or tw volunt$ or tw volunteer$) and not (ct animal and not (ct human and ct animal) and (multiple sclerosis or multiple sclerosis$ or multiple sclerosis acute fulminant or multiple sclerosis recurrent acute or multiple sclerosis chronic progressive or multiple sclerosis progressive chronic or multiple sclerosis progressive relapsing or multiple sclerosis remitting relapsing or multiple sclerosis relapsing progressive or &#8220;esclerosis multiple&#8221; or (&#8220;esclerosis multiple and aguda fulminante&#8221;) or (&#8220;esclerosis multiple and recurrente&#8221;) or (&#8220;esclerosis multiple and  cronica progresiva&#8221;) or (&#8220;esclerosis multiple and brotes&#8221;) or (&#8220;esclerosis multiple and progresiva brotes&#8221;) or beta interferon or (&#8220;interferon beta&#8221;) or (multiple sclerosis$ and beta interferon$) or (&#8220;esclerosis multiple$&#8221; and &#8220;interferon beta&#8221;)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-09-21 09:24:59 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-09-21 09:24:44 +0200" MODIFIED_BY="[Empty name]">NICE strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-09-21 09:24:59 +0200" MODIFIED_BY="[Empty name]">
<P>Central nervous system/multiple sclerosis OR Multiple sclerosis OR Demyelinating Diseases OR interferon-beta OR Rebif<SUP>®</SUP> OR beta interferon OR Betaferon<SUP>®</SUP>  OR Betaseron<SUP>®</SUP>  OR Avonex<SUP>®</SUP>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>